To, Date: 24th August, 2026

National Stock Exchange of India Ltd.
Exchange Plaza,
Bandra Kurla Complex,
Bandra (E),
Mumbai- 400051

Ref: MAITREYA

Sub: Annual Report for the F.Y. 2025-26

Dear Sir/Madam,

In compliance with SEBI Obligations and Disclosure Requirements) Regulations 2015, please find enclosed herewith the Annual Report of the Company for the F.Y. 2025-2026 which will be circulated to the members.

Kindly take the same on your record.

Thanking you,

Yours faithfully,

For **Maitreya Medicare Limited**

SURANA KASHISH
Digitally signed by SURANA KASHISH
Date: 2026.08.24 13:22:10 +05'30'

Kashish Surana
Company Secretary & Compliance Officer
ACS- 76674

TABLE OF CONTENTS

Corporate information

Board of Directors
Dr. Narendra Singh Tanwar
Chairman cum Managing Director

*Dr. Pranav Rohitbhai Thaker
Whole-time Director

Mr. Vimalkumar Natverlal Patel
Whole-time Director

Mr. Hardik Vikrambhai Patel
Non-Executive Independent Director

Mrs. Abha Surana
Non-Executive Independent Director

Audit Committee
Mr. Hardik Vikrambhai Patel, Chairman
Mrs. Abha Surana, Member
Dr. Narendra Singh Tanwar, Member

Nomination & Remuneration Committee
Mr. Hardik Vikrambhai Patel, Chairman
Mrs. Abha Surana, Member
Mr. Vimalkumar Natverlal Patel, Member

Chief Financial Officer
Dr. Narendra Singh Tanwar

Company Secretary & Compliance Officer
Ms. Kashish Surana

Statutory Auditors
M/s. Saherwala & Co.
Chartered Accountants

Secretarial Auditors
M/s. JDM and Associates LLP
Company Secretaries

Internal Auditors
M/s. Bhavesh Saraiya & Co.
Chartered Accountants
{April – July}

M/s. Anyuta Govind Modi & Co.
Chartered Accountants
{August – March}

Bankers
HDFC Bank Limited
Indusind Bank Limited
Kotak Mahindra Bank Limited

Registrar & Transfer Agent
MUFG Intime India Pvt Ltd
C 101, 247 Park, L.B.S. Marg,
Vikhroli (West), Mumbai - 400083

Registered & Corporate Office
Sai Palace Nr. Someshwara Char
Rasta, UM Road, Surat,
Gujarat, India, 395007

CIN: L24290GJ2019PLC107298
ISIN: INE0PLQ01011
Script Code: MAITREYA
Tel. No. (0261) 2299000

*Resigned W.e.f 25th May, 2026

NOTICE

Notice is hereby given that the 07th Annual General Meeting of the members of **MAITREYA MEDICARE LIMITED** will be held on Monday, 21/09/2026 through Video Conferencing (VC)/Other Audio Visuals Mode (OAVM). The venue of the meeting shall be deemed to be the Registered Office of the Company situated at Nr. Someshwara Char Rasta, UM Road, Surat - 395007 Gujarat at 03:00 PM to transact the following business: -

ORDINARY BUSINESS:

1. To receive, consider and adopt the Audited Financial Statement of the Company for the financial year ended March 31, 2026 together with the reports of the Board of Directors and Auditors thereon and in this regard, pass the following resolutions as **Ordinary Resolution**:

   a. "**RESOLVED THAT** the Audited Financial Statement of the Company for the financial year ended March 31, 2026 together with the reports of the Board of Directors and Auditors thereon presented before this meeting, be and are hereby considered and adopted.".

   b. "**RESOLVED THAT** the Audited Consolidated Financial Statement of the Company for the financial year ended March 31, 2026 together with the reports of Auditors thereon presented before this meeting, be and are hereby considered and adopted."

2. Re-appointment of Mr. Vimalkumar Natverlal Patel (DIN: 08458999) as a Whole time Director who retires by rotation and being eligible offers himself for re-appointment.

For & on behalf of the Board of Directors
Maitreya Medicare Limited

Date: 24/08/2026
Place: Surat

Kashish Surana
(Company Secretary & Compliance Officer)
ACS - 76674

Registered Office
Sai Palace, Nr. Someshwara Char Rasta,
Um Road, Surat – 395007
CIN: L24290GJ2019PLC107298
Website: https://maitreyamedicareltd.com/
Tel: 0261 229 9000

NOTES:

1. **As the AGM shall be conducted through VC / OAVM, the facility for appointment of Proxy by the Members is not available for this AGM and hence the Proxy Form and Attendance Slip including Route Map are not annexed to this Notice.**

2. The Ministry of Corporate Affairs (MCA), vide its General Circular No. 09/2023 dated 25th September, 2023 read with General Circular No. 20/2020 dated 5th May, 2020, General Circular No. 02/ 2022 dated 5th May, 2022 and General Circular No. 10/2022 dated 28th December, 2022 and other applicable circulars, if any, has allowed the Companies to conduct the AGM through Video Conferencing (VC) or Other Audio-Visual Means (OAVM) on or before 30th September, 2023. In accordance with, the said circulars, the 7th AGM of the Company shall be conducted through VC / OAVM. "MUFG Intime India Private Limited" will be providing facility for voting through remote e-voting, for participation in the AGM through VC / OAVM facility and e-voting during the AGM.

3. The Voting rights of members shall be in proportion to their shares in the paid-up equity share capital of the company as on the cut-off date. A person, whose name is recorded in the register of members or in the register of beneficial owners maintained by the depositories as on the cut-off date i.e., 14th September, 2026, only shall be entitled to avail facility of voting at the venue of meeting. A person who is not a member as on the cut-off date should treat this notice for information only.

4. The Register of Members and Share Transfer Books of the Company will remain closed from 15th September, 2026 to 21st September, 2026 (both days inclusive) for the purpose of determining the names of Members eligible for voting at the AGM.

5. Shareholders may be aware that the Companies Act, 2013, permits the service of the Notice of the Annual General Meeting through electronic mode. In view of this, the company would communicate the important and relevant information, and events and send the documents including the intimations, notices, Annual Reports, Financial Statements, etc. in electronic form, to the email address of the respective member. To support the green initiative of the Government in full measure, members who have not registered their email address, so far, are requested to register their e-mail addresses in the following manner

    - For members holding shares in physical mode-please provide necessary details like Folio No, Name of shareholder by email cs@maitreyamedicareltd.com.

- Members holding shares in Demat mode can get their e-mail id registered by contacting their respective Depository Participant or by email to cs@maitreyamedicareltd.com.

  The electronic copy of the Annual Report including Notice of the 07th Annual General Meeting of the company inter-alia indicating the manner of voting along with login details is being sent to all the members whose email ids are registered with the company/Depository Participant(s) for communication purposes. The Annual Report of the company will also be available on the company's website https://maitreyamedicareltd.com/.

6. Section 20 of the Companies Act, 2013 permits service of documents on Members by a Company through electronic mode. So, in accordance with the Companies Act, 2013 read with the Rules framed thereunder, the Annual Report for the year 2025-26 is being sent through electronic mode to those members whose email addresses are registered with the Company/Depository Participant. Members are requested to note that SEBI vide Circular no. SEBI/HO/CFD/PoD-2/P/CIR/2023/4 dated January 05, 2023 read with MCA General Circular no. 10/2022 dated December 28, 2022, compliance norms pertaining to requirement of sending physical copies of annual reports to shareholders for general meeting to be held up-to September 21, 2026 has been dispensed off. In view of the above the Company will not be printing physical copies of the Annual Report. The Annual Report and Notice of the AGM is being sent to members who have registered their email ID with the Company / Depositories. The Members who have not registered their email ID with the Company can access the Annual Report on the website of the Company https://maitreyamedicareltd.com/, website of the Stock Exchange, NSE Limited at https://www.nseindia.com/ and on the website of NSDL (agency for providing the Remote e-Voting facility) i.e., www.e-voting.nsdl.com. Members who would like to obtain pdf copy on their email ID may write an email to cs@maitreyamedicareltd.com.

7. The company or its Registrar and Transfer Agents, MUFG Intime India Private Limited, cannot act on any request received directly from the Members holding shares in electronic form for any change of bank particulars or bank mandates, such changes are to be advised only to the Depository Participants. Members holding the shares in dematerialized form are requested to notify immediately, the information regarding change of address and bank particulars to their respective Depository Participant.

8. The Securities and Exchange Board of India (SEBI) has mandated the submission of a Permanent Account Number (PAN) by every participant in the securities market. Members

holding shares in electronic form are, therefore, requested to submit their PAN to the Depository Participants with whom they maintain their Demat accounts.

9. The Company has appointed Mr. Jaisal Mohatta, Partner of JDM and Associates LLP, Company Secretaries in Whole-time Practice (Membership No A35017; CP No. 16090), to act as the Scrutinizer for conducting the voting process in a fair and transparent manner.

10. To prevent fraudulent transactions, members are advised to exercise due diligence and notify the company/ Registrar of any change in address or demise of any member as soon as possible. Members are also advised not to leave their demat account(s) dormant for long. A periodic statement of holding should be obtained from the concerned Depository Participant and holding should be verified.

11. Subject to the receipt of requisite number of votes, the Resolutions forming part of the AGM Notice shall be deemed to be passed on the date of the AGM, i.e., 21st September, 2026.

12. Those shareholders who have already registered their e-mail address are requested to keep their e-mail addresses validated with their depository participants / the Company's Registrar and Share Transfer Agent, MUFG Intime India Private Limited to enable servicing of notices / documents / annual Reports electronically to their e-mail address.

13. **Voting through electronic means:**

    Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (as amended), and the Circulars issued by the Ministry of Corporate Affairs dated April 08, 2020, April 13, 2020 and May 05, 2020 the Company is providing facility of remote e-Voting to its Members in respect of the business to be transacted at the AGM. For this purpose, the Company has entered into an agreement with National Securities Depository Limited (NSDL) for facilitating voting through electronic means, as the authorized agency. The facility of casting votes by a member using remote e-Voting system as well as venue voting on the date of the AGM will be provided by NSDL.

    Commencement of e-voting: From 9.00 a.m. on September 18, 2026
    End of e-voting: Up to 5.00 p.m. on September 20, 2026

    E-voting shall not be allowed beyond September 20, 2026. During the E-voting period, the shareholders of the company, holding shares either in physical form or dematerialized form, as on the closing of business hours of the cut-off date, may cast their vote electronically. The cut-off date for eligibility for e-voting is Monday, September 14, 2026. Any person, who acquires shares of the company and becomes a member of the company after dispatch of the notice and holding shares as on cut-off date i.e., 14th September, 2026, may cast vote as provided in the notice convening the Meeting, which is available on the website of the company.

THE INSTRUCTIONS FOR MEMBERS FOR REMOTE E-VOTING ARE AS UNDER: -

The remote e-voting period begins on Friday, September 18, 2026 at 9:00 A.M. and ends on Sunday, September 20, 2026 at 05:00 P.M. The remote e-voting module shall be disabled by NSDL for voting thereafter. The Members, whose names appear in the Register of Members / Beneficial Owners as on the record date (cut-off date) i.e., September 14, 2026 may cast their vote electronically. The voting right of shareholders shall be in proportion to their share in the paid-up equity share capital of the Company as on the cut-off date, being September 14, 2026.

How do I vote electronically using NSDL e-Voting system?

The way to vote electronically on NSDL e-Voting system consists of "Two Steps" which are mentioned below:

STEP 1: Access to NSDL e-Voting system

A. Login method for e-Voting for Individual shareholders holding securities in demat mode

In terms of SEBI circular no. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants.

Login method for Individual shareholders holding securities in demat mode is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in demat	**METHOD 1 - NSDL OTP based login** a) Visit URL: https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp

mode with NSDL.	b) Enter your 8 - character DP ID, 8 - digit Client Id, PAN, Verification code and generate OTP. c) Enter the OTP received on your registered email ID/ mobile number and click on login. d) Post successful authentication, you will be re-directed to NSDL depository website wherein you will be able to see e-Voting services under Value added services. Click on "Access to e-Voting" under e-Voting services. e) Click on "MUFG InTime" or "evoting link displayed alongside Company's Name" and you will be redirected to InstaVote website for casting the vote during the remote e-voting period. **METHOD 2 - NSDL IDeAS facility** Shareholders registered for IDeAS facility: a) Visit URL: https://eservices.nsdl.com and click on "Beneficial Owner" icon under "IDeAS Login Section". b) Enter IDeAS User ID, Password, Verification code & click on "Log-in". c) Post successful authentication, you will be able to see e-Voting services under Value added services section. Click on "Access to e-Voting" under e-Voting services. d) Click on "MUFG InTime" or "evoting link displayed alongside Company's Name" and you will be redirected to InstaVote website for casting the vote during the remote e-voting period. Shareholders not registered for IDeAS facility: a) To register, visit URL: https://eservices.nsdl.com and select" Register Online for IDeAS Portal" or click on https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp b) Enter 8-character DP ID, 8-digit Client ID, Mobile no, Verification code & click on "Submit". c) Enter the last 4 digits of your bank account / generate 'OTP' d) Post successful registration, user will be provided with Login

<table>
<tr>
<td></td>
<td>ID and password.
e) Follow steps given above in points (a-d).

Shareholders/ Members can also download NSDL Mobile App “NSDL Speede” facility by scanning the QR code mentioned below for seamless voting experience.
Google Play App Store

METHOD 3 - NSDL e-voting website

a) Visit URL: https://www.evoting.nsdl.com
b) Click on the “Login” tab available under ‘Shareholder/Member’ section.
c) Enter User ID (i.e., your 16-digit demat account no. held with NSDL), Password/OTP and a Verification Code as shown on the screen & click on “Login”.
d) Post successful authentication, you will be re-directed to NSDL depository website wherein you will be able to see e-Voting services under Value added services. Click on “Access to e-Voting” under e-Voting services.
e) Click on “MUFG InTime” or “evoting link displayed alongside Company’s Name” and you will be redirected to InstaVote website for casting the vote during the remote e-voting period.</td>
</tr>
<tr>
<td>Individual Shareholders holding securities in demat mode with CDSL</td>
<td>METHOD 1 - CDSL e-voting page

a) Visit URL: https://www.cdslindia.com.
b) Go to e-voting tab.
c) Enter 16-digit Demat Account Number (BO ID) and PAN No. and click on “Submit”.
d) System will authenticate the user by sending OTP on registered Mobile and Email as recorded in Demat Account
e) Post successful authentication, user will be able to see e-voting option. The evoting option will have links of e-voting service providers i.e., MUFG InTime. Click on “MUFG InTime” or “evoting link displayed alongside Company’s Name” and you will be redirected to InstaVote website for casting the vote during the remote e-voting period.</td>
</tr>
</table>

	METHOD 2 - CDSL Easi/ Easiest facility: <u>Shareholders registered for Easi/ Easiest facility:</u> a) Visit URL: https://web.cdslindia.com/myeasitoken/Home/Login or Visit URL: www.cdslindia.com, click on "Login" and select "My Easi New (Token)". b) Enter existing username, Password & click on "Login". c) Post successful authentication, user will be able to see e-voting option. The evoting option will have links of e-voting service providers i.e., MUFG InTime. Click on "MUFG InTime" or "evoting link displayed alongside Company's Name" and you will be redirected to InstaVote website for casting the vote during the remote e-voting period. <u>Shareholders not registered for Easi/ Easiest facility:</u> a) To register, visit URL: https://web.cdslindia.com/myeasitoken/Home/EasiRegistration / https://web.cdslindia.com/myeasitoken/Home/EasiestRegistration. b) Proceed with updating the required fields for registration. c) Post successful registration, user will be provided username and password on the registered email id. Follow steps given above in points (a-c).
Individual Shareholders (holding securities in demat mode) login through their depository participants	Individual shareholders can also login using the login credentials of your demat account through your depository participant registered with NSDL / CDSL for e-voting facility. a) Login to DP website b) After Successful login, user shall navigate through "e-voting" option. c) Click on e-voting option, user will be redirected to NSDL / CDSL Depository website after successful authentication, wherein user can see e-voting feature. d) Post successful authentication, click on "MUFG InTime" or

	"evoting link displayed alongside Company's Name" and you will be redirected to InstaVote website for casting the vote during the remote e-voting period.

B. Login method for shareholders holding securities in physical mode / Non-Individual Shareholders holding securities in demat mode:

Shareholders holding shares in physical mode / Non-Individual Shareholders holding securities in demat mode as on the cut-off date for e-voting may register for InstaVote as under:

STEP 1: LOGIN / SIGNUP on InstaVote

Shareholders registered for INSTAVOTE facility:

a) Visit URL: https://instavote.linkintime.co.in & click on "Login" under 'SHARE HOLDER' tab.

b) Enter details as under:

A. User ID: Enter User ID
B. Password: Enter existing Password
C. Enter Image Verification (CAPTCHA) Code
D. Click "Submit".

InstaVote USER ID	
NSDL	User ID is 8 Character DP ID followed by 8 Digit Client ID (e.g.IN123456) and 8 digit Client ID (eg.12345678).
CDSL	User ID is 16 Digit Beneficiary ID.
Shares held in physical form	User ID is Event No + Folio no. registered with the Company

(Home page of e-voting will open. Follow the process given under "Steps to cast vote for Resolutions")

Shareholders not registered for INSTAVOTE facility:

a) Visit URL: https://instavote.linkintime.co.in & click on "Sign Up" under 'SHARE HOLDER' tab & register with details as under:

A. User ID: Enter User ID
B. PAN: Enter your 10-digit Permanent Account Number (PAN) (Shareholders who have not updated their PAN with the Depository Participant (DP)/ Company shall use the sequence number provided to you, if applicable.
C. DOB/DOI: Enter the Date of Birth (DOB) / Date of Incorporation (DOI) (As recorded with your DP/Company - in DD/MM/YYYY format)
D. Bank Account Number: Enter your Bank Account Number (last four digits), as recorded with your DP/Company.

InstaVote USER ID	
NSDL	User ID is 8 Character DP ID followed by 8 Digit Client ID (e.g.IN123456) and 8 digit Client ID (eg.12345678).
CDSL	User ID is 16 Digit Beneficiary ID.
Shares held in physical form	User ID is Event No + Folio no. registered with the Company

- Shareholders, holding shares in NSDL form, shall provide 'point 4' above.

- Shareholders, holding shares in CDSL form, shall provide 'point 3' or 'point 4' above.
- Shareholders, holding shares in physical form but have not recorded 'point 3' and 'point 4', shall provide their Folio number in 'point 4' above

E. Set the password of your choice.
(The password should contain minimum 8 characters, at least one special Character (!#$&*), at least one numeral, at least one alphabet and at least one capital letter).
F. Enter Image Verification (CAPTCHA) Code.
G. Click "Submit" (You have now registered on InstaVote).

Post successful registration, click on "Login" under 'SHARE HOLDER' tab & follow steps given above in points (a-b).

STEP 2: Steps to cast vote for Resolutions through InstaVote

A. Post successful authentication and redirection to InstaVote inbox page, you will be able to see the "Notification for e-voting".
B. Select 'View' icon. E-voting page will appear.
C. Refer the Resolution description and cast your vote by selecting your desired option 'Favour / Against' (If you wish to view the entire Resolution details, click on the 'View Resolution' file link).
D. After selecting the desired option i.e. Favour / Against, click on 'Submit'.
E. A confirmation box will be displayed. If you wish to confirm your vote, click on 'Yes', else to change your vote, click on 'No' and accordingly modify your vote.

NOTE: Shareholders may click on "Vote as per Proxy Advisor's Recommendation" option and view proxy advisor recommendations for each resolution before casting vote. "Vote as per Proxy Advisor's Recommendation" option provides access to expert insights during the e-Voting process. Shareholders may modify their vote before final submission.

Once you cast your vote on the resolution, you will not be allowed to modify or change it subsequently.

Non-Individual Body corporate shareholders shall send a scanned copy of the board resolution authorising its representative to vote, to the scrutinizer at registered email address with a copy marked to RTA at enotices@in.mpms.mufg.com and the company at registered email address.

Guidelines for Institutional shareholders ("Custodian / Corporate Body/ Mutual Fund")

STEP 1 – Custodian / Corporate Body/ Mutual Fund Registration

A. Visit URL: https://instavote.linkintime.co.in
B. Click on "Sign Up" under "Custodian / Corporate Body/ Mutual Fund"
C. Fill up your entity details and submit the form.
D. A declaration form and organization ID is generated and sent to the Primary contact person email ID (which is filled at the time of sign up). The said form is to be signed by the Authorised Signatory, Director, Company Secretary of the entity & stamped and sent to insta.vote@linkintime.co.in.
E. Thereafter, Login credentials (User ID; Organisation ID; Password) is sent to Primary contact person's email ID. (You have now registered on InstaVote)

STEP 2 – Investor Mapping

A. Visit URL: https://instavote.linkintime.co.in and login with InstaVote Login credentials.
B. Click on "Investor Mapping" tab under the Menu section
C. Map the Investor with the following details:

1. 'Investor ID' – Investor ID for NSDL demat account is 8 Character DP ID followed by 8 Digit Client ID i.e., IN00000012345678; Investor ID for CDSL demat account is 16 Digit Beneficiary ID.
2. 'Investor's Name - Enter Investor's Name as updated with DP.
3. 'Investor PAN' - Enter your 10-digit PAN.
4. 'Power of Attorney' - Attach Board resolution or Power of Attorney.

   NOTE: File Name for the Board resolution/ Power of Attorney shall be – DP ID and Client ID or 16 Digit Beneficiary ID.

Further, Custodians and Mutual Funds shall also upload specimen signatures.

D. Click on Submit button. (The investor is now mapped with the Custodian / Corporate Body/ Mutual Fund Entity). The same can be viewed under the "Report section".

STEP 3 – Steps to cast vote for Resolutions through InstaVote

The corporate shareholder can vote by two methods, during the remote e-voting period.

METHOD 1 - VOTES ENTRY

a) Visit URL: https://instavote.linkintime.co.in and login with InstaVote Login credentials.

b) Click on "Votes Entry" tab under the Menu section.

c) Enter the "Event No." for which you want to cast vote.
Event No. can be viewed on the home page of InstaVote under "On-going Events".

d) Enter "16-digit Demat Account No.".

e) Refer the Resolution description and cast your vote by selecting your desired option 'Favour / Against' (If you wish to view the entire Resolution details, click on the 'View Resolution' file link). After selecting the desired option i.e. Favour / Against, click on 'Submit'.

f) A confirmation box will be displayed. If you wish to confirm your vote, click on 'Yes', else to change your vote, click on 'No' and accordingly modify your vote.

(Once you cast your vote on the resolution, you will not be allowed to modify or change it subsequently).

METHOD 2 - VOTES UPLOAD

a) Visit URL: https://instavote.linkintime.co.in and login with InstaVote Login credentials.

b) After successful login, you will see "Notification for e-voting".

c) Select "View" icon for "Company's Name / Event number".

d) E-voting page will appear.

e) Download sample vote file from "Download Sample Vote File" tab.

f) Cast your vote by selecting your desired option 'Favour / Against' in the sample vote file and upload the same under "Upload Vote File" option.

g) Click on 'Submit'. 'Data uploaded successfully' message will be displayed.

(Once you cast your vote on the resolution, you will not be allowed to modify or change it subsequently).

NOTE: Non-Individual Body corporate shareholders shall send a scanned copy of the board resolution authorising its representative to vote, to the scrutinizer at registered email address with a copy marked to RTA at enotices@in.mpms.mufg.com and the company at registered email address.

Helpdesk:

Shareholders holding securities in physical mode / Non-Individual Shareholders holding securities in demat mode:

Shareholders holding securities in physical mode / Non-Individual Shareholders holding securities in demat mode facing any technical issue in login may contact INSTAVOTE helpdesk by sending a request at enotices@in.mpms.mufg.com or contact on: - Tel: 022 – 4918 6000.

Individual Shareholders holding securities in demat mode:

Individual Shareholders holding securities in demat mode may contact the respective helpdesk for any technical issues related to login through Depository i.e., NSDL and CDSL.

Login type	Helpdesk details
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending request at evoting@nsdl.co.in or call at: 022 - 4886 7000
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800 22 55 33

Forgot Password:

Individual Shareholders holding securities in physical mode / Non-Individual Shareholders holding securities in demat mode:

Individual Shareholders holding securities in physical mode / Non-Individual Shareholders holding securities in demat mode have forgotten the USER ID [Login ID] or Password or both then the shareholder can use the "Forgot Password" option available on: https://instavote.linkintime.co.in

- Click on **"Login"** under 'SHARE HOLDER' tab.
- Further Click on **"forgot password?"**
- Enter User ID, select Mode and Enter Image Verification code (CAPTCHA).
- Click on "SUBMIT".



InstaVote USER ID	
NSDL	User ID is 8 Character DP ID followed by 8 Digit Client ID (e.g.IN123456) and 8 digit Client ID (eg.12345678).
CDSL	User ID is 16 Digit Beneficiary ID.
Shares held in physical form	User ID is Event No + Folio no. registered with the Company

In case Custodian / Corporate Body/ Mutual Fund has forgotten the USER ID [Login ID] or Password or both then the shareholder can use the "Forgot Password" option available on: https://instavote.linkintime.co.in

- Click on 'Login' under "Custodian / Corporate Body/ Mutual Fund" tab
- Further Click on **"forgot password?"**

- Enter User ID, Organization ID and Enter Image Verification code (CAPTCHA).
- Click on "SUBMIT".

In case shareholders have a valid email address, Password will be sent to his / her registered e-mail address. Shareholders can set the password of his/her choice by providing information about the particulars of the Security Question and Answer, PAN, DOB/DOI etc. The password should contain a minimum of 8 characters, at least one special character (!#$&*), at least one numeral, at least one alphabet and at least one capital letter.

Individual Shareholders holding securities in demat mode with NSDL/ CDSL has forgotten the password:

Individual Shareholders holding securities in demat mode have forgotten the USER ID [Login ID] or Password or both, then the Shareholders are advised to use Forget User ID and Forget Password option available at above mentioned depository/ depository participants website.

General Instructions - Shareholders

- It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.
- For shareholders/ members holding shares in physical form, the details can be used only for voting on the resolutions contained in this Notice.
- During the voting period, shareholders/ members can login any number of time till they have voted on the resolution(s) for a particular "Event".

Shareholders are advised to update their mobile number and email Id correctly in their demat accounts to access InstaMeet *facility.*

Login method for shareholders to attend the General Meeting through InstaMeet:

a) Visit URL: https://instameet.in.mpms.mufg.com & click on **"Login"**.
b) Select the "Company Name" and register with your following details:
c) Select Check Box - **Demat Account No**. / **Folio No.** / **PAN**

- Shareholders holding shares in NSDL/ CDSL demat account shall select check box Demat Account No. and enter the 16-digit demat account number.
- Shareholders holding shares in physical form shall select check box – Folio No. and enter the Folio Number registered with the company.

- Shareholders shall select check box – PAN and enter 10-digit Permanent Account Number (PAN). Shareholders who have not updated their PAN with the Depository Participant (DP)/ Company shall use the sequence number provided by MUFG Intime, if applicable.
- Mobile No: Mobile No. as updated with DP is displayed automatically. Shareholders who have not updated their Mobile No with the DP shall enter the mobile no.
- Email ID: Email Id as updated with DP is displayed automatically. Shareholders who have not updated their Email Id with the DP shall enter the Email Id.

d) Click "Go to Meeting"
You are now registered for InstaMeet, and your attendance is marked for the meeting.

Instructions for shareholders to Speak during the General Meeting through InstaMeet:

a) Shareholders who would like to speak during the meeting must register their request with the company at company's registered email address.
b) Shareholders will get confirmation on first cum first basis depending upon the provision made by the company.
c) Shareholders will receive "speaking serial number" once they mark attendance for the meeting. Please remember speaking serial number and start your conversation with panellist by switching on video mode and audio of your device.
d) Other shareholder who has not registered as "Speaker Shareholder" may still ask questions to the panellist via active chat-board during the meeting.

**Shareholders are requested to speak only when moderator of the meeting/ management will announce the name and serial number for speaking.*

Instructions for Shareholders to Vote during the General Meeting through InstaMeet:

Once the electronic voting is activated during the meeting, shareholders who have not exercised their vote through the remote e-voting can cast the vote as under:

a. On the Shareholders VC page, click on link "Cast your vote".
b. Enter your 16-digit Demat Account No. / Folio No. and OTP (received on the registered mobile number/ registered email Id) received during registration for InstaMeet.
c. Click on 'Submit'.

d. After successful login, you will see "Resolution Description" and against the same the option "Favour/ Against" for voting.
e. Cast your vote by selecting appropriate option i.e. "Favour/Against" as desired. Enter the number of shares (which represents no. of votes) as on the cut-off date under 'Favour/Against'.
f. After selecting the appropriate option i.e. Favour/Against as desired and you have decided to vote, click on "Save". A confirmation box will be displayed. If you wish to confirm your vote, click on "Confirm", else to change your vote, click on "Back" and accordingly modify your vote. Once you confirm your vote on the resolution, you will not be allowed to modify or change your vote subsequently.

Note:

Shareholders/ Members, who will be present in the General Meeting through InstaMeet facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting facility during the meeting.

Shareholders/ Members who have voted through Remote e-Voting prior to the General Meeting will be eligible to attend/ participate in the General Meeting through InstaMeet. However, they will not be eligible to vote again during the meeting.

Shareholders/ Members are encouraged to join the Meeting through Tablets/ Laptops connected through broadband for better experience.

Shareholders/ Members are required to use Internet with a good speed (preferably 2 MBPS download stream) to avoid any disturbance during the meeting.

Please note that Shareholders/ Members connecting from Mobile Devices or Tablets or through Laptops connecting via Mobile Hotspot may experience Audio/Visual loss due to fluctuation in their network. It is therefore recommended to use stable Wi-FI or LAN connection to mitigate any kind of aforesaid glitches.

Helpdesk:

Shareholders facing any technical issue in login may contact INSTAMEET helpdesk by sending a request at instameet@in.mpms.mufg.com or contact on: - Tel: 022 – 4918 6000 / 4918 6175.

DETAILS OF THE DIRECTORS SEEKING APPOINTMENT/ RE-APPOINTMENT AT THIS ANNUAL GENERAL MEETING (AGM), PURSUANT TO REGULATION 36(3) OF SEBI (LISTING OBLIGATION AND DISCLOSURE REQUIREMENTS) REGULATIONS,2015 AND SECRETARIAL STANDARD-2:

Particulars	Retire by Rotation
Name of the Director	Mr. VimalKumar Natverlal Patel
DIN	08458999
PAN	ASSPP1613J
Date of Birth	06th November, 1979
Age	46 years
Date of Appointment	27/05/2019
Educational Qualification	Bachelor of Science in Chemistry Master of Business Administration in Marketing
Expertise in specific functional areas - Job profile and suitability	He looks after human resource related activity in our Company. He has over 17 years of rich experience in Healthcare Business Development. He initiated in 2008 as Sr Executive at Wockhardt Hospital and then was Territory Manager till 2012, later he was associated with Bankers Heart Institute and Tristar Hospitals, Surat as Manager Marketing till 2018. Since last 6 years he is associated with Maitreya Hospital as Founding partner and director and is responsible for Business growth, expansion and operations at group level.
Directorships held in other companies (excluding foreign companies, Section 8 companies and Struck off Companies and our Company)	1. Maitreya Lifescience Private Limited 2. Maitreya Hospital Private Limited 3. Torin Pharmaceuticals Private Limited 4. Vividh Health Private Limited
Shares held	7,06,800 shares
Inter-se Relationship with other Directors	No relation

Director's Report

To,

The Members of
MAITREYA MEDICARE LIMITED
Sai Palace, Nr Someshwara Char Rasta, Um Road,
Surat - 395007 Gujarat

Your Directors have pleasure in presenting the 07th Annual Report of your Company together with the Audited Standalone and Consolidated financial statements of the company for the financial year ended, 31st March, 2026.

FINANCIAL SUMMARY AND HIGHLIGHTS (STANDALONE) **(Rs. In '000')**

PARTICULARS	Year ended 31st March, 2026	Year ended 31st March, 2025
Revenue from Operations	442212	444132
Other Income	7321	4398
Total Revenue	**449533**	**448530**
Less- Expenses		
Purchase of stock-in-trade	47356	58629
Changes in inventories of Finished goods, work-in-progress and stock-in-Trade	56	-103
Employee Benefit Expenses	50917	52188
Finance Costs	12792	7544
Depreciation & amortization Expense	13809	13459
Other Expenses	336834	284589
Total Expenses	**461765**	**416306**
Profit / Loss Before Tax	**-12232**	**32224**
Exceptional Items	545	0.00
Less: Current Tax	0.00	13117
Less: Deferred Tax	471	113
Profit / Loss After Tax	**-13248**	**18993**

FINANCIAL SUMMARY AND HIGHLIGHTS (CONSOLIDATED) **(Rs. In '000')**

PARTICULARS	Year ended 31st March, 2026	Year ended 31st March, 2025
Revenue from Operations	448499	466620

Other Income	9871	5722
Total Revenue	**458370**	**472342**
Less- Expenses		
Purchase of stock-in-trade	47846	59139
Changes in inventories of Finished goods, work-in-progress and stock-in-Trade	485	-248
Employee Benefit Expenses	55649	61278
Finance Costs	14840	8020
Depreciation & amortization Expense	15220	14964
Other Expenses	347862	297629
Total Expenses	**481902**	**440783**
Profit / Loss Before Tax	**-23533**	**31559**
Exceptional Items	545	0.00
Less: Current Tax	0.00	13314
Less: Deferred Tax	576	63
Profit / Loss After Tax	**-24653**	**18181**

BUSINESS OVERVIEW

The Company is a growing organization that aims at strengthening and establishing itself as the foremost healthcare services provider. The Company strive to serve with its ultra-modern medicinal practices and state of the art infrastructure for medical solutions. The Company aims towards continuous improvement of its healthcare facilities. The Company has a team of medical practitioners who ensures that patients get the quality healthcare services. The dedicated team is trained to take care of the patients and handle health related emergencies. The Company's healthcare staff members comprise of Unit Head, Consultant Doctors, Clinical Pharmacist, X-Ray Technician, Medical Officers, Clinical Assistants, Medical Executives, OT Assistant, Infection Control Nurse, Other Nursing Staff, Attendants, Maintenance Head, Dietician/Nutritionist etc. Also, the Company is associated with several organizations' for providing regular healthcare check-up facilities to their employees at affordable rates.

The Company is a part of Ayushman Bharat-Pradhan Mantri Jan Arogya Yojana, a flagship scheme of Government of India which was launched and recommended by the National Health Policy 2017, to achieve the vision of universal health coverage (UHC). The initiative has been designed on the lines as to meet SDG and its underlining commitment. Ayushman Bharat is an attempt to move from sectoral and segmented approach of health service delivery to a comprehensive need-based health care service.

<u>STATE OF THE COMPANIES AFFAIRS (“000”)</u>

STANDALONE

During the year under review, the revenue from operations of the company has been decreased from Rs. 444132 to Rs. 442212 as compared to last year. The total expenditure (including cost of goods consumed, purchase & depreciation) has been also increased from Rs. 4,16,306 to Rs. 4,61,765 as compared to last year. The company has incurred Loss before tax of Rs. 12,232 at the end of the financial year.

CONSOLIDATED

During the year under review, the revenue from operations of the company has been decreased from Rs. 4,66,620 to Rs. 4,48,499 as compared to last year. The total expenditure (including cost of goods consumed, purchase & depreciation) has been also increased from Rs. 4,40,783 to Rs. 4,81,902 as compared to last year. The company has incurred a consolidated loss before tax of Rs. 24,077 at the end of the financial year.

TRANSFER TO GENERAL RESERVE

The Directors do not propose to transfer any amount to the Reserves. Total amount of net profit is carried to the Reserves & Surplus as shown in the Balance Sheet of the Company.

<u>DIVIDEND</u>

With a view to conserve resources and expansion of business, your directors do not recommend any dividend for the financial year under review.

<u>STATE OF AFFAIRS OF THE SUBSIDIARY OF THE COMPANY</u>

Maitreya Hospital Private Limited, a subsidiary of Maitreya Medicare Limited, has been established at Valsad, Gujarat as part of the Group’s strategic expansion in the healthcare sector. The hospital has been developed as a state-of-the-art facility equipped with modern infrastructure, advanced medical technology, and a team of highly qualified healthcare professionals. The hospital commenced its operations on 8th March 2026**.**

The commencement of operations marks an important milestone in the Group’s expansion plans and strengthens Maitreya Medicare Limited’s presence and healthcare service offerings in the Valsad region. The hospital is expected to contribute to the Group’s objective of providing high-quality and accessible healthcare services to patients in the region.

MATERIAL CHANGES AND COMMITMENTS

There have been no material changes and commitments affecting the financial position of the Company which have occurred between the end of the financial year of the Company to which the financial statements relate and the date of this Report.

SHARE CAPITAL STRUCTURE OF THE COMPANY:

The Capital structure of the Company is given below:

Sr. No.	Particulars	As on 31/03/2026 (Rs.)	As on 31/03/2025 (Rs.)
1	**Authorised Capital of the Company**		
	7750000 (7750000 PFY) Equity shares of Rs. 10/- each	7,75,00,000	7,75,00,000
	5750000 (5750000 PFY) Preference Shares of Rs 10/- each	5,75,00,000	5,75,00,000
	Total Authorised Capital	**13,50,00,000**	**13,50,00,000**
2	**Issued, subscribed and paid-up Capital of the Company**		
	67,76,000 (67,76,000 PFY) Equity shares of Rs. 10/- each	6,77,60,000	6,77,60,000
	47,76,300 (53,16,300 PFY) Preference Shares of Rs 10/- each	4,77,63,000	5,31,63,000
	Total paid-up Capital	**11,55,23,000**	**12,09,23,000**

During the Financial Year 2025-26, Company has redeemed 1,80,000 6% Redeemable Preference Shares of Rs 10 each aggregating to Rs. 18,00,000/- (Rupees Eighteen Lacs Only) at Board meeting held on 30th May 2025.

The Company has further redeemed 3,60,000 6% Redeemable Preference Shares of Rs 10 each aggregating to Rs. 36,00,000/- (Rupees Thirty-Six Lacs Only) at Board meeting held on 02nd September 2025.

BOARD OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

Your Company's Board is duly constituted which is in compliance with the requirements of the Act, the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015 [hereinafter referred to as "Listing Regulations"] Regulations, 2015 and provisions of the Articles of

Association of the Company. The Board of Directors comprises of four (4) directors which include two (2) Executive Directors and two (2) Independent Directors. The overall composition of Board of Directors includes one-woman director. As on the date of this report, the Board of the company constitutes of the following Directors:

Sr. No.	Name of Directors/KMPs	Designation
1.	Dr. Narendra Singh Tanwar	Managing Director and Chairman
2.	Mr. Vimalkumar Natverlal Patel	Whole-time director
3.	Mr. Hardik Vikrambhai Patel	Non-Executive Independent Director
4.	Mrs. Abha Surana	Non-Executive Independent Director

The Board received a declaration from all the directors under Section 164 and other applicable provisions, if any, of the Companies Act, 2013 that none of the directors of the company is disqualified under the provisions of the Companies Act, 2013 ("Act") or under the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015.

As on the date of this report, Mr. Pranav Rohitbhai Thaker, Whole-time Director of the Company, resigned from the office of Whole-time Director with effect from 25th May 2026. The Board places on record its appreciation for the valuable contribution and services rendered by Mr. Pranav Rohitbhai Thaker during his tenure with the Company.

RE-APPOINTMENT

In accordance with the provisions of section 152 of the Companies Act 2013 and the Articles of Association of the Company, Mr. Vimalkumar Natverlal Patel (DIN: 08458999) Whole-time Director who retires by rotation at the ensuing Annual General Meeting and is eligible, offers himself for his re-appointment. The board recommends his re-appointment for the consideration of the Members of the company at the ensuing Annual General Meeting. A brief resume and other details of the above director seeking re-appointment are provided in the Notice of Annual General meeting.

KEY MANAGERIAL PERSONNEL

Ms. Kashish Surana was appointed as the Company Secretary of the Company at the Board Meeting held on 30th May, 2025.

MEETINGS OF THE BOARD OF DIRECTORS

During the Year under the review the Board of Directors met 5 (Five) times, Details of the Meetings are as under:

SN	Date of Meeting	Board Strength	No. of Directors Present
1	30/05/2025	5	5
2	08/07/2025	5	5
3	02/09/2025	5	5
4	14/11/2025	5	5
5	10/03/2026	5	5

In respect of said meetings proper notices were given and proceedings were properly recorded and signed in the Minute Book maintained for the purpose.

PRESENCE/ATTENDANCE OF DIRECTORS IN THE MEETINGS

Name of Director	Category of Directors	Attendance	
		Board	**Last AGM**
Dr. Narendra Singh Tanwar	Managing Director	5	Yes
Dr. Pranav Rohitbhai Thaker	Whole-time director	5	Yes
Mr. Vimalkumar Natverlal Patel	Whole-time director	5	Yes
Mr. Hardik Vikrambhai Patel	Independent Director	5	Yes
Mrs. Abha Surana	Independent Director	5	Yes

STATEMENT OF DECLARATION GIVEN BY INDEPENDENT DIRECTORS

The Company has received necessary declaration of independence from all Independent Directors of the Company, under Section 149(7) of the Act, that he/she meets the criteria of Independent Directors envisaged in Section 149(6) of the Act and rules made thereunder and SEBI (LODR) Regulations, 2015 and is not disqualified from continuing as Independent Directors.

The Independent Directors have also confirmed that they have registered themselves with the Independent Director’s Database maintained by the Indian Institute of Corporate Affairs. Further Company has also received statements from all the Independent Directors that they have complied with Code of Conduct for Independent Directors prescribed in Schedule IV of the act and also statement on compliance of code of conduct for Directors and Senior Management Personnel formulated by Company

SEPARATE MEETING OF INDEPENDENT DIRECTORS OF THE COMPANY

The Independent Directors met on 08th July 2025, without the attendance of Non-independent Directors and members of the Management. The Independent Directors reviewed the performance of non-independent directors and the Board as a whole; the performance of the Chairperson of the company, taking into account the views of Executive Directors and Non-Executive Directors and assessed the quality, quantity, and timeliness of the flow of information between the Company Management and the Board that is necessary for the Board to effectively and reasonably perform the duties.

COMMITTEES OF BOARD OF DIRECTORS

As on 31st March, 2026, the Board has 2 (Two) committees as per the provisions of the Companies Act, 2013 and SEBI (LODR) Regulations, 2015 read with rules, made thereunder, with proper composition of its members which are focused on financial reporting, audit & internal controls, compliance issues, appointment and remuneration of Directors and Senior Management Employees and the risk management framework. The Board periodically evaluates the performance of all the Committees as a whole. All observations, recommendations and decisions of the Committees are placed before the Board for consideration and approval.

The Board has the following committees as under:

- Audit Committee;
- Nomination and Remuneration Committee;

I. AUDIT COMMITTEE

Constitution & Composition of Audit Committee:

The Board of Directors of your company has duly constituted Audit Committee in terms of the provisions of Section 177 of the Companies Act, 2013 read with the Rules framed thereunder and Regulation 18 of the SEBI (LODR), Regulations, 2015. The powers, role and terms of reference of the Audit Committee covers the areas as contemplated under Regulation 18 of SEBI (LODR), Regulations, 2015 and Section 177 of the Act and such other functions as may be specifically delegated to the Committee by the Board from time to time. The Board has accepted all recommendations made by the Audit Committee during the year.

During the financial year ended 31st March, 2026, Audit Committee meetings were held on the following dates:

(1) 30th May, 2025 (2) 08th July, 2025 (3) 14th November, 2025 and (4) 10th March, 2026
Attendance of Committee members during 2025-26 is as follows:

Name	Designation	Category	No. of Meetings held during the Period	
			Held	Attended
Mr. Hardik Vikrambhai Patel	Chairman	Non-Executive-Independent Director	4	4
Mrs. Abha Surana	Member	Non-Executive-Independent Director	4	4
Dr. Pranav Rohitbhai Thaker	Member	Whole-time director	4	4

II. Nomination and Remuneration Committee:

Constitution & Composition of Remuneration Committee:

The Nomination and Remuneration Committee is constituted in accordance with Section 178 of the Companies Act, 2013 read with Rule 6 of the Companies (Meetings of the Board and its Powers) Rules, 2014 as amended from time to time. The powers, role and terms of reference of the Nomination and Remuneration Committee cover the areas as contemplated under Regulation 19 of SEBI (LODR) Regulations, 2015 and Section 178 of the Act, besides other terms as may be referred by the Board of Directors. The Board has accepted all recommendations made by the Nomination and Remuneration Committee during the year.

During the financial year ended 31st March, 2026, Nomination and Remuneration Committee meeting was held on the 30th May, 2025 and 10th March, 2026.

Attendance of Committee members during 2025-26 is as follows:

Name	Designation	Category	No. of Meetings held during the Period	
			Held	Attended
Mr. Hardik Vikrambhai Patel	Chairman	Non-Executive-Independent Director	2	2
Mrs. Abha Surana	Member	Non-Executive-Independent Director	2	2
Mr. Vimalkumar Natverlal Patel	Member	Whole-time Director	2	2

The Policy of nomination and Remuneration committee has been placed on the website of the Company. There has been no change in the policy since last financial year.

CORPORATE SOCIAL RESPONSIBILITY (CSR)

Pursuant to the provisions of Section 135 of the Companies Act, 2013 and the rules made thereunder, the Company is required to spend a certain percentage of its average net profits of the preceding three financial years towards Corporate Social Responsibility activities. However, CSR provisions are not applicable to the Company for the financial year 2025-2026 as the company does not have a net worth of Rs. 500 crore or more, a turnover of Rs. 1000 crore or more, or a net profit of Rs. 5 crore or more in the preceding financial year.

WHISTLE BLOWER POLICY/ VIGIL MECHANISM

In line with the best corporate governance practices, Company has put in place a system through which the Directors and employees may report concerns about unethical behavior, actual or suspected fraud or violation of the Company's Code of Conduct & Ethics without fear of reprisal. The employees and Directors may report to the Compliance Officer and have direct access to the Chairman of the Audit Committee. The Whistle Blower Policy is also available on the website of the Company at https://maitreyamedicareltd.com/.

INTERNAL CONTROL SYSTEMS AND THEIR ADEQUACY

The Company has an adequate system of internal control to safeguard and protect from loss, unauthorized use or disposition of its assets. All the transactions are properly authorized, recorded and reported to the Management. The Company is following all the applicable Accounting Standards for properly maintaining the books of accounts and reporting financial statements. The Internal auditor of the company checks and verifies the internal control and monitors then in accordance with policy adopted by the company. The company continues to ensure proper and adequate systems and procedures commensurate with its size and nature of its business.

DIRECTORS' RESPONSIBILITY STATEMENT

Pursuant to Section 134(5) of the Companies Act, 2013 the Board of Directors of the Company confirms that-

(a) In the preparation of the annual accounts, the applicable accounting standards had been followed along with proper explanation relating to material departures;

(b) The directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the profit and loss of the company for that period;

(c) The directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;

(d) The directors had prepared the annual accounts on a going concern basis; and

(e) Company being an listed/unlisted company, the said para is applicable and complied accordingly / not applicable.

(f) The directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

CORPORATE GOVERNANCE

The Company strives to incorporate the appropriate standards for corporate governance. However, pursuant to Regulation 15(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Company is not required to mandatorily comply with the provisions of certain regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and therefore the Company has not provided a separate report on Corporate Governance.

NON-APPLICABILITY OF THE INDIAN ACCOUNTING STANDARD (IND-AS) FOR YEAR 25-26

As per Provision to regulation Rule 4(1) of the companies (Indian Accounting Standards) Rules, 2015 notified vide Notification No. G.S.R 111 (E) on 16th Feb,2015, companies whose shares are listed on SME exchange as referred to in Chapter XB of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009, are exempted from the compulsory requirements of adoption of IND-AS w.e.f 1st April, 2017. Accordingly, our company, during the year 2024-25 under the review, is listed on SME Platform of NSE Limited is covered under the exempted category and is not required to comply with IND-AS for preparation of financial statements beginning with period on or after 1st April, 2017.

EVALUATION OF BOARD, ITS COMMITTEE, AND INDIVIDUAL DIRECTORS

The Board of Directors has carried out an annual evaluation of its own performance, board committees, and individual directors pursuant to the provision of the Act and SEBI Listing Regulations.

The Performance of the Board was evaluated by the Board after seeking inputs from all the directors on the basis of criteria such as the board composition and structure, effectiveness of board processes, information and functioning etc.

The performance of the committees was evaluated by the Board after seeking inputs from the committee members on the basis of criteria such as the composition of committees, effectiveness of committee meetings etc.

The above criteria are broadly based on the Guideline Note on Board Evaluation issued by the Securities and Exchange Board of India on 5th January, 2017.

In a separate meeting of independent directors, the performance of non-independent directors, the Board as a whole, and the chairman of the company were evaluated, taking into account the views of executive directors and non-executive directors.

The Board and the Nomination and Remuneration Committee reviewed the performance of individual directors on the basis of criteria such as the contribution of the individual director to the board and committee meetings like preparedness on the issues to be discussed, meaningful and constructive contribution,_and inputs in meetings etc.

The Performance evaluation criteria for independent directors is determined by the Nomination and Remuneration Committee. An indicative list of factors on which evaluation was carried out include participation and contribution by a director, commitment, effective development of knowledge and expertise, integrity and maintenance of confidentiality and independence of behavior and judgment.

INFORMATION ABOUT SUBSIDIARY/JOINT VENTURES/ASSOCIATE COMPANY

As on March 31, 2026 there were 3 (Three) subsidiaries of the Company out of 1 (One) are wholly owned. Namely:

1. Maitreya Lifescience Private Limited (Wholly Owned Subsidiary)
2. Maitreya Hospital Private Limited
3. Tulip Agility Private Limited

During the year under review, Maitreya Hospital Private Limited ceased to be a wholly owned subsidiary of the Company pursuant to the allotment of Equity Shares on a private placement basis, resulting in a dilution of the Company's shareholding.

Pursuant to the provisions of Section 129(3) of the Act, a statement containing the salient features of financial statements of the Company's subsidiary in Form AOC- 1 forms part of this report as Annexure - A. The financial statements of all the above-mentioned subsidiaries have been considered in the annual audited consolidated financial results of the Company.

Further, pursuant to the provisions of Section 136 of the Act, the financial statements of the Company, consolidated financial statements along with relevant documents and separate audited financial statements in respect of subsidiary, are available on the website of the Company at https://maitreyamedicareltd.com/.

There are no associate companies or joint venture companies within the meaning of Section 2(6) of the Companies Act, 2013 ("Act").

CONSOLIDATED FINANCIAL STATEMENTS

Your directors have pleasure in attaching the consolidated financial statements pursuant to section 129(3) of the Act and SEBI Listing Regulations and prepared in accordance with the Accounting Principles generally accepted in India including the Indian Accounting Standards specified under Section 133 of the Act.

In accordance with Section 129(3) of the Act, the audited consolidated financial statements are provided in this Annual Report.

DEPOSITS

During the year under review, the Company has not accepted any deposit within the meaning of Section 73 and 74 of the Companies Act, 2013 read with the companies (Acceptance of Deposits) Rules, 2014 and as such no amount on account of principal and interest was outstanding as on the date of the balance sheet. As such no amount of deposit is unpaid or unclaimed at the end of the year. Hence there is no non-compliance with any of the provisions of chapter V of the Companies Act, 2013.

PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS MADE UNDER SECTION 186 OF THE COMPANIES ACT, 2013

Loans, Investment, guarantees and securities in respect of which provisions of Section 185 and 186 of the Companies Act, 2013 are applicable have been compiled by the company and provided in the notes to the standalone financial statements forming part of this annual report.

RELATED PARTY TRANSACTIONS

All Related Party Transactions that were entered into during the financial year 2025-26 were in the ordinary course of business and on arm's length basis. The Company has not entered into any contract/arrangement/transaction with related parties which could be considered material in nature as per Regulation 23 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and amendments thereto and as per Company's policy on Related Party Transactions. All Related Party Transactions are placed before the Audit Committee and Board for approval. The details of the related party transactions including material are provided in the Annexure-B (AOC-2) pursuant to Section 134(3)(h) of the Act read with rule 8(2) of the Companies (Accounts) Rules, 2014. Your directors draw attention of the members to note to the financial statements which sets out related party disclosures.

In Pursuant to the amendment made by SEBI in the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the new materiality policy has been adopted by the Board on Material Related Party Transactions which is available on the website of the Company at https://maitreyamedicareltd.com/.

However, there are no materially significant related party transactions made by the company with Promoters, Key Managerial Personnel or other designated persons which may have potential conflict with interest of the company at large.

ENERGY CONSERVATION, TECHNOLOGY ABSORPTION & FOREIGN EXCHANGE EARNINGS AND OUTGO

Since the Company does not own any manufacturing facility, the other particulars relating to conservation of energy and technology absorption stipulated in the with Rule (8)(3) of the Companies (Accounts) Rules, 2014 are not applicable to the Company

The Company has not made any foreign exchange outgo towards traveling, marketing and import of Capital Goods.

STATUTORY AUDITOR & AUDITORS' REPORT

At the Annual General Meeting held on 14/09/2023, M/s. Saherwala & Co., Chartered Accountants (FRN No. 108969W) was appointed as statutory auditors of the company to hold office till the conclusion of the Annual General Meeting to be held in the calendar year 2028. In terms of the first proviso to Section 139 of the Companies Act, 2013.

Company has received certificate from the Auditors to the effect they are not disqualified to continue as statutory auditors under the provisions of applicable laws.

There are no observations (including any qualification, reservation, adverse remark or disclaimer) of the Auditors in their Audit Report that may call for any explanation from the Directors. Further, the notes to accounts referred to in the Auditor`s Report are self-explanatory.

COST AUDITORS

The Company is not required to maintain cost records as specified by the Central Government under sub-section (1) of section 148 of the Companies Act, 2013. Accordingly, such accounts and records are not made and maintained by the Company.

SECRETARIAL AUDITORS

Pursuant to the provisions of Section 204 of the Companies Act, 2013 read with Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, your Company had appointed Mr. Jaisal Mohatta, Partner of JDM and Associates LLP, Practicing Company Secretaries, (ACS – 35017 & COP – 16090) to conduct the Secretarial Audit of the Company for the year ended March 31, 2026 and is annexed to this Report as Annexure - C.

The Secretarial Auditor has made the following observations in their report:

Observation(s) by Secretarial Auditor:

1. *There was a delay in submission of the Financial Results for the half year ended 30th September 2025 to the Exchange within the prescribed timeline under the Regulation 33 of the SEBI (LODR) Regulations, 2015. The Board Meeting was held on 14th November 2025 and concluded at 11:35 p.m. (IST), whereas the financial results were uploaded on the Stock Exchange portal on 15th November 2025.*

2. *The Company has not complied with the requirement of disclosure of related party transactions for the half year ended 30th September 2025 under Regulation 23 of the SEBI (LODR) Regulations, 2015, which became applicable to the Company pursuant to the amendments effective from 1st April 2025 extending the said provisions to SME listed entities meeting the prescribed thresholds.*

Board's Reply:

1. The delay in submission of the financial results for the half year ended 30 September 2025 was unintentional and occurred due to unavoidable circumstances. One of the Directors, Dr. Narendra Tanwar, who is also the Hospital's Senior Cardiologist, was required to attend to a critical cardiac emergency immediately prior to the scheduled

Board Meeting, resulting in the meeting commencing at 10:50 p.m. instead of the scheduled time and concluding at 11:35 p.m.

Further, while uploading the financial results on the Stock Exchange portal, the Company faced an unexpected technical/system error, despite the documents being ready for submission immediately after the Board Meeting. Multiple attempts were made to upload the documents, and the issue was resolved after clearing the system cache and re-authentication.

Accordingly, the delay was purely unintentional and due to unavoidable circumstances and technical difficulties, and there was no deliberate intention to delay the submission.

2. The non-disclosure of related party transactions for the half year ended 30th September 2025 was unintentional and occurred due to an inadvertent oversight in implementing the amended requirements of Regulation 23 of the SEBI (LODR) Regulations, 2015, which became applicable to the Company with effect from 1 April 2025.

   The Company has since taken note of the applicable requirements and has strengthened its internal compliance and reporting processes to ensure timely and complete disclosure of related party transactions in accordance with the applicable provisions going forward.

   The Company submits that there was no deliberate intention to non-comply with the applicable disclosure requirements, and the omission was purely inadvertent.

INTERNAL AUDITORS

Pursuant to the provisions of Section 138 of the Companies Act, 2013 read with Rule 13 of the Companies (Accounts) Rules, 2014, M/s. Bhavesh Saraiya & Co., Chartered Accountants (Firm Registration No. 117515W), was appointed as the Internal Auditor of the Company for conducting the Internal Audit for the financial year 2025-26.

However, M/s. Bhavesh Saraiya & Co. expressed their intent to resign as Internal Auditors of the Company with effect from 1st August, 2025.

Consequently, Ms. Anyuta Govind Modi, Proprietor of M/s. Anyuta Govind Modi & Co., Chartered Accountants, was appointed as the Internal Auditor of the Company and conducted the Internal Audit for the remaining period from August 2025 to March 2026.

ANNUAL RETURN

Pursuant to sub-section (3) of Section 92 of the Companies Act 2013, read with relevant Rules, the Company is required to place its Annual Return on its website and provide a link of the same in the Boards' Report. However, the Company is maintaining a functional website, the link of the Annual Return is https://maitreyamedicareltd.com/.

DISCLOSURES UNDER SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION & REDRESSAL) ACT, 2013

In order to comply with provisions of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and Rules framed thereunder, the Company has formulated and implemented a policy on prevention, prohibition and redressal of complaints related to sexual harassment of women at the workplace. All women employees either permanent, temporary or contractual are covered under the above policy. The said policy has been uploaded on the internal portal of the Company for information of all employees. An Internal Complaint Committee has been set up in compliance with the said Act.

Internal Complaints Committee (ICC) has been set up to redress complaints received regarding sexual harassment. All employees (permanent, contractual, temporary, trainees) are covered under this policy.

The details of compliant(s) are as under: -

1.	Number of complaints of Sexual Harassment received in the year	Nil
2.	Number of complaints disposed off during the year	Nil
3.	Number of cases pending for more than ninety days	Nil

RISK MANAGEMENT POLICY

A well-defined risk management mechanism covering the risk mapping and trend analysis, risk exposure, potential impact and risk mitigation process is in place. The objective of the mechanism is to minimize the impact of risks identified and taking advance actions to mitigate it. The mechanism works on the principles of probability of occurrence and impact, if triggered. A detailed exercise is being carried out to identify, evaluate, monitor and manage both business and non-business risks.

SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS/COURTS, IF ANY

There were no significant and material orders passed by the Regulators /Courts that would impact the going concern status of the Company and its future operations.

SECRETARIAL STANDARDS

Pursuant to Section 118(10) of the Companies Act, 2013 the Company has complied with Secretarial Standards issued by the Institute of Company Secretaries of India on Meetings of the Board of Directors and General Meetings.

OTHER DISCLOSURE

Your Directors state that no disclosure or reporting is required in respect of the following matters as there were no transactions on these matters during the year under review

- Neither the Managing Director nor the Whole-time Directors of the Company receive any remuneration or commission from any of its subsidiaries
- There is no proceeding pending under the Insolvency and Bankruptcy Code, 2016.
- There was no instance of onetime settlement with any Bank or Financial Institution.

MANAGEMENT DISCUSSION AND ANALYSIS REPORT

In terms of Schedule V of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, details on Management Discussion and Analysis Report are annexed as "Annexure – D".

PARTICULARS OF EMPLOYEES & MANAGERIAL REMUNERATION:

Details Pertaining to Remuneration as Required under Section 197(12) Of the Companies Act, 2013 Read with Rule 5(1), 5(2) & (3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is attached as "Annexure-E".

APPRECIATION AND ACKNOWLEDGEMENT

Your Directors place on record their deep appreciation to employees at all levels for their hard work, dedication and commitment. The Board places on record its appreciation for the support and co-operation, your company has been receiving from its Suppliers, Retailers, Dealers & Distributors and others associated with the Company. The Directors also take this opportunity to thank all Clients, Vendors, Banks, Government and Regulatory Authorities for their continued support.

For & on behalf of the Board of Directors

Date: 24/08/2026
Place: Surat

Dr. Narendra Singh Tanwar
Chairman & Managing Director & CFO
DIN : 08459007

ANNEXURE-A TO THE BOARD'S REPORT

Form AOC-1

(Pursuant to first proviso to sub-section (3) of Section 129 read with rule 5 of Companies (Accounts) Rules, 2014) Statement containing salient features of the financial statement of subsidiaries/associate/companies /joint ventures)

Statement containing salient features of the financial statement of subsidiaries or associate companies or joint ventures

Part "A": Subsidiary

Sr. No.	Particulars	Amount (Rs. In "000")	Amount (Rs. In "000")	Amount (Rs. In "lakhs")
1.	Name of the subsidiary/Associate	Maitreya Hospital Private Limited	Maitreya Lifescience Private Limited	Tulip Agility Private Limited
2.	Reporting period for the subsidiary concerned, if different from the holding company's reporting period	Reporting period same as Holding Company	Reporting period same as Holding Company	Reporting period same as Holding Company
3.	Reporting currency and Exchange rate as on the last date of the relevant financial year in the case of foreign subsidiaries	Not Applicable	Not Applicable	Not Applicable
4.	Share capital	79300.00	2900.00	10.00
5.	Reserves & surplus	(1833.00)	(1635.00)	(83.51)

6.	Total assets	141776.00	7653.00	528.11
7.	Total Liabilities	141776.00	7653.00	528.11
8.	Investments	0.00	0.00	0.00
9.	Turnover	79.00	0.00	62.45
10.	Profit/Loss before taxation	(2196.00)	(2238.00)	(68.67)
11.	Provision for taxation	0.00	0.00	0.00
12.	Profit after taxation	(2196.00)	(2239.00)	(69.72)
13.	Proposed Dividend	0	0	0
14.	% of shareholding	95.06%	100.00%	52.00%

Notes: The following information shall be furnished at the end of the statement:

1. Names of subsidiaries which are yet to commence operations: Not Applicable
2. Names of subsidiaries which have been liquidated or sold during the year: Not Applicable

For and behalf of Board of Directors
For MAITREYA MEDICARE LIMITED

Date: 24/08/2026
Place: Surat

Dr. Narendra Singh Tanwar
Chairman & Managing Director & CFO
DIN: 08459007

Form No. AOC-2 **ANNEXURE-B**

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

Form for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arms length transactions under third proviso thereto

1. Details of contracts or arrangements or transactions not at arm's length basis

SN	Name(s) of the related party and nature of relationship	Nature of contracts /arrangements/trans actions	Duration of the contracts / arrangements / transactions	Salient terms of the contracts or arrangements or transactions including the value, if any	Justification for entering into such contracts or arrangements or transactions	Date(s) of approval by the Board	Amount paid as advances, if any	Date on which the special resolution was passed in general meeting as required under first proviso to Section 188

2. Details of material contracts or arrangement or transactions at arm's length basis

Amount (Rs. In '000')

S N	Name(s) of the related party and nature of relationship	Nature of contracts / arrangements / transactions	Duration of the contracts / arrangements / transactions	Salient terms of the contracts or arrangements or transactions including the value, if any	Date(s) of approval by the Board, if any	Amount paid as advances, if any
1	Dr. Pranav Rohitbhai Thaker - Whole-time Director)	Sale of Pharmacy	On-going transaction (Continuous)	Company is pharmaceutical trading Company and it has sold Pharmaceutical Products to Dr. Pranav Rohitbhai Thaker amounting to Rs. 3.16 on an Arm's Length basis.	30/05/2025	-
2	Dr. Pranav Rohitbhai Thaker - Whole-time Director)	Professional Service availed	On-going transaction (Continuous)	Dr. Pranav Rohitbhai Thaker is ENT surgeon. He has rendered professional services to Company amounting to Rs. 4937.36 on an Arm's Length basis.	30/05/2025	-
3	Mr. Vimal Natverlal Patel - Whole-time Director	Professional Service availed	On-going transaction (Continuous)	Mr. Vimal Natverlal Patel is Healthcare professional. He has rendered professional services to Company amounting to Rs. 1281.27 on an Arm's Length basis.	30/05/2025	
4	Dr. Narendra Singh Tanwar - Managing Director)	Sale of Pharmacy	On-going transaction (Continuous)	Company is pharmaceutical trading Company and it has sold Pharmaceutical Products to Dr. Narendra Singh Tanwar amounting to Rs. 3.47	30/05/2025	

				on an Arm's Length basis.		
5	Dr. Narendra Singh Tanwar - Managing Director)	Professional Service availed	On-going transaction (Continuous)	Dr. Narendra Singh Tanwar is Cardiologist. He has rendered professional services to Company amounting to Rs. 12979.80 on an Arm's Length basis.	30/05/2025	
6	Tulip Agility Private Limited – Subsidiary Company	laboratory charges	On-going transaction (Continuous)	Tulip Agility Private Limited runs hospital. It has availed laboratory services during the financial year from Company amounting to Rs. 37.98 on an Arm's Length basis.	30/05/2025	
7	Mrs. Darshana Pranav Thaker - Spouse of Whole-time Director of Company Dr. Pranav Rohitbhai Thaker	Professional Service paid	On-going transaction (Continuous)	Mrs. Darshana Pranav Thaker is professional. She has rendered Professional services to the Company amounting to Rs. 1800.00 on an Arm's Length basis.	30/05/2025	-
8	Mrs. Yamini Vimalkumar Patel - Spouse of Whole-time Director of Company Mr. Vimalkumar Natverlal Patel	Professional Service paid	On-going transaction (Continuous)	Mrs. Yamini Vimalkumar Patel is professional. She has rendered Professional services to the Company amounting to Rs. 1800.00 on an Arm's Length basis.	30/05/2025	-
9	Dr. Vibha Singh Tanwar - Spouse of Managing Director of Company Dr. Narendra Singh Tanwar	Professional Service availed	On-going transaction (Continuous)	Dr. Vibha Singh Tanwar is Cardiologist. She has rendered professional services to Company amounting to Rs. 4800.00 on an Arm's Length basis.	30/05/2025	-
10	Dr. Vibha Singh Tanwar - Spouse of Managing Director	Sale of Pharmacy	On-going transaction	Company is pharmaceutical trading Company and it has sold Pharmaceutical Products to Dr.	30/05/2025	

	of Company Dr. Narendra Singh Tanwar		(Continuous)	Vibha Singh Tanwar amounting to Rs. 33.57 on an Arm's Length basis.		
11	Purvesh Harshadbhai Mali - Key Managerial Personal	Professional Service availed	On-going transaction (Continuous)	Mr. Purvesh Harshadbhai Mali is professional. He has rendered Professional services to the Company amounting to Rs. 600.00 on an Arm's Length basis.	30/05/2025	
12	Jayesh S Patel - Key Managerial Personal	Professional Service availed	On-going transaction (Continuous)	Mr. Jayesh S Patel is professional. He has rendered Professional services to the Company amounting to Rs. 5.69 on an Arm's Length basis.	30/05/2025	
13	Parimal Arvindbhai Desai - Key Managerial Personal	Professional Service availed	On-going transaction (Continuous)	Mr. Parimal Arvindbhai Desai is professional. He has rendered Professional services to the Company amounting to Rs. 24.73 on an Arm's Length basis.	30/05/2025	
14	Girish Surajmal Pokharna - Key Managerial Personal	Professional Service availed	On-going transaction (Continuous)	Mr. Girish Surajmal Pokharna is professional. He has rendered Professional services to the Company amounting to Rs. 2057.09 on an Arm's Length basis.	30/05/2025	
15	OHM MRI Private Limited – Associate Concern of the Company	laboratory charges	On-going transaction (Continuous)	It has availed laboratory services during the financial year from Company amounting to Rs. 301.10 on an Arm's Length basis.	30/05/2025	

For and behalf of Board of Directors
For MAITREYA MEDICARE LIMITED

Date: 24/08/2026
Place: Surat

Dr. Narendra Singh Tanwar
Chairman & Managing Director & CFO
DIN: 08459007

Form MR-3

Secretarial Audit Report

***for the Financial Year Ended* 31st March, 2026**

[Pursuant to section 204(1) of the Companies Act, 2013 and Rule 9 of the Companies (Appointment and Remuneration Personnel) Rules, 2014]

To,

The Members
MAITREYA MEDICARE LIMITED
CIN: L24290GJ2019PLC107298
Sai Palace, Nr. Someshwara Char Rasta,
UM Road, Surat - 395007 GUJARAT.

We have conducted the Secretarial Audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **MAITREYA MEDICARE LIMITED** (hereinafter called the Company). Secretarial Audit was conducted in a manner that provided me a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Based on our verification of the **MAITREYA MEDICARE LIMITED,** books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of Secretarial Audit, We hereby report that in our opinion, the Company has, during the audit period covering the financial year ended on **March 31, 2026** reasonably complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter :

We have examined the books, papers, minute books, forms and returns filed and other records maintained by **MAITREYA MEDICARE LIMITED** ("**the Company**") for the financial year ended on **March 31, 2026** according to the provisions of:

(i) The Companies Act, 2013 (the Act) and the Rules made there under;

(ii) The Securities Contracts (Regulation) Act, 1956 ('**SCRA'**) and the Rules made there under;

(iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed there under to the extent of Regulation 55A;

(iv) Foreign Exchange Management Act, 1999 and the Rules and Regulations made there under to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings;

(v) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'): -

a. The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
b. The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992;
c. The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009; **[Not Applicable as there was no reportable event during the period under review];**
d. The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008**; [Not Applicable as there was no reportable event during the period under review];**
e. The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client;
f. The Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2015; **[Not Applicable as there was no reportable event during the period under review];**
g. The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009; **[Not Applicable as there was no reportable event during the period under review];**
h. The Securities and Exchange Board of India (Buyback of Securities) Regulations, 1998; **[Not Applicable as there was no reportable event during the period under review];**
i. The Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018;

(vi) Other Laws those are applicable specifically to the Company:

a. Atomic Energy Act, 1962 and Atomic Energy (Radiation Protection) Rules, 2004.
b. Blood Bank Regulations under Drugs and Cosmetics Act, 1940 & NACO Guidelines.
c. The Clinical Establishments (Registration and Regulation) Act, 2010.
d. The Pharmacy Act, 1948.
e. Drugs and Cosmetics Act, 1940 and Rules, 1945.
f. Birth and Death and Marriage Registrations Act, 1886.
g. Medical Termination of Pregnancy Act, 1971 and Medical Termination of Pregnancy Regulations, 2021.
h. Mental Healthcare Act, 2017.
i. Narcotic Drugs and Psychotropic Substances Act, 1985 and Narcotic Drugs and Psychotropic Substances Rules, 1985.
j. Pre-Conception and Prenatal Diagnostic Techniques Act, 1994 and Pre-Conception and Prenatal Diagnostic Techniques, Prohibition of Sex Selection Rules, 1996 and 2014.
k. The Bio Medical Waste Management Rules, 2016.
l. Transplantation of Human Organs and Tissues Act, 1994 and Transplantation of Human Organs and Tissues Rules, 1995 and 2014
m. National Medical Commission Act, 2019.
n. The National Commission for Allied and Healthcare Professions Act, 2021.
o. The Indian Nursing Council Act, 1947.
p. Legal Metrology Act, 2009 and Rules, 2011.
q. Food Safety and Standards Rules, 2011 and Food Safety and Standards (Licensing and Registration of Food Businesses) Regulations, 2011.
r. State Fire Safety Act.
s. The Gas Cylinder Rules, 2016.
t. The Environmental Protection Act, 1986.
u. The Air (Prevention and Control of Pollution) Act, 1981.
v. The Water (Prevention and Control of Pollution) Act, 1974.
w. The Hazardous Wastes (Management, Handling and Transboundary Movement) Rules, 2016.
x. The Plastic Waste Management Rules, 2016.
y. The Solid Waste Management Rules 2016.
z. E-waste management Rules, 2022.

In relation to the period under review, the Company has, to the best of our knowledge and belief and based on the records, information, explanations and representations furnished to us, complied with the laws specifically applicable to the Company mentioned in point VI.

We have also examined compliance with the applicable clauses of:

(i) the Secretarial Standards issued by the Institute of Company Secretaries of India

(ii) The Listing Agreement entered by the Company with the National Stock Exchange Limited (NSE).

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. except:

- *There was a delay in submission of the Financial Results for the half year ended 30th September 2025 to the Exchange within the prescribed timeline under the Regulation 33 of the SEBI (LODR) Regulations, 2015. The Board Meeting was held on 14th November 2025 and concluded at 11:35 p.m. (IST), whereas the financial results were uploaded on the Stock Exchange portal on 15th November 2025.*

- *The Company has not complied with the requirement of disclosure of related party transactions for the half year ended 30th September 2025 under Regulation 23 of the SEBI (LODR) Regulations, 2015, which became applicable to the Company pursuant to the amendments effective from 1st April 2025 extending the said provisions to SME listed entities meeting the prescribed thresholds.*

We further report that we have relied on Statutory Auditor's Reports in relation to the financial statements and accuracy of financial figures for Goods Service Tax, Related Party Transactions, Provident Fund, ESIC etc. as disclosed under financial statements & Accounting Standard 18 during our audit period, and We have not verified the correctness and appropriateness of the books of accounts of the Company.

We further report that

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notice is given to all directors to schedule the Board Meetings, agenda and detailed notes on agenda were generally sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting by the directors.

All decisions at Board Meetings and committee Meetings are carried out unanimously as recorded in the minutes of the meetings of the Board of Directors or Committee of the Board, as the case may be.

We further report that based on the review of the Compliance mechanism established by the Company and on the basis of Compliance Certificates issued by the Chairman and taken in record by the Board of Directors at their meetings, We are of the opinion that there are generally adequate systems & processes in the Company commensurate with its size & operation to monitor and ensure compliance with applicable laws, rules, regulations, circulars, notifications, directions and guidelines.

We further report that during the audit period, the Company has undertaken following event / action having a major bearing on the Company's affairs in pursuance of the above referred laws, rules, regulations, guidelines, standards, etc. referred to above viz:

For **JDM and Associates LLP**
Company Secretaries
ICSI Identification No.: L2025GJ019100

(**Jaisal Mohatta**)
Designated Partner
ACS - 35017, **COP** – 16090
Peer Review Certificate No. 6787/2025

Surat | 29th May 2026
UDIN: A035017H000488382

Note: This report is to be read with our letter of even date which is annexed as **Annexure A** and forms an integral part of this report.

ANNEXURE-A

To,
The Members
MAITREYA MEDICARE LIMITED
CIN: L24290GJ2019PLC107298
Sai Palace, Nr. Someshwara Char Rasta,
UM Road, Surat - 395007 GUJARAT

1. Maintenance of secretarial record is the responsibility of the management of the Company. Our responsibility is to express an opinion on these secretarial records based on my audit.
2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the secretarial records. The verification was done on the random test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices that we have followed provide a reasonable basis for our opinion.
3. We have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.
4. The compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedures on random test basis.
5. Where ever required, we have obtained the Management representation about the compliance of laws, rules and regulations and happening of events etc.
6. The Secretarial Audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

For **JDM and Associates LLP**
Company Secretaries
ICSI Identification No.: L2025GJ019100

(**Jaisal Mohatta**)
Designated Partner
ACS - 35017, **COP** – 16090
Peer Review Certificate No. 6787/2025

Surat | 29th May 2026
UDIN: A035017H000488382

ANNEXURE-D

Management Discussion & Analysis

Industry Structure and Developments

The overall economic development and increasing population have propelled the healthcare sector to become one of India's largest sectors, both in revenue generation and job creation.

The healthcare industry in India continues to play a crucial role in the nation's economic framework, making substantial contributions to growth and employment across diverse sectors such as hospitals, medical devices, clinical trials, telemedicine, medical tourism, health insurance and medical equipment.

The Indian Government is further strengthening the healthcare sector by undertaking structural and sustained reforms and has been announcing conducive policies for encouraging FDI. The Aatmanirbhar Bharat Abhiyaan packages include several short – term and longer – term measures for the health system, including Production – Linked Incentive (PLI) schemes for boosting domestic manufacturing of pharmaceuticals and medical devices. Additionally, India is working towards becoming a hub for spiritual and wellness tourism, as the country has much to offer in Ayurveda and Yoga.

The sector has undergone significant transformations in recent years, fuelled by technological advancements, policy reforms and growing investments. With a population exceeding 1.4 billion, India faces unique challenges in providing accessible and affordable healthcare to its citizens. However, it also presents immense opportunities for innovation and growth.

Despite these advancements, challenges persist, including disparities in healthcare access between urban and rural areas, inadequate infrastructure and the need for skilled healthcare professionals. Nevertheless, with continued efforts towards innovation, collaboration and policy reforms, the Indian healthcare sector is poised for healthy growth and improvement in the coming years.

Opportunities and Threats

India's healthcare sector continues to offer significant long-term growth opportunities, supported by favourable demographics, rising healthcare awareness, increasing prevalence of chronic and lifestyle diseases, expanding health insurance coverage, and growing investments in healthcare infrastructure. An ageing population, increasing disposable incomes, and greater emphasis on preventive healthcare, wellness, diagnostics, and digital health solutions are expected to drive sustained demand for quality healthcare services.

The Government of India continues to strengthen the healthcare ecosystem through initiatives such as Ayushman Bharat, expansion of Health and Wellness Centres, the Ayushman Bharat Digital Mission (ABDM), Production Linked Incentive (PLI) schemes for medical devices and pharmaceuticals, and increased investments in public healthcare infrastructure. These initiatives are expected to improve healthcare accessibility, affordability, and quality while encouraging greater private sector participation.

Medical tourism remains a major growth opportunity for India owing to its internationally accredited hospitals, skilled medical professionals, advanced treatment capabilities, and significant cost advantage compared with developed countries. Growing global demand for specialized treatments, coupled with improvements in healthcare infrastructure and digital connectivity, is expected to further strengthen India's position as a preferred healthcare destination.

Tier II and Tier III cities continue to represent one of the largest untapped opportunities for healthcare providers. Increasing urbanisation, improving purchasing power, enhanced connectivity, and limited availability of quality tertiary healthcare services have encouraged both national hospital chains and regional healthcare providers to expand their presence in these markets through greenfield projects, acquisitions, and strategic partnerships.

Rapid adoption of digital technologies—including telemedicine, artificial intelligence, electronic health records, remote patient monitoring, robotics, and data analytics—is transforming healthcare delivery by improving operational efficiency, patient outcomes, and accessibility. The continued digital transformation of the sector is expected to create new opportunities for innovation and service delivery.

At the same time, the industry faces several challenges. Rising operating costs, inflationary pressures, increasing manpower expenses, and shortages of skilled healthcare professionals continue to impact hospital profitability. The sector also operates within an evolving regulatory framework, with increasing focus on quality standards, patient safety, pricing regulations, data privacy, and compliance requirements, which may increase operational complexity and costs.

The healthcare sector remains highly competitive, with continued capacity expansion by established hospital chains, private equity-backed healthcare platforms, and regional healthcare providers. Pricing pressures, talent retention, and the need for continuous investment in technology and infrastructure present additional challenges. Further, geopolitical uncertainties, global supply chain disruptions, fluctuations in imported medical equipment costs, and economic volatility may affect capital expenditure and operating margins.

Despite these challenges, the long-term outlook for the Indian healthcare industry remains positive. Strong structural demand drivers, supportive government policies, rising health awareness, increasing insurance penetration, technological innovation, and continued investment in healthcare infrastructure are expected to sustain the sector's growth momentum over the coming years.

Outlook

The global economy is expected to witness steady but moderate growth amid persistent geopolitical tensions, trade uncertainties, inflationary pressures, and evolving monetary policies across major economies. According to the International Monetary Fund (IMF), global Gross Domestic Product (GDP) growth is projected at approximately 3.1% in 2026, improving marginally to 3.2% in 2027. The outlook is supported by easing inflation, resilient labour markets in several advanced economies, and gradual stabilization in global supply chains. However, downside risks remain due to geopolitical conflicts, commodity price volatility, tighter financial conditions, and trade-related uncertainties.

India continues to be one of the fastest-growing major economies in the world despite global economic headwinds. The IMF projects India's real GDP growth at around 6.4% in 2026, while other estimates place growth in the range of 6.5–6.6%, supported by strong domestic consumption, sustained public infrastructure investment, robust services sector performance, digital transformation, and ongoing structural reforms. Although external risks such as higher energy prices and geopolitical uncertainties persist, India's macroeconomic fundamentals, improving manufacturing activity, and resilient investment climate are expected to support long-term economic expansion.

The Indian healthcare industry continues to be one of the country's fastest-growing sectors, driven by rising healthcare awareness, increasing prevalence of chronic diseases, expanding health insurance coverage, growing investments in healthcare infrastructure, rapid adoption of digital health technologies, and favourable government initiatives. The sector comprises hospitals, diagnostics, pharmaceuticals, medical devices, telemedicine, health insurance, clinical research, and medical tourism. The Indian healthcare market is projected to reach approximately USD 610–640 billion by 2026, reflecting sustained double-digit growth driven by increasing healthcare expenditure and improved access to quality healthcare services. The hospital segment remains the largest contributor to the sector and is expected to continue expanding due to increasing demand for quality healthcare services, rising private sector investments, and capacity expansion across Tier II and Tier III cities. The industry's long-term outlook remains positive, supported by favourable demographics, technological advancements, and continued policy support for strengthening healthcare infrastructure.

Risks and Concerns

Risks are an unavoidable and integral part of any enterprise. Efficient management of business risks is a key factor that determines growth, profitability and at times, even survival. In the last few years, the healthcare industry in India has been witnessing increased consolidation even among the larger players. Further, Government intervention, by way of an active regulatory regime, be it in terms of price control or capping of margins on medicines and implants has been stepped up. State and Central Healthcare coverage schemes are also impacting industry margins. At Maitreya Hospitals, we continue to strive for a focused approach on risk identification, management and mitigation. We are documenting operational risks and concerns at the unit level as well as the strategic and financial risks at the enterprise level in the form of a robust risk register. The aim is to improve responsibility accounting and bring the right stakeholders to focus on appropriate risk mitigation and monitoring measures at various levels within an organisation.

Segment - Wise or Product - Wise Performance.

Your Company operates in only one segment

Internal Control Systems and Their Adequacy

The Company has an adequate system of internal control to safeguard and protect from loss, unauthorized use or disposition of its assets. All the transactions are properly authorized, recorded and reported to the Management. The Company is following all the applicable Accounting Standards for properly maintaining the books of accounts and reporting financial statements. The Internal auditor of the company checks and verifies the internal control and monitors then in accordance with policy adopted by the company. The company continues to ensure proper and adequate systems and procedures commensurate with its size and nature of its business.

Discussion on Financial Performance with respect to Operation Performance (In '000')

During the current period, your company has earned total revenue of Rs. 449532.78 as against Rs. 448530.34 in the previous year. The company has earned a net profit of Rs. (13248) as compared to Rs. 18993.43 in the previous year.

Human Resource

The primary objective of any human resource management is to ensure the availability of competent and willing workforce to the organisation as well as to meet the needs, aspirations, values and dignity of individuals / employees and having due concern for the socio – economic problems of the community and the country. During the year, your company focused on these objectives keeping mind the disastrous Covid Pandemic that has engulfed the entire world.

Annexure-E

Disclosure required in Board's Report pursuant to Companies
(Appointment and Remuneration of Managerial Personnel) Rules, 2014

Sr	Particulars	Details
1	**Median Remuneration of employees for FY 2025-26**	NIL
2	**Ratio of remuneration of each director to the median remuneration of employees of the company for FY 2025-26**	Ratio
	a. Pranav Rohitbhai Thaker	N.A., since not drawing any salary
	b. Narendra Singh Tanwar	N.A., since not drawing any salary
	c. Vimalkumar Natverlal Patel	N.A., since not drawing any salary
	d. Hardik Vikrambhai Patel	N.A., since not drawing any salary
	e. Abha Surana	N.A., since not drawing any salary
3	**Percentage increase in remuneration of each director, CFO, CEO & CS in financial year 2025-26**	% increase in FY 2025-26 as compared to FY 2024-25
	a. Narendra Singh Tanwar, Chairman and Managing Director	NA
	b. Pranav Rohitbhai Thaker, Non-Executive Director	NA
	c. Vimalkumar Natverlal Patel, Non-Executive Director	NA
	d. Hardik Vikrambhai Patel, Non-Executive & Independent Director	NA
	e. Abha Surana, Non-Executive & Independent Director	NA
	i. Narendra Singh Tanwar, Chief Financial Officer	Not comparable
	ii. Chandan Chetnani, Company Secretary	NA
4	**Percentage increase in median remuneration of employee in the financial year 2025-26**	NA
5	**Number of permanent employees on roll of the company as on 31-03-2026**	
6	**average percentile increases already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof and point out if there are any exceptional circumstances for increase in the managerial remuneration**	NA
7	**Affirmation: It is hereby affirmed that the remuneration paid during the year is as per the Remuneration Policy of the Company.**	

DECLARATION OF COMPLIANCE WITH CODE OF CONDUCT

I, Narendra Singh Tanwar, Chairman & Managing Director of the Company hereby declare that, Members of the Board and Senior Management Personnel have confirmed their compliance with the Code of Conduct for the year ended March 31, 2026.

For & on behalf of the Board of Directors

Date: 24/08/2026
Place: Surat

Dr. Narendra Singh Tanwar
Chairman & Managing Director & CFO
DIN : 08459007

INDEPENDENT AUDITOR'S REPORT

To the Members of MAITREYA MEDICARE LIMITED

Formerly known as MAITREYA MEDICARE PRIVATE LIMITED

Report on the Audit of the Standalone Financial Statements

1. We have audited the accompanying Standalone financial statements of Maitreya Medicare Limited (*Formerly known as Maitreya Medicare Private Limited)*, which comprise the balance sheet as at 31st March 2026, and the statement of profit and loss, statement of cash flows for the period then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Standalone Financial Statements

2. The management and Board of Directors of the Company are responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ('the act') with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with rule 7 of Companies (Accounts) Rules, 2014. This responsibility includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of

appropriate accounting policies; making judgments and estimates that are reasonable and prudent; design, implementation and maintenance of adequate internal financial controls, that are operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

3. Our responsibility is to express an opinion on these standalone financial statements based on our audit. We have considered the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made there under. We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

4. An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the financial statements, that give a true and fair view, in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on whether the Company has in place an adequate internal financial controls system over financial reporting and the operating effectiveness of such controls. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by the Company's management and Board of Directors, as well as evaluating the overall presentation of the financial statements.

5. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the standalone financial statements.

Opinion

6. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India of the state of affairs of the Company as at 31st March 2026, its ~~profit~~/loss and its cash flows for the period ended on that date.

Report on Other Legal and Regulatory Requirements

7. As required by the Companies (Auditor's Report) Order, 2020 issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, and on the basis of such checks of the books and records of the company as we considered appropriate and according to the information and explanations given to us, we give in the "Annexure A" a statement on the matters Specified in paragraphs 3 and 4 of the Order report as per this order.

8. As required by section 143(3) of the Act, we further report that:

a) we have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;

b) in our opinion proper books of account as required by law have been kept by the Company so far as appears from our examination of those books;

c) the Balance Sheet, Statement of Profit and Loss, and Cash Flow Statement dealt with by this Report are in agreement with the books of account;

d) in our opinion, the aforesaid Standalone financial statements comply with the applicable Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules 2014.

e) on the basis of written representations received from the directors as on March 31, 2026, and taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2026, from being appointed as a director in terms of Section 164(2) of the Act.

f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B".

g) In our opinion and to the best of our information and according to the explanations given to us, we report as under with respect to other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014:

    i. The Company does not have any legal pending court litigations which would impact its financial position; except cases under the consumer court filed by patients against various insurance companies in which company is co-respondent. (Please see Notes No. 31.24 to the Balance Sheet)

    ii. The Company did not have any long-term contracts including derivative contracts; as such the question of commenting on any material foreseeable losses thereon does not arise;

iii. There has not been an occasion in case of the Company during the period under report to transfer any sums to the Investor Education and Protection Fund. The question of delay in transferring such sums does not arise.

h) The company, has used such accounting software for maintaining its books of account which:

i. Has a built-in Feature of recording audit trail (edit log) facility and

ii. The audit trail has operated throughout the year for all transactions recorded in the software and

iii. The audit trail feature has not been tampered with.

iv. The audit trail has been preserved by the company as per the statutory requirements for record retention.

FOR SAHERWALA & CO
CHARTERED ACCOUNTANTS
FRN 108969W

PLACE: SURAT
DATE: 29.05.2026

ESMAYEEL O. SAHERWALA
PARTNER
M. No. 122386
UDIN: 26122386YLRSTC9026

Annexure "A" to the Independent Auditor's Report of even date to the members of Maitreya Medicare Limited (Formerly known as Maitreya Medicare Private Limited), on the financial statements for the year ended 31st March 2026.

Based on the audit procedures performed for the purpose of reporting a true and fair view on the financial statements of the Company and taking into consideration the information and explanations given to us and the books of account and other records examined by us in the normal course of audit, we report that:

(i) (a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment.

(B) The Company has maintained proper records showing full particulars of Intangible Assets.

(b) The Property, Plant and Equipment of the company have been physically verified by the management at reasonable intervals during the year and no material discrepancies were noticed on such verification.

(c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there are no immovable properties held in the name of company. Accordingly, clause 3(i)(c) of the order is not applicable.

(d) The Company has not revalued its Property, Plant and Equipment (including Right of Use assets) or intangible assets or both during the year and hence not applicable.

(e) According to the information and explanation given to us, no proceedings have been initiated or are pending against the company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made thereunder during the year.

(ii) (a) The management has conducted physical verification of inventory at reasonable intervals during the year, in our opinion, the coverage and procedure of such verification by the management is appropriate in relation to the size of the company and nature of its business. As informed to us, the discrepancies were noticed on such verification between the physical stock and the books records were not material.

(b) The company has not been sanctioned working capital limits in excess of five crore rupees (at any point of time during the year), in aggregate, from banks or financial institutions on the basis of security of current assets; therefore submission of quarterly returns or statements by the company with such banks or financial institutions arises. Accordingly, clause 3(ii)(b) of the Order is not applicable;

(iii) During the year under consideration companies has granted Loan to the subsidiary namely Tulip Agility Private Limited to the tune of Rs. 75,00,000/- and Maitreya Hospital Private Limited Rs.50,00,000 and Maitreya Life science Private Limited Rs. 40,000,00. During the year under consideration to the tune of Rs. 1,10,29,200/- has been repaid out of the earlier year loans by Subsidiary Maitreya Hospital Private Limited and Maitreya Life science Private Limited Rs 53,00,000.

According to the information and explanation given to us, the investments made, guarantees provided, security given and the terms and conditions of the grant of all loans and advances in the nature of loans and guarantees provided are not prejudicial to the company's interest; Schedule of repayment of the principal amount and the payment of the interest have not been stipulated and hence we are unable to comment as to whether receipt of the principal amount and the interest is regular or not.

(iv) According to the information and explanation given to us, the company has complied with requirements of section 185 and 186 in respect of loans, investments, guarantees or security made by it during the year under audit subject to above point no. (iv).

(v) The Company has not accepted any deposits or amounts which are deemed to be deposits under the directives of the Reserve Bank of India and the provisions of Sections 73 to 76 or any other relevant provisions of the Companies Act, 2013 and the rules framed thereunder, where applicable. Hence, the provisions of clause 3(v) of the Order are not applicable.

(vi) In our opinion and according to the information and explanations given to us the Central Government has not prescribed the maintenance of cost records under sub-section (1) of section 148 of the Companies Act for any of the services rendered by the company. Accordingly, the clause vi of the order is not applicable;

(vii) (a) The Company is regular in depositing undisputed statutory dues including Goods and Services Tax, provident fund, employees' state insurance, income-tax, sales-tax, service tax, duty of customs, duty of excise, value added tax, cess and any other statutory dues, as applicable, with the appropriate authorities. Further, no undisputed amounts payable in respect thereof were outstanding at the year-end for a period of more than six months from the date they became payable.

(b) There are no dues in respect of Goods and Services Tax, provident fund, employees' state insurance, income-tax, sales-tax, service tax, duty of customs, duty of excise, value added tax, cess and any other statutory dues that have not been deposited with the appropriate authorities on account of any dispute.

(viii) According to the information and explanation given to us, There were no transactions relating to previously unrecorded income that have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (43 of 1961). Accordingly, clause 3(viii) of the Order is not applicable.

(ix) (a) In our opinion, the company has not defaulted in repayment of loans or other borrowings or in the payment of interest thereon to any lender during the year;

(b) According to the information and explanations given to us, and based on our examination we report that the Company is not declared wilful defaulter by any bank or financial institution or other lender;

(c) According to the information and explanation given to us and based on our examination the amount of loan is not diverted and utilized for the purpose for which it is borrowed;

(d) According to the information and explanation given to us and based on our examination, funds raised on short term basis have not been utilised for long term purposes;

(e) According to the information and explanation given to us and based on our examination, the company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures;

(f) According to the information and explanation given to us and based on our examination, the company has not raised loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies.

(x) (a) The Company has not raised moneys by way of initial public offer or further public offer (including debt instruments) during the year;

(b) According to the information and explanation given to us, the company has made initial public offer of Equity shares during the earlier year and the requirement of section 42 and Section 62 of the companies act, 2013 have been complied with and according to information and explanations given to us, the amount raised have been used for the purposes for which the funds were raised.

(xi) (a) According to the information and explanations given to us and as represented by the Management and based on our examination of the books and records of the Company and in accordance with generally accepted auditing practices in India, no material case of frauds by the Company or on the Company has been noticed or reported during the year;

(b) According to the information and explanation given to us, no report under sub-section (12) of section 143 of the Companies Act has been filed by the auditors in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government during the year;

(c) According to the information and explanation given to us, no whistle-blower complaints have been received during the year by the company.

(xii) Company is not a Nidhi company, accordingly provisions of the Clause 3(xii) of the Order is not applicable to the company.

(xiii) According to the information and explanations given to us, we are of the opinion that all transactions with related parties are in compliance with Section 177 and 188 of Companies Act, 2013 where applicable and the details have been disclosed in the Financial Statements etc., as required by the Accounting Standards and the Companies Act, 2013.

(xiv) (a) According to the information and explanations given to us and based on our examination, the company with the size and nature of its business is required to have an internal audit system.

(b) Company has internal audit system commensurate with the size and nature of business and has appointed internal auditor for the same, and internal auditors has covered whole system of the Company and has issued audit report, we have considered the said report.

(xv) According to the information and explanations given to us and based on our examination, we are of the opinion that the company has not entered in to any non-cash transactions specified under section 192 of the Act with directors or persons connected with directors during the year and accordingly, the provisions of clause 3(xv) of the Order is not applicable.

(xvi) According to the information and explanations given to us, we are of the opinion that the company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934 and the company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India, accordingly the provisions of clause 3(xvi) of the Order are not applicable;

(xvii) According to the information and explanations given to us and based on the audit procedures conducted we are of opinion that the company has not incurred any cash losses in the financial year and the immediately preceding financial year;

(xviii) There has not been resignation of the statutory auditors during the year, and accordingly, the provisions of clause 3(xviii) of the Order is not applicable.

(xix) On the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report indicating that company is incapable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the company as and when they fall due.

(xx) The provisions of Section 135 towards corporate social responsibility are not applicable on the company during the year under consideration. Accordingly, Company is not required to apply the required amount of CSR limits as prescribed us/. 135(1) of the Companies Act, 2013.

(xxi) The reporting under clause (xxi) is not applicable in respect of audit of standalone financial statements of the Company. Accordingly, no comment has been included in respect of said clause under this report.

FOR SAHERWALA & CO
CHARTERED ACCOUNTANTS
FRN 108969W

PLACE: SURAT
DATE: 29/05/2026

ESMAYEEL O. SAHERWALA
PARTNER
M. No. 122386
UDIN: 26122386YLRSTC9026

ANNEXURE "B" TO THE INDEPENDENT AUDITOR'S REPORT OF EVEN DATE ON THE FINANCIAL STATEMENTS OF MAITREYA MEDICARE LIMITED *Formerly known as MAITREYA MEDICARE PRIVATE LIMITED*

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of **MAITREYA MEDICARE LIMITED** *Formerly known as MAITREYA MEDICARE PRIVATE LIMITED* ('the Company') as of 31-Mar-2026 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects. Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness.

Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls Over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that

(1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;

(2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and

(3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31-Mar-2026.

FOR SAHERWALA & CO
CHARTERED ACCOUNTANTS
FRN 108969W

PLACE: SURAT
DATE: 29/05/2026

(ESMAYEEL O SAHERWALA)
PARTNER
M. No. 122386
UDIN: 26122386YLRSTC9026

MAITREYA MEDICARE LIMITED

(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)

AUDITED BALANCE SHEET AS ON 31st March 2026

CIN No. - U24290GJ2019PTC107298

(Currency: Rs in '000')

Particulars	Note No.	As at 31st March 2026	As at 31st March 2025
I. EQUITY & LIABILITIES			
(1) Shareholders''s Funds			
a) Share capital	1	115523	120923
b) Reserve & Surplus	2	186593	199841
c) Money received against share warrants			
(2) Share application money pending allotment			
(3) Non-Current Liabilities			
a) Long-term Borrowings	3	216977	19594
b)Deffered tax liability (Net)	4	7878	6953
c)Other long term Liabilities			
d)Long term Provisions			
(4) Current Liabilities			
a) Short-term Borrowings	5	11786	15744
b) Trade payables			
(A) total outstanding dues of micro enterprises and small enterprises; and	6	4696	2876
(B) total outstanding dues of creditors other than micro enterprises and small enterprises.		28045	24937
c) Other curent Liabilites	7	61404	45193
d) Short term Provisions	8		8075
Total		632902	444136
II. Assets			
(1) Non-current assets			
(a) Property, Plant and Equipment and Intangible Assets			
(i) Property, Plant and Equipment	9	329784	118212
(ii) Intangible Assets		1149	1445
b) Non Current Investments	10	75730	75830
c) Deffered tax asset (net)			
d) Long term loans and advances	11	54912	52238
e) Other Non current assets	12	10859	12722
(2) Current assets			
a) Current Investments	13	522	422
b) Inventories	14	7740	4798
c) Trade receivables	15	116155	151850
d) Cash & Cash equivalents	16	28937	19090
e) Short-term loans and advances	17	3794	5019
f) Other current assets	18	3321	2510
Total		632902	444136

As Per Our Report of Even Dated Annexed

Saherwala & Co.

FRN 108969W

For MAITREYA MEDICARE LIMITED

(ESMAYEEL O. SAHERWALA)
Chartered Accountant
M. NO. 122386
29th May 2026, Surat.
UDIN :

VIMAL PATEL
DIN- 08458999
Wholetime Director

NARENDRA TANWAR
DIN - 0008459007
MD AND CFO

MAITREYA MEDICARE LIMITED
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)
AUDITED PROFIT AND LOSS STATEMENT FOR THE PERIOD ENDED ON 31st March 2026
CIN No. - U24290GJ2019PTC107298
(Currency: Rs in '000')

Particulars	Note No.	As at 31st March 2026	As at 31st March 2025
I. Revenue from operations	19	442212	444132
II. Other Income	20	7321	4398
III. Total Income (I+II)		449533	448530
IV, Expenses:			
Consumption of Stores and Pharmacy	21	47311	28680
Purchase of stock-in-Trade	22	47356	58629
Changes in inventories of finished goods, work-in-progress and stock-in-Trade	23	56	-103
Employee benefit expense	24	50917	52188
Financial Costs	25	12792	7544
Depreciation and amortization expense	26	13809	13459
Other expense	27	289523	255909
Total Expense		461765	416306
V.Profit Before exceptional and extradinary items and tax	(III-IV)	-12232	32224
VI. Exceptional Items			
Adjustment of GST Liability			
Reversal of Previous Year Income Tax		-634	
Rectification of Previous Year Mutual Fund Value			
Rectification of Depreciation			
Prior Period Adjustment		1179	
Operating lease Prior Period Adjustment			
VII. Profit Before extraorinary items and tax (V-VI)		-12777	32224
VIII. Extraordinary Items			
IX. Profit before tax (VII-VIII)		-12777	32224
X. Tax expense:			
(1) Current Tax	28		8075
(2) Deferred Tax	29	471	113
(3) MAT Credit Entitlement			
(4) Income Tax Paid 2023-2024			5042
XI. Profit(Loss) from the period from continuing operations		-13248	18993
XII. Profit/(Loss) from discontinuing operations			
XIII. Tax expense of discontinuing operations			
XIV. Profit/(Loss) from discountinuing operations (XII- XIII)			
XV. Profit/Loss for the period (XI+XIV)		-13248	18993
XVI. Earning per equity share:	30		
Basic		(1.96)	2.80
Diluted		(1.96)	2.80

As Per Our Report of Even Dated Annexed
Saherwala & Co.
FRN 108969W

For MAITREYA MEDICARE LIMITED

(ESMAYEEL O. SAHERWALA)
Chartered Accountant
M. NO. 122386
29th May 2026, Surat.
UDIN :

VIMAL PATEL
DIN- 08458999
Wholetime Director

NARENDRA TANWAR
DIN - 0008459007
MD AND CFO

MAITREYA MEDICARE LIMITED
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)
AUDITED CASH FLOW STATEMENT
CIN No. - U24290GJ2019PTC107298
(Currency: Rs in '000')

PARTICULARS		As at 31st March 2026		As at 31st March 2025	
A. Cash Flow from Operating Activities:					
Profit Before exceptional and extradinary items and tax			**-12232**		**32224**
Adjustments for :					
Depreciation		13809		13459	
Interest Income		-2387		-695	
Gratuity				1677	
Interest & Finance Charges Paid		12792		7544	
Profit on sale of Investment				-225	
Prior Period Adjustment - gst		-725			
Reversal of Previous Year Income Tax		634			
Profit on sale of Fixed Assets		-20			
			24104		21761
Operating Profit before Working Capital Changes			11872		53985
Adjustments for :					
Increase / Decrease in Inventories		-2942		-113	
Increase / Decrease in Short-term loans and advances		1225		-3478	
Increase / Decrease in Trade Receivables		35695		-21142	
Increase / Decrease in Trade Payables		4928		4312	
Increase / Decrease in other Current Assets		-811		3312	
Increase / Decrease in Other Non Current Assets		1864		4174	
Increase/Decrease in Provision		-8075		-3918	
Increase/Decrease in short term Borrowings		-3957		2143	
Increase/Decrease in other current liabilities		16211	44137	25559	10849
Cash Generated from Operations			56009		64834
Direct Taxes Paid (Net)		1203.17	1203	14547	14547
Net Cash inflow in Operating Activities		**Total A**	**54806**	**Total A**	**50287**
B. Cash Flow from Investing Activities:					
Purchases of Fixed assets		-225197		-23741	
Purchase of Investment		-100		-44206	
Capital Government Grant of Fixed Assets					
Loans given to Associates and Subsidiaries		-1471		-9073	
Repayment of Loans given to Associates and Subsidiaries					
Interest Income		2387		695	
Gain on Sale of Fixed Assets					
Sale of Fixed Assets		131			
Gain on Sale of Investment					

Sale of Investment		100	-224150	4300	-72026
Net Cash used in Investing Activities		Total B	**-224150**	Total B	**-72026**
C. Cash Flow from Financing Activities:					
Issue of Equity Capital					
Share Premium					
Dividend					
Issue of Preference Shares					
Redemption of Preference shares		-5400		-800	
Repayment of Borrowing		197383		-7441	
Interest & Finance Charges Paid		-12792	179191	-7544	-15785
Net Cash from Financing Activities		Total C	**179191**	Total C	**-15785**
Net increase /(decrease) in cash and cash equivalents (A+B+C)		Total (A+B+C)	**9847**	Total (A+B+C)	**-37524**
Opening Cash and Cash equivalents			19090		56614
Closing Cash and Cash equivalents			**28937**		**19090**

Notes :

(i) Figures in brackets represent outflow.

(ii) The above Cash Flow statement has been prepared under the indirect method set out in AS-3 notified under Section 133 of the Companies Act,2013

(iii) Cash and Cash Equivalents represent cash and bank balances.

For MAITREYA MEDICARE LIMITED

As Per Our Report of Even Dated Annexed
Saherwala & Co.
FRN 108969W

(ESMAYEEL O. SAHERWALA)
Chartered Accountant
M. NO. 122386
29th May 2026, Surat.
UDIN :

VIMAL PATEL
DIN- 08458999
Wholetime Director

NARENDRA TANWAR
DIN - 0008459007
MD AND CFO

MAITREYA MEDICARE LIMITED
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)
CIN No. - U24290GJ2019PTC107298
Notes to the financial statements as March 31,2026
(Currency: Rs in '000')

Note No. 1
Share Capital

Particulars	As at 31st March 2026	As at 31st March 2025
Authorized Share capital;		
7750000 Equity shares of Rs. 10/- each	77500.00	77500.00
(Previous year 7750000 equity shares of Rs. 10 each)		
(5750000) 6% Preferrence Shares of Rs. 10/- each.	57500.00	57500.00
(Previous year 5750000 equity shares of Rs. 10 each)		
Issued & Subscibed & fully paid up capital; Annexure - I		
EQUITY SHARES	67760.00	67760.00
(6776000) Equity Shares of Rs. 10/- each.		
(Previous year 6776000 equity shares of Rs. 10 each fully paid up)		
REDEEMABLE NON COVERTIBLE NON CUMULATIVE PREFERENCE SHARES	47763.00	53163.00
(4776300) 6% Preference Shares of Rs. 10/- each.		
(Previous year 5316300 6% Preference Shares of Rs. 10/- each.		
TOTAL	**115523.00**	**120923.00**

Note No. 1.1 Terms attached to Equity Shares

The Company has only one class of equity shares referred to as equity shares having a par value of Rs. 10/- each. Each holder of Equity Share is entitled to one vote per share. In the event of liquidation of the company, the holders of equity shares will be entitled to receive the remaining assets of the company in proportion to the number of equity shares held.

Note No. 1.2 Terms attached to Preference Shares

The Company has only one class of preference shares referred to as Redeemable Non Convertible Non Cumulative Preference shares having a par value of Rs. 10/- each.

Preference shares issued by the Company shall be redeemable at any time in one or more tranches at the dicretion of the Company or share holder after allotment of shares but not later than 10 years from the date of allotment of the preference shares.

Dividend on Preference shares issued by the Company shall be 6% p.a. on face value which will remain fixed over the tenure of preference shares and shall have priority with respect to payment of dividend or repayment of capital over equity shares.

Note No. 1.2 Reconciliation of Number of Equity Shares

Particulars	As at 31st March 2026		As at 31st March 2025	
	Number	Amount(Rs)	Number	Amount(Rs)
Shares outstanding at the beginning of the year	6,776,000	67760.00	6,776,000	67760.00
Shares issued during the Year	0	.00	0	.00
Shares outstanding at the end of the year	6,776,000	67760.00	6,776,000	67760.00

Note No. 1.3 Reconciliation of Number of Preference Shares

Particulars	As at 31st March 2026		As at 31st March 2025	
	Number	Amount(Rs)	Number	Amount(Rs)
Shares outstanding at the beginning of the year	5,316,300	53163.00	5,396,300	53963.00
Shares issued during the Year	0	.00	0	.00
Shares Redemption During the year	540,000	5400.00	80,000	800.00
Shares outstanding at the end of the year An	4,776,300	47763.00	5,316,300	53163.00

Note No. 1.4 Details of shares held by each shareholder holding more than 5%

Name of Shareholder	As at 31st March 2026		
	No. of Equity Share held	Percentage	Amount (Rs.)
Narendra Singh Prem Singh Tanwar	3,185,808	64.307%	31858.08
Vimalkumar Natverlal Patel	706,800	14.267%	7068.00
Pranav Rohitbhai Thaker	1,061,440	21.426%	10614.40
Total	**4,954,048**	**100.000%**	**49540.48**

Note No. 1.4 Details of shares held by each shareholder holding more than 5%

Name of Shareholder	As at 31st March 2025		
	No. of Equity Share held	Percentage	Amount (Rs.)
Narendra Singh Prem Singh Tanwar	3,185,808	64.307%	31858.08
Vimalkumar Natverlal Patel	706,800	14.267%	7068.00
Pranav Rohitbhai Thaker	1,061,440	21.426%	10614.40
Total	**4,954,048**	**100.000%**	**49540.48**

Note No. 1.5 Shares held by promotors at 31st March,2026 is set out below:-

Name of Shareholder	No. of Shares	% of Total Shares	% change during the year
Narendra Singh Prem Singh Tanwar	3,185,808	64.307%	0%
Vimalkumar Natverlal Patel	706,800	14.267%	0%
Pranav Rohitbhai Thaker	1,061,440	21.426%	0%
Total	**4,954,048**	**100.00%**	**0.00%**

Note No. 1.6 Shares held by promotors at 31st March 2025 is set out below:-

Name of Shareholder	No. of Shares	% of Total Shares	% change during the year
Narendra Singh Prem Singh Tanwar	3,185,808	64.307%	0%
Vimalkumar Natverlal Patel	706,800	14.267%	0%
Pranav Rohitbhai Thaker	1,061,440	21.426%	0%
Total	**4,954,048**	**100.00%**	**0%**

Note No. 1.7

All share are ranking pari-passu in all respects.

Note No. 1.8

The company does not have reserved any shares for issue under options and contracts/ commitments for the sale of shares/ disinvestment, including the terms and amounts.

Note No. 1.9

As the company does not have issued any securities convertible into equity/preference shares hence the details regarding Terms of any securities convertible into equity/preference shares issued (along with the earliest date of conversion in descending order starting from the farthest such date) are not applicable.

Note No. 1.10

The company has not forfeited any shares at any time.

Note No. 1.11

Disclosure pursuant to unpaid Call

Unpaid Calls	Amount
By Directors	NIL
By Officers	NIL

Note No. 1.12

There is no Shares held by its holding company or its ultimate holding company including shares held by or by subsidiaries or associates of the holding company or the ultimate holding company in aggregate.

Note No. 2

Reserve & Surplus

Particulars	**As at 31st March 2026**	**As at 31st March 2025**
<u>Profit and Loss account:</u>		
Opening Balance	75895.14	61101.70
Add: Profit/(Loss) for the year	-13247.51	18993.43
Less: Capital redemption reserve	-5400.00	-4200.00
Less: Preference Share Dividend	.00	.00
Closing Balance	**57247.63**	**75895.14**
Other Reserves:		
Capital Redemption Reserves	14900.30	9500.30
Share Premium	114445.07	114445.07
TOTAL	**186593.00**	**199840.51**

Note No. 3

Long Term Borrowings

Particulars	**As at 31st March 2026**	**As at 31st March 2025**
Secured Loans		
(A) Term Loan From Banks:	186006.24	19594.39
Unsecured Loans		
(A) Loan & Advances from Related Party		
Maitreya Hospital Pvt Ltd (Subsidery)	30970.80	.00
TOTAL	**216977.04**	**19594.39**

Note No. 3.1

1) 10.65% Healtcare Equipments/Infra Loan A/c. No. 84007783 is repayable in 84 EMI of Rs. 441374/- with HDFC Bank is secured agaisnt hypothication of Fixed Deposit of Rs. 60,00,000/- with HDFC Bank,All the stock in trade both present and future consisiting of raw materials, finished goods, goods in process of manufacturing and any other goods, All the book debts, amounts outstanding, monies receivable, claims, bills, which are now due and owing or which may at any time, All the plant and machinery both present and future consisting of as mentioned in Deed of Hypothecation which is executed with the Bank by the Company. These all loans are also secured by personal gaurantee of the Directors of the Company.

2) 12.05% Healtcare Equipments/Infra Loan A/c. No. 84145456 is repayable in 84 EMI of Rs. 560439/- with HDFC Bank is secured agaisnt hypothication of Fixed Deposit of Rs. 60,00,000/- with HDFC Bank,All the stock in trade both present and future consisiting of raw materials, finished goods, goods in process of manufacturing and any other goods, All the book debts, amounts outstanding, monies receivable, claims, bills, which are now due and owing or which may at any time, All the plant and machinery both present and future consisting of as mentioned in Deed of Hypothecation which is executed with the Bank by the Company. These all loans are also secured by personal gaurantee of the Directors of the Company.

3) 11.30% Healtcare Equipments/Infra Loan A/c. No. 84702766 is repayable in 60 EMI of Rs. 402584/- with HDFC Bank is secured agaisnt hypothication of Fixed Deposit of Rs. 60,00,000/- with HDFC Bank,All the stock in trade both present and future consisiting of raw materials, finished goods, goods in process of manufacturing and any other goods, All the book debts, amounts outstanding, monies receivable, claims, bills, which are now due and owing or which may at any time, All the plant and machinery both present and future consisting of as mentioned in Deed of Hypothecation which is executed with the Bank by the Company. These all loans are also secured by personal gaurantee of the Directors of the Company.

4) 9.04% Healtcare Equipments/Infra Loan A/c. No. 732000016070 is repayable in 60 EMI of Rs. 124149/- with Indusind Bank is secured agaisnt hypothication of All the stock in trade both present and future consisiting of raw materials, finished goods, goods in process of manufacturing and any other goods, All the book debts, amounts outstanding, monies receivable, claims, bills, which are now due and owing or which may at any time, All the plant and machinery both present and future consisting of as mentioned in Deed of Hypothecation which is executed with the Bank by the Company. These all loans are also secured by personal gaurantee of the Directors of the Company.

5) 8.80% Healtcare Equipments/Infra Loan A/c. No. 0871TL0100000759 is repayable in 60 EMI of Rs. 88342/- with Kotak Mahindra Bank Limited is secured agaisnt hypothication of All the stock in trade both present and future consisiting of raw materials, finished goods, goods in process of manufacturing and any other goods, All the book debts, amounts outstanding, monies receivable, claims, bills, which are now due and owing or which may at any time, All the plant and machinery both present and future consisting of as mentioned in Deed of Hypothecation which is executed with the Bank by the Company. These all loans are also secured by personal gaurantee of the Directors of the Company.

6) 8.00 % Healthcare Project Finance Loan A/c. No. 802707696 is repayable in 177 EMI of Rs. 1699067/- with HDFC Bank Limited is secured agaisnt hypothication of immovable Property owned by Company as mentioned in Deed of Hypothecation which is executed with the Bank by the Company. These all loans are also secured by personal gaurantee of the Directors of the Company.

6) 7.75% HEALTH CARE INFRA FINANCE Loan A/c. No. 802841943 is repayable in 180 EMI of Rs. 27925/- with HDFC Bank Limited is secured agaisnt hypothication of All the stock in trade both present and future consisiting of raw materials, finished goods, goods in process of manufacturing and any other goods, All the book debts, amounts outstanding, monies receivable, claims, bills, which are now due and owing or which may at any time, All the plant and machinery both present and future consisting of as mentioned in Deed of Hypothecation which is executed with the Bank by the Company. These all loans are also secured by personal gaurantee of the Directors of the Company.

Note No. 4

Deffered Tax Liability

Particulars	As at 31st March 2026	As at 31st March 2025
Deferred Tax Liability	7877.94	6953.09
TOTAL	**7877.94**	**6953.09**

Note No. 4.1

As required by the Accounting Standard AS 22 Accounting for Taxes on Income issued by Institute of Chartered Accountants of India, the relevant details are as under.

i) The opening balance of DTL is Rs. 6953.09 and the balance amount Rs. 470.66 is created for the year ended 31-03-2026.

ii) During the year DTL of Rs. 470.66 is created due to originating of Timing difference between accounting and Tax Depreciation, and Rs. 454.18 was also created through rectification of mistake of earlier year which shown in profit and loss account separetly under the prior period adjustment.
ii) Net deferred Tax liability as on 31-03-2026 works out to Rs. 7877.94

The DTL of Rs. 7877.94 comprises DTL of Rs. 7877.94 on account of difference between accounting and tax depreciation

Note No. 5

Short Term Borrowings

Particulars	As at 31st March 2026	As at 31st March 2025
Secured Loans		
(A) Equipments and Infrastructure Loan	11786.40	15743.74
Total	**11786.40**	**15743.74**

Note No. 5.1

1) 9.40% Healtcare Equipments/Infra Loan A/c. No. 84007783 is repayable in 84 EMI of Rs. 441374/- with HDFC Bank is secured agaisnt hypothication of Fixed Deposit of Rs. 60,00,000/- with HDFC Bank,All the stock in trade both present and future consisiting of raw materials, finished goods, goods in process of manufacturing and any other goods, All the book debts, amounts outstanding, monies receivable, claims, bills, which are now due and owing or which may at any time, All the plant and machinery both present and future consisting of as mentioned in Deed of Hypothecation which is executed with the Bank by the Company. These all loans are also secured by personal gaurantee of the Directors of the Company.

2) 11.80% Healtcare Equipments/Infra Loan A/c. No. 84145456 is repayable in 84 EMI of Rs. 560439/- with HDFC Bank is secured agaisnt hypothication of Fixed Deposit of Rs. 60,00,000/- with HDFC Bank,All the stock in trade both present and future consisiting of raw materials, finished goods, goods in process of manufacturing and any other goods, All the book debts, amounts outstanding, monies receivable, claims, bills, which are now due and owing or which may at any time, All the plant and machinery both present and future consisting of as mentioned in Deed of Hypothecation which is executed with the Bank by the Company. These all loans are also secured by personal gaurantee of the Directors of the Company.

3) 11.05% Healtcare Equipments/Infra Loan A/c. No. 84702766 is repayable in 60 EMI of Rs. 402584/- with HDFC Bank is secured agaisnt hypothication of Fixed Deposit of Rs. 60,00,000/- with HDFC Bank,All the stock in trade both present and future consisiting of raw materials, finished goods, goods in process of manufacturing and any other goods, All the book debts, amounts outstanding, monies receivable, claims, bills, which are now due and owing or which may at any time, All the plant and machinery both present and future consisting of as mentioned in Deed of Hypothecation which is executed with the Bank by the Company. These all loans are also secured by personal gaurantee of the Directors of the Company.

4) 9.04% Healtcare Equipments/Infra Loan A/c. No. 732000016070 is repayable in 60 EMI of Rs. 124149/- with Indusind Bank is secured agaisnt hypothication of All the stock in trade both present and future consisiting of raw materials, finished goods, goods in process of manufacturing and any other goods, All the book debts, amounts outstanding, monies receivable, claims, bills, which are now due and owing or which may at any time, All the plant and machinery both present and future consisting of as mentioned in Deed of Hypothecation which is executed with the Bank by the Company. These all loans are also secured by personal gaurantee of the Directors of the Company.

5) 8.80% Healtcare Equipments/Infra Loan A/c. No. 0871TL0100000759 is repayable in 60 EMI of Rs. 88342/- with Kotak Mahindra Bank Limited is secured agaisnt hypothication of All the stock in trade both present and future consisiting of raw materials, finished goods, goods in process of manufacturing and any other goods, All the book debts, amounts outstanding, monies receivable, claims, bills, which are now due and owing or which may at any time, All the plant and machinery both present and future consisting of as mentioned in Deed of Hypothecation which is executed with the Bank by the Company. These all loans are also secured by personal gaurantee of the Directors of the Company.

Note No. 6
Trade payables

Particulars	As at 31st March 2026	As at 31st March 2025
Unsecured, Considered Good		
Sundry Creditors for Doctor		
Annexure - III	4654.14	3564.66
Sundry Creditors for Purchase		
Annexure - IV	28086.814	24248.48
TOTAL	**32740.95**	**27813.14**

Note No. 6.1

Particulars	As at 31st March 2026	As at 31st March 2025
Micro, Small and Medium Enterprises	4696.15	2876.46
Others	28044.81	24936.68
Total	**32740.95**	**27813.14**

Note No. 6.2
Dues of small enterprises and micro enterprises

Particulars	As at 31st March 2026	As at 31st March 2025
(a) Dues remaining unpaid to any supplier at the end of each accounting year		
- Principal	4696.15	2876.46
- Interest on the above	.00	.00
(b) the amount of interest paid by the buyer in terms of section 16 of the Micro, Small and Medium Enterprises Development Act, 2006, along with the amount of the payment made to the supplier beyond the appointed day during each accounting year;	.00	.00
(c) the amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the Micro, Small and Medium Enterprises Development Act, 2006;	.00	.00
(d) the amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues above are actually paid to the small enterprise, for the purpose of disallowance of a deductible expenditure under section 23 of the Micro, Small and Medium Enterprises Development Act, 2006	.00	.00

Note No. 6.3

Ageing of Trade Payables	As at 31st March 2026				
Particulars	**Less than 1 year**	**1-2 years**	**2-3 years**	**More than 3 years**	**Total**
Undisputed Trade Payables					
MSME	4636.61	59.54	.00	.00	**4696.15**
Other Creditors	25858.29	2186.52	.00	.00	**28044.81**
Disputed Trade Payables					
MSME	.00	.00	.00	.00	**.00**
Other Creditors	.00	.00	.00	.00	**.00**
Total	**30494.90**	**2246.05**	**.00**	**.00**	**32740.95**

Note No. 6.3

Ageing of Trade Payables	As at 31st March 2025				
Particulars	**Less than 1 year**	**1-2 years**	**2-3 years**	**More than 3 years**	**Total**
Undisputed Trade Payables					
MSME	2876.46	.00	.00	.00	**2876.46**
Other Creditors	23036.44	1868.50	31.74	.00	**24936.68**
Disputed Trade Payables					
MSME	.00	.00	.00	.00	**.00**
Other Creditors	.00	.00	.00	.00	**.00**
Total	**25912.90**	**1868.50**	**31.74**	**.00**	**27813.14**

Note No. 7
Other Current Liabilites

Particulars	As at 31st March 2026	As at 31st March 2025
PF Payable	213.52	207.11
Professional Tax Payable	26.00	24.60
GST RCM Payable	190.30	.00
CGST	221.85	180.21
SGST	221.85	180.21
Tax Deducted At Sources for Contractor	85.10	31.14
Tax Deducted At Sources for Professional Fees Non Comp	1328.27	1205.32
Tds	175.97	169.54
IGST	40.49	76.89
Salary Payable	3945.73	3569.81
Retention		
Annexure - V	3072.18	2922.80
Book Overdraft HDFC Bank	51219.53	35953.95
Preference Share dividend payable earliyer years	663.32	671.54
TOTAL	**61404.13**	**45193.12**

1) 09.15% Book Overdraft A/c. No. 50200088059300 is repayable in on demand for the tenure of 60 months with annual renewal with HDFC Bank is secured agaisnt First and exclusive charge on the entire current assets including stocks and book debts, present and future, First and exclusive charge on entire immovable fixed assets of company including various medical equipment, CGTMSE guarantee, Personal Guarantee of Promoter Directors 1. Dr Pranav Thaker, 2. Dr. Narendra Tanwar and 3. Mr. Vimal Patel.

Note No. 8
Short Term Provisions

Particulars	As at 31st March 2026	As at 31st March 2025
Provision for Current Tax (FY 2024-2025)	.00	8075.47
TOTAL	**.00**	**8075.47**

MAITREYA MEDICARE LIMITED
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)
CIN No. - U24290GJ2019PTC107298
Notes to the financial statements as March 31,2026
(Currency: Rs in '000')

Note No. 9
Property, Plant and Equipment

Sr. No.	Particulars	Gross Block				Depreciaton				Net Block	
		Value at the beginning as on 01.04.2025	Addition during the year	Deduction during the year	Value at the end as on 31.03.2026	Value at the beginning as on 01.04.2025	Addition during the year	Deduction during the year	Value at the end as on 31.03.2026	WDV as on 31.03.2026	WDV as on 31.03.2025
I	**Property**										
*	BUILDINGS	18456.01	212093.27	.00	230549.27	5369.42	1116.84	.00	6486.26	224063.01	13086.58
II	**Tangible Assets**										
	Plant and Machinery										
*	PLANT AND MACHINERY	137141.21	11569.73		148710.94	44343.38	10141.48		54484.85	94226.09	92797.83
*	ELECTRICAL INSTALLATIONS AND EQUIPMENT	2363.38	960.53	.00	3323.91	1153.58	224.52	.00	1378.10	1945.81	1209.80
	Office Equipments										
	COMPUTERS AND DATA PROCESSING UNITS	4352.92	.00	.00	4352.92	3495.81	303.92	.00	3799.73	553.18	857.11
*	OFFICE EQUIPMENT	6820.52	.00	.00	6820.52	6166.26	200.24	.00	6366.50	454.01	654.25
	Furniture & Fixtures										
*	FURNITURE AND FITTINGS	9574.17	573.13	131.00	10016.30	2380.57	947.94	19.67	3308.84	6707.46	7193.60
	Vehicles:										
*	MOTOR VEHICLES	4870.42	.00	.00	4870.42	2457.35	578.61	.00	3035.96	1834.46	2413.07
	SUB TOTAL (A)	**183578.62**	**225196.66**	**131.00**	**408644.28**	**65366.37**	**13513.55**	**19.67**	**78860.25**	**329784.03**	**118212.25**
II	**Intangible Assets**										
*	INTANGIBLE ASSETS	1695.46	.00	.00	1695.46	250.58	295.92	.00	546.50	1148.96	1444.88
	SUB TOTAL (B)	**1695.46**	**.00**	**.00**	**1695.46**	**250.58**	**295.92**	**.00**	**546.50**	**1148.96**	**1444.88**
III	**Intangible Assets Under Development**	.00	.00	.00	.00	.00		.00	.00	.00	.00
	SUB TOTAL (C)	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00
	Total [A + B + C] (Current Year)	**185274.08**	**225196.66**	**131.00**	**410339.74**	**65616.95**	**13809.48**	**19.67**	**79406.75**	**330932.99**	**119657.14**
	(Previous Year)	**161533.05**	**24066.04**	**325.00**	**185274.08**	**52157.63**	**13459.32**	**.00**	**65616.95**	**119657.14**	**109375.42**

MAITREYA MEDICARE LIMITED
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)
CIN No. - U24290GJ2019PTC107298
Notes to the financial statements as March 31,2026
(Currency: Rs in '000')

Note No.10
Non Current Investments

Particulars	As at 31st March 2026	As at 31st March 2025
Quoted Investment	.00	.00
Unquoted Investment:		
7510000 Equity Shares (Previous Year 10000) of Maitreya Hospital Private Limited having face value of Rs. 10 each.	75100	75100
10000 Equity Shares (Previous Year 10000) of Maitreya Lifescience Private Limited having face value of Rs. 10 each.	100	100
1000 Equity Shares (Previous Year 451000) OHM MRI PVT LTD having face value of Rs. 10 each.	10	10
Share Application Money for 752000 Equity Shares (Previous Year 235000) of Maitreya Hospital Private Limited having face value of Rs. 10 each out of which pending for allotment.		100.00
52000 Equity Shares (Previous year 52000) of Tulip Agility Private Limited having face value of Rs. 10 each.	520.00	520.00
TOTAL	**75730**	**75830**
Aggregate amount of quoted investments		
Aggregate market value thereof		
Aggregate amount of unquoted investments	**75730**	**75830**
Aggregate provision for diminution in value of investments		

Note No.10.1

Maitreya Hospital Private Limited shares are not tradeable or listed therefore market value can not be deternined and therefore not reported herein.

Maitreya Lifeschience Private Limited. Shares are not tradeable or listed therefore market value can not be deternined and therefore not reported herein.

OHM MRI Private Limited. Shares are not tradeable or listed therefore market value can not be deternined and therefore not reported herein.

Maitreya Hospital Private Limited has not issued shares agaisnt the share application money and that are not tradeable or listed therefore market value can not be deternined and therefore not reported herein.

Tulip Agility Private Limited. Shares are not tradeable or listed therefore market value can not be deternined and therefore not reported herein.

Note No.11
Long term loans and advances

Particulars	As at 31st March 2026	As at 31st March 2025
Loans to others:		
Unsecured and Considered Good		
Tax Deducted At Source On Income	20638.10	19434.93
Loan to Related parties		
Unsecured and Considered Good	34274.10	32803.30
TOTAL	**54912.20**	**52238.23**

Note No 11.1

Company has granted loan to Subsidiary and Related party entity for which no terms have been agreed regarding tenure/ repayment shedule of the loan as well as interest rate on it.

Note No. 12
Other Non Current Assets

Particulars	As at 31st March 2026	As at 31st March 2025
Rent Deposit (including machinery rent deposit)	6000.00	6000.00
Fixed Deposit with HDFC Bank 50300678347925 (Lien Machine/Infra Loan)	.00	4597.38
Deposit	11.00	11.00
Telephone Deposit	10.00	10.00
Sidni Earth Protectors(Deposit)	12.00	.00
NSE Deposit	.00	1489.12
NSDL Deposit	8.00	18.00
Gratuity Planed Assets	4817.63	596.71
Total	**10858.63**	**12722.21**

Fixed Deposit with HDFC Bank is under lien against the Loan for Equipment and Infrastructure loans taken from HDFC Bank
Fixed Deposit with HDFC Bank reported above is Principal Amount of Fixed deposit and it also includes accrued interest on it up to 31.03.2025

In the Opinion of the Board of Directors Current Assets, Loans and Advances (including capital Advances) have a value on realisation in the ordinary course of business, at least equal to the amount which they are stated herein Balance Sheet.

Note No. 13
Current Investments

Particulars	As at 31st March 2026	As at 31st March 2025
Quoted Investment;		
	.00	**.00**
Unquoted Investment;		
Axis Ultra Short Term Mutual Fund	134.12	134.12
ICICI Prudential Ultra Short Term Fund	288.03	288.03
Bandhan Small Cap Fund	25.00	.00
Motilal Oswal Nifty Microcap 250 Index Fund	25.00	.00
HDFC Diversified Equity All Cap Active FOF	25.00	.00
ICICI Prudential Thematic Advantage Fund (FOF)	25.00	.00
Total	**522.15**	**422.15**
Aggregate amount of quoted investments	**.00**	**.00**
Aggregate market value thereof	**.00**	**.00**
Aggregate amount of unquoted investments	**522.15**	**422.15**
Aggregate provision for diminution in value of investments	**.00**	**.00**

Company is holding 10060.196 (Previous year 10060.196) unit of Axis Ultra Short Term Mutual Fund, NAV of the same as on 31.03.2026 is Rs. 15.3373 (Previous Year 14.4696) accordingly it market value as on 31.03.2026 is Rs. 154.296 (Previous Year 145.567)

Company is holding 11557.3620 (Previous year 11557.3620) unit of ICICI Prudential Ultra short Term Fund, NAV of the same as on 31.03.2026 is Rs. 28.9546 (Previous Year 27.1758) accordingly it market value as on 31.03.2026 is Rs. 334.638 (Previous Year 314.081)

Company is holding 527.6670 unit of Bandhan Small Cap Fund Growth, NAV of the same as on 31.03.2026 is Rs.40.5640 accordingly it market value as on 31.03.2026 is Rs. 21.404

Company is holding 2417.44 unit of HDFC Diversified Equity All Cap Active FOF Growth, NAV of the same as on 31.03.2026 is Rs.8.9549 accordingly it market value as on 31.03.2026 is Rs. 21.647

Company is holding 107.281 unit of ICICI Prudential Aggressive Hybrid Active FOF, NAV of the same as on 31.03.2026 is Rs.203.4921 accordingly it market value as on 31.03.2026 is Rs. 21.831

Company is holding 1475.444 unit of Motilal Oswal Nifty Microcap 250 Index Fund Growth, NAV of the same as on 31.03.2026 is Rs.13.5647 accordingly it market value as on 31.03.2026 is Rs. 20.014

Note No. 14

Inventories

Particulars		As at 31st March 2026	As at 31st March 2025
Closing Stock Pharmacy		4625.72	4681.94
Closing Stock Store		3114.14	115.75
Total		**7739.86**	**4797.70**

Note No. 15

Trade receivables

Particulars		As at 31st March 2026	As at 31st March 2025
Unsecured, Considered Good			
Centre Debtors	**Annexure - VI**	350.16	11122.52
IPD Debtors	**Annexure - VII**	88921.45	113076.49
Pharmacy Debtors	**Annexure - VIII**	23605.90	24010.00
OPD Debtors		3268.53	3313.81
Sponsorship Debtor		9.00	327.00
Total		**116155.05**	**151849.82**

MAITREYA MEDICARE LIMITED
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)
CIN No. - U24290GJ2019PTC107298
Notes to the financial statements as March 31,2026
(Currency: Rs in '000')

Note No. 15.1

Ageing of Trade Receivables	As on 31st March 2026						
Particulars	Not due	Outstanding for following periods from due date of Payments					
		Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	Total
Undisputed Trade Receivables							
Considered good	-	56815	25333	6460	8988	18560	**116155**
	-		-	-	-	-	
Disputed Trade Receivables							
Considered good	-	-	-	-	-	-	
	-	-	-	-	-	-	
Gross Total	**-**	56815	25333	6460	8988	18560	**116155**
Less : Impairment for doubtful receivables	-	-	-	-	-	-	-
Net Total	**-**	**56815**	25333	6460	8988	18560	**116155**

Ageing of Trade Receivables	As on 31st March 2025						
Particulars	Not due	Outstanding for following periods from due date of Payments					
		Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	Total
Undisputed Trade Receivables							
Considered good	-	76927	15212	41624	13660	4426	**151850**
	-	-	-	-	-	-	
Disputed Trade Receivables							
Considered good	-	-	-	-	-	-	
	-	-	-	-	-	-	
Gross Total	**-**	76927	15212	41624	13660	4426	**151850**
Less : Impairment for doubtful receivables	-	-	-	-	-	-	
Net Total	**-**	**76927**	**15212**	**41624**	**13660**	**4426**	**151850**

MAITREYA MEDICARE LIMITED
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)
CIN No. - U24290GJ2019PTC107298
Notes to the financial statements as March 31,2026
(Currency: Rs in '000')
Note No.16
Cash and Bank Balances

Particulars	As at 31st March 2026	As at 31st March 2025
Cash and Cash Equivalents		
a) Cash-in-Hand		
Cash in Hand	761.29	620.20
	761.29	620.20
Bank Balance with Scheduled Bank		
a) Current Account		
HDFC Bank	6883.09	4351.80
b) Other Bank Balance		
Fixed Deposit with HDFC Bank 50300383852597 (Lien Machine/Infra Loan)	5609.37	5294.14
Fixed Deposit with HDFC Bank 50300426670211	1356.18	1277.86
Fixed Deposit with HDFC Bank 50300522850081 (Lien ESIC Deposit)	644.41	609.04
Fixed Deposit with HDFC Bank 50300962911096 (Lien MA Yojana)	2958.37	2788.96
Fixed Deposit with HDFC Bank 50301304559541	1507.86	.00
Fixed Deposit with HDFC Bank 50301324437709	4356.13	.00
Fixed Deposit with HDFC Bank 50301129146043	.00	4142.73
Fixed Deposit with HDFC Bank 50300948262845	.00	.00
Fixed Deposit with HDFC Bank 50300966788542 (Lien MA Yojana)	5.60	5.28
Fixed Deposit with HDFC Bank 50300678347925 (Lien Machine/Infra Loan)	4854.76	.00
	28175.78	18469.81
Total cash and cash equivalents (as per AS 3 Cash flow statement)(A)	28937.07	19090.00
TOTAL	**28937.07**	**19090.00**

Fixed Deposit with HDFC Bank 50300383852597 is under lien against the Loan for Equipment and Infrastructure loans taken from HDFC Bank.

Fixed Deposit with HDFC Bank 50300522850081 is under lien against the Bank Guarantee issued by HDFC Bank to Nodal Office of ESIC.

Fixed Deposit with HDFC Bank 50300962911096 is under lien against the Bank Guarantee issued by HDFC Bank to State Nodal Office of MA & PMJAY Yojana.

Fixed Deposit with HDFC Bank 50300966788542 is under lien against the Bank Guarantee issued by HDFC Bank to State Nodal Office of MA & PMJAY Yojana.

Fixed Deposit with HDFC Bank 50300678347925 is under lien against the Loan for Equipment and Infrastructure loans taken from HDFC Bank.

Fixed Deposit with HDFC Bank reported above is Principal Amount of Fixed deposit and it also includes accrued interest on it up to 31.03.2026

Note No. 17
Short Term Loans & Advances

Particulars		As at 31st March 2026	As at 31st March 2025
Unsecured, consider good(unless otherwise stated):			
Loan to Related Parties		.00	.00
Loan to Other		.00	.00
Advances to Related Parties		.00	.00
Advances to Other		.00	.00
Advances to Sundry Creditors	**Annexure - IX**	2821.22	3243.18
Advacnes to Staff	**Annexure - X**	972.63	1776.15
TOTAL		**3793.85**	**5019.33**

Note No. 18
Other Current Assets

Particulars	As at 31st March 2026	As at 31st March 2025
Prepaid Charges	3320.67	2509.88
Total	**3320.67**	**2509.88**

MAITREYA MEDICARE LIMITED
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)
CIN No. - U24290GJ2019PTC107298
Notes to the financial statements as March 31,2026

Note No. 19
Revenue From Operation (Currency: Rs in '000')

Particulars	As at 31st March 2026	As at 31st March 2025
Centre Income	23432.53	27676.85
IPD Income	293228.17	279585.12
OPD Income	20686.22	15498.41
Sale of Pharmacy Income	104864.94	121372.02
TOTAL	**442211.86**	**444132.40**

Note No. 19.1
Revenue from Operation of the Company are exclusive of any Duty, GST, VAT or other refund/ Tax

Note No. 20
Other Income

Particulars	As at 31st March 2026	As at 31st March 2025
Interest on Fixed Deposit	1198.33	1095.52
Gratuity Exess Provision Writen back	3120.92	.00
Profit on Sale of Fixed Assets	19.67	.00
Notice Pay	50.48	73.63
Profit on Sale of Investment	.00	225.09
Business Development Fees	600.00	175.00
Sundry Balance Write Off	.00	372.91
Sponsorship Income	1143.22	2014.83
Interest Income	578.52	401.00
Vatav Kasar	.00	40.01
Interest on Income Tax Refund	609.77	.00
TOTAL	**7320.92**	**4398.00**

Note No. 21
Consumption of Stores and Pharmacy

Particulars	As at 31st March 2026	As at 31st March 2025
Consumption of Stores:		
Opening Stock	115.75	106.31
Purchase Store	38126.01	6273.35
Closing Stock	3114.14	115.75
Total Consumption of Stores	35127.63	6263.91
Consumption of Pharmacy	12183.52	22416.15
TOTAL	**47311.15**	**28680.06**

Note No. 22
Purchase of stock-in-Trade

Particulars	As at 31st March 2026	As at 31st March 2025
Purchase Pharmacy	59539.79	81045.22
Less : Consumption of Pharmacy	12183.52	22416.15
TOTAL	**47356.27**	**58629.06**

Note No. 23

Changes in stock-in-Trade

Particulars	As at 31st March 2026	As at 31st March 2025
Opening Stock		
Opening Stock Pharmacy	4681.94	4578.78
Less: Closing Stock		
Closing Stock Pharmacy	4625.72	4681.94
Increase/Decrease	56.22	-103.16
TOTAL	**56.22**	**-103.16**

Note No.24

Employee benefit expense

Particulars	As at 31st March 2026	As at 31st March 2025
Bonus	.00	1068.18
EDLI	97.53	103.94
Gratuity Expenses	.00	1676.59
Employer Contribution to PF	1189.24	1145.39
Overtime Expenses	1267.78	916.29
Salary	48143.43	46878.90
Staffwelfare Expenses	160.38	186.21
Employer Contribution to ESIC	58.86	.00
Stipend Expenses	.00	212.13
TOTAL	**50917.22**	**52187.62**

Note No.25

Finance Cost

Particulars	As at 31st March 2026	As at 31st March 2025
Bank Charges	203.22	351.97
Bank Charges Credit Card	287.27	260.46
Bank Charges Credit Card (Pharmacy)	51.76	56.50
Loan Stamp Duty / Franking	1528.60	151.80
Loan Interest	6192.33	3805.44
Loan Interest Overdraft	4028.06	2561.09
Overdraft Expense	162.49	.00
Processing Fees	336.00	357.13
Interest on Tds	1.80	.00
TOTAL	**12791.52**	**7544.39**

Note No.26

Depreciation and amortization expense

Particulars	As at 31st March 2026	As at 31st March 2025
ACT Machine	24.56	24.56
AIR CONDITIONER	155.66	693.20
AMBULANCE FABRICATION	37.95	37.95
ARTIS ONE CARD CATHLAB	1490.87	1490.87
ARTIS ZEE FLOOR COMBO CATHLAB	2010.25	2010.25
ATTENDENCE MACHINE	.00	3.41
BOLERO AMBULANCE	91.86	91.86
BORWELL	2.53	2.53
CAPEX	1114.30	1083.14
Cardiac Probe	38.93	38.93
CARL ZEISS VARIO MICROSCOPE	255.85	255850
CIAZ BS VI DELTA	112.08	111061.82
COLOUR DOPPLER MACHINE [ULTRASOUND]	83.48	83.48
COMPUTER EQUIPMENT	84.69	63216.35
DATASCOPE CS 100 IABP MACHINE	54.83	54.83
DG SET [GENERATOR]	122.55	122.55
DRAGER EVITA XL VENTILATOR	444.96	444.96
ECG ANALYSIS SOFTWARE	12.83	12.83
ECG RECODER MACHINE	35.79	35.79
ECHO MACHINE	51.10	43.50
EECO AMBULANCE	77.68	77.68
ELECTRIC OWN	.78	100.03
ELECTRICAL FITTING	100.03	.78
ERTIGA MOTOR CAR	135.25	135.25
ETO STERILIZER MACHINE	25.13	25.13
FAN	4.25	38.12
FIRE SYSTEM	14.57	51.19
FORCE AMBULANCE	160.48	160.48
FURNITURE	947.94	858.32
FURNITURE FIXTURE	.00	.45
GE Healthcare Innova 2100 Angiography System (Cath)	957.90	543248.76
Gear Less Motor	2.54	0
HMS SOFTWARE	7.09	7.09
HOSPITAL EQUIPMENT	924.96	845.64
IABP Machine	53.22	17.79
IND. WATER HEATING MACHINE	1.17	1.17
LG REFRIGATOR	.00	8.68
LOGO	6.93	6.93
MACHINERY EQUIPMENT	233.18	214.24
MACQUET ECMO PUMP	84.07	84.07
MEDIAN INFUSION PUMP IP100	8.19	8.19
Medical Equipment	1326.76	1245.47
MEDION ASTEROS 9000	5.85	5.85
MEDRED MARK V PROVIS CATHLAB DYE INJECTOR	29.24	29.24
MEDTRONICS PACEMAKER	10.80	10.80
MIS MEDICAL EQUIPMENT	91.79	91.79
NETWORKING EQUIPMENT	219.24	382.88
OXYGEN PLANT	662.90	662.90
PHILLIPS ETCO2 MAINSTREAM CABLE CMOP	11.40	11.40
PHILLIPS HEARTSTART XL DEFIB-9018	35.09	35.09
PHILLIPS MP 70 MULTIPARA MONITER	156.89	156.89
RO SYSTEM	.00	17.30
SARNS STERNAL SAW5590	18.28	18.28
SARNS SYSTEM 1HLM	219.30	219.30
SCHILLER SPANDAN PC BASED CARDIAC WORK STATION	15.56	15.56
SECURITY SOFTWARE	3.50	3.50
SOFTWARE	272.31	102.00
SURGICAL DRILL	11.70	11.70
SYRINGE INFUSION PUMP 101P	69.45	69.45
TALLY SOFTWARE	6.10	6.10
TELEVISION	25.77	102.18
ULTRASOUND MACHINE RS ACUSON S2000	277.78	277.78
VEHICLE EQUIPMENT	1.25	1.25
Vela Vantilator	350.88	81.71
WARMTOUCH PATENT WARMING SYSTEM	11.70	11.70
Mobile	5.55	.00
TOTAL	**13809.48**	**13459.32**

Notes No. 27

Other expenses

Particulars	As at 31st March 2026	As at 31st March 2025
Administrative Expenses	10.20	258.15
Advertisement Exp	303.66	285.12
AMC Charges	2932.82	2639.50
Audit Fees	870.90	570.00
Listing Annual Fees	488.62	.00
CGTMSE Fee	1450.70	57.98
Blood Charges	152.46	358.47
Cables Connection Charges	52.92	124.09
Canteen Exp	8664.92	8523.24
Computer Exp	274.59	123.94
Conveyance Exp	65.69	46.21
Annual Subscription Fee	.00	178.37
CMC Charges	1694.18	1155.95
Tally Software Services	15.93	.00
Dialysis Charges Exp	.00	67.20
Diesel Exp	823.20	818.62
Discount IPD	28109.47	16693.01
Discount Pharmacy	.00	.45
Donation	31.00	.00
Applicaion Fee	.00	11.80
Electrical Exp	34.59	29.75
Electricity Exp	5847.83	5928.40
Gardening Exp	20.00	26.25
Gas Expenses	233.68	153.50
Hospital Expenses	1350.79	1165.67
Waiver Fees	.00	11.80
Hospitality Expenses	536.32	169.27
Housekeeping Exp	7806.98	6617.52
Insurance	2876.02	6616.21
Internal Auditor Fees	245.00	529.92
Internet Exp	95.94	21.83
IP Refund	6321.42	3903.36
IPO Expenses	.03	165.19
Laboratory Charges	2995.32	3746.03
Laundry Charges	1642.61	1532.94
Legal Charges	.00	20.00
License Fees	232.27	.00
Market Making Fees	1416.00	1180.00
MA Conveyance	140.10	142.50
Membership Fee	389.66	389.66
NABH Annual Fees	472.00	168.16
NABL Fees	18.29	70.80
Penal Charge	80.03	7.86
Postage & Telegrame Exp	139.02	154.68
Printing & Stationery	241.44	139.24
Professional Fees Outside	138909.52	131669.39
Professional Fees Salary	33998.00	26651.24
Professional Tax Yearly	4.50	4.50
Property Tax	1557.85	1558.80
Rent Exp	24427.13	23456.85
Rent,Rates & Taxes	278.13	317.27
Repairs & Maintenance Charges	2372.31	1456.46
Reparing Expenses	86.41	280.37
ROC & Legal Charges	6.26	18.10
Round Off	8.39	3.90
Security Expenses	1057.23	.00
LEL Charges	.00	15.69
SMS Charges	60.40	37.01
Telephone Expenses	148.94	115.74
Travelling Expenses	3155.57	3701.59
Vatav Kasar	75.27	.00
Vehicle Expenses	409.03	374.28
Water Expenses	1207.43	1444.86
Dismantling & Re-Installation Services	1500.00	.00
Sundry Balance Write Off	1184.36	.00
TOTAL	**289523.33**	**255908.64**

Note No. 28
Provision for Income tax

Particulars	As at 31st March 2026	As at 31st March 2025
Current Year Tax (2024-2025)	.00	8075.47
Add/(Less) Mat Credit		
	.00	**8075.47**

Note No. 29
Deffered Tax

Particulars	As at 31st March 2026	As at 31st March 2025
Deffered Tax Expenses	470.66	113.17
	470.66	**113.17**

Note No.30
Earning Per Share

Particulars	As at 31st March 2026	As at 31st March 2025
(A) Profit attributable to Equity Shareholders (Rs.)		
Profit as per Profit & Loss Account	-13247.51	18993.43
Less: Dividend on Preference Shares for the Year	.00	.00
Net Profit attributable to Equity Shareholders (Rs.)	-13247.51	18993.43
(B) Weighted average No. of Equity Share outstanding during the year, after giving effect of Bonus shares in previous year	6,776,000	6,776,000
(C) Face Value of each Equity Share (Rs.)	10	10
(D) Basic earning per Share (Rs.)	(1.96)	2.80
(E) Diluted earning per Share (Rs.)	(1.96)	2.80

Note No.30.1

During the year Company has issued Bonus shares to the Shareholders accordingly previous year EPS has been recalcualted and adjusted with regards to effect of Bonus share as per AS 20

	As at 31st March 2026	As at 31st March 2025
Details of Weighted average no. of shares		
No. of Shares outstanding at the beginning of the year	6,776,000	6,776,000
Add: Issued during the YEAR / previous year (Bonus)	-	-
Less: Buyback of Shares	-	-
Total Weighted Average No. of Shares	**6,776,000**	**6,776,000**

Note No 31

Significant Accounting Policies

Additional Regulatory Information pursuant to Clause 6L of General Instructions for preparation of Balance Sheet as given in Part I of Division II of Schedule III to the Companies Act, 2013, are given hereunder to the extent relevant and other than those given elsewhere in any other notes to the Financial Statements.

31.01 **Basis of preparation of financial statement:**

These financial statements have been prepared in accordance with the generally accepted accounting principles in India under the historical cost convention on an accrual basis. Pursuant to section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (accounts) Rule, 2014, till the Standards of Accounting or any addendum thereto are prescribed by Central Government in consultation and recommendation of the National Financial Reporting Authority, the existing Accounting Standards notified under the Companies Act, 1956 shall continue to apply. Consequently, these financial statements have been prepared to comply in all material aspect with the accounting standards notified under section 211(3C) Companies (Accounting Standards), 2006 as amended and other relevant provisions of the Companies Act, 2013.

31.02 Revenue/incomes and costs/expenditures are generally accounted on accrual, as they are earned and incurred. Sales of Pharmacy accounted as and when delivery has been completed. Income of IPD has been accounted for at the time of discharge of patient.

31.03 **Property, Plant and Equipment (AS-10):**

Tangible Fixed assets are comprises of Building on rented land are stated at cost of construction less accumulated depreciation (except land). Cost comprises of the purchase price and attributed cost of bringing the asset to working condition for its intended use. Company has invested in Hospital Building on the rented land, there are no other investment in properties. There are no Capital Work in Progress and Intangible assets under development.

An item of Property, Plant and Equipment (PPE) is recognized as an asset when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. The carrying amount of PPE will be depreciated over the remaining useful lives on written down value method as prescribed in the Schedule II of the Companies Act, 2013. Assets which are added during the year will be amortized over useful lives on written down value method prescribed in Schedule II of the Companies Act. Depreciation on assets added / disposed off during the year has been provided on prorate basis from the date of additions. The carrying amount of an item of PPE is derecognized upon disposal or when no future economic benefit is expected to arise from its continued use. Any gain or loss arising on the de recognition of an item of PPE is determined as the difference between the net disposal proceeds and the carrying amount of the item and is recognized in Statement of Profit and Loss. However during the year there is addition in Furniture and Fixture as well as Plant and Machinery out of which some equipments are not put to use and therefore no depreciation has been provided during the year.

The Company has not revalued its Property, Plant and Equipment and intangible assets during the year.

31.04 **Depreciation:**

The depreciation on fixed asset is provided on S.L.M in the books of accounts at the rates based on the on useful life prescribed as per Sch. II to the companies act, 2013.

31.05 **Investments:**

Investments that are readily realizable and are intended to be not held for more than one year from the date, on which such investments are made, are classified as current investments. All the other investments are classified as Long Term Investment. Long Term Investments are carried at cost.

31.06 **Inventories (AS-2):**

Inventories are valued at cost or Net Realizable Value whichever is lower.

31.07 **Employee Benefits (AS-15):**

Short Term Employee Benefits

All the employee benefits payable wholly within twelve months of rendering the services are classified as short – term employee benefits and they are recognized in the period in which the employee renders the related services.

The benefit in the form of Leave Encashment is a non-accumulating short term compensated absences. It is accounted in the year when absences occur and charged to Statement of Profit & Loss of the year.

Post-Employment Benefits

Defined Contribution Plans

Defined contribution plans are employee and Government administrated provident fund scheme and ESI scheme for all the applicable employees. The Company makes specified monthly contribution towards Employee Provident Fund scheme as per the norms prescribed by the Central Government. The Company's contribution to defined contribution plans are recognized in the Statement of Profit and Loss accounts in the reporting period to which they relate.

Defined Benefits Plans

Gratuity Scheme

The Company operates a defined benefit gratuity plan for employees with Life Insurance Corporation, and accordingly, the Company pays the gratuity to the employee whoever has completed five year of service with the Company at the time of resignation or superannuation. The Gratuity is calculated as required under payment of Gratuity Act, 1972.

Contributions are made to Group Gratuity Fund scheme, administered by Life Insurance Corporation of India (LIC), in respect of gratuity based upon demand as raised by the LIC. Provision for liability as at the year end is based on actuarial valuation done by an independent actuary using the 'Projected Unit Credit' method. Major drivers in actuarial assumptions, typically, are years of service and employee compensation. Gains and losses on changes in actuarial assumptions are accounted for in the Statement of Profit and Loss. The Company has considered Actuarial Valuation performed by LIC for Policy -1 & Policy - 2. However, for Policy - 3, LIC didn't provided the actuarial valuation report and hence, the company has considered actuarial valuation conducted by an Independent Actuary as per AS-15.

Based on the actuarial valuation obtained in this respect, the following table sets out the status of the gratuity plan and the amounts recognised in the Company's financial statements as at the balance sheet date.

I. ASSUMPTIONS:	**As at March 31, 2026**	**As at March 31, 2025**
Expected Return on Plan Assets		
Discount Rate	7.25% p.a.	7.25% p.a.
Salary Escalation	7% p.a.	7% p.a.
Withdrawal rate	1% to 3% depending on age	1% to 3% depending on age
Mortality Rate	Indian Assured Lives Mortality (2012-14) Table	Indian Assured Lives Mortality (2012-14) Table
Retirement	60	60

II. CHANGE IN THE PRESENT VALUE OF DEFINED BENEFIT OBLIGATION:	As at March 31, 2026	As at March 31, 2025
Status of plan	Funded	Funded
Present Value of Defined Benefit of Obligation as at the beginning of the year	5942.67	4526.87
Current Service Cost	1007.97	1926.53
Interest Cost	352.63	324.69
(Benefit paid)	-85.80	.00
Past Service Cost	-2900.34	.00
Actuarial (Gains)/Losses on Obligations - Due to Change in Demographic assumptions	.00	.00
Actuarial (Gains)/Losses on Obligations - Due to Change in Financial assumptions	-264.64	-835.41
Present value of Defined Benefit of Obligation as at the end of the year	**4052.49**	**5942.67**

III. CHANGE IN THE FAIR VALUE OF PLANNED ASSET	As at March 31, 2026	As at March 31, 2025
Fair value of plan assets at the beginning of the year	6539.29	6100.08
Expected return on plan assets	446.73	507.32
Actuarial gain/(loss)	575.69	-68.11
Contributions by the employer	1394.11	.00
Benefits Paid	-85.80	.00
Fair value of plan assets at the end of the year	**8870.03**	**6539.29**

IV. RECONCILAITION OF DEFINED BENEFIT OLIGATION AND FAIR VALUE OF PLANNED ASSET	As at March 31, 2026	As at March 31, 2025
Defined Benefit obligation at the end of the year	4052.49	5942.67
Fair value of plan assets at the end of the year	8870.03	6539.29
Net liability/(asset) as at end of the year	-4817.54	-596.62

V. EXPENSES RECOGNIZED IN THE INCOME STATEMENT:	As at March 31, 2026	As at March 31, 2025
Current service cost	1007.97	1926.53
Interest cost	352.63	324.69
Actuarial (Gains)/Losses on Obligations - Due to Change in Demographic	.00	.00
Actuarial (Gains)/Losses on Obligations - Due to Change in Financial assumptions	-264.64	-835.41
Past Service Cost	-2900.34	.00
Experience adjustments on Plan asset	-575.69	68.11
Expected return on plan assets	-446.73	-507.32
Expense recognized in Statement of Profit & Loss	**-2826.81**	**976.59**

VI.CATEGORY OF ASSETS AT THE END OF THE YEAR		
	As at March 31, 2026	**As at March 31, 2025**
Insurer Managed Funds (100%) (Funds managed by LIC as per IRDA guidelines, category-wise composition of the plan assets is not available)	8870.03	6539.29
Expense recognized in Statement of Profit & Loss	**8870.03**	**6539.29**

VII. ACTUAL RETURN ON PLAN ASSET		
	As at March 31, 2026	**As at March 31, 2025**
Actual return on planned asset	446.73	507.32

VIII. RECONCILAITION OF DEFINED BENEFIT OLIGATION AND FAIR VALUE OF PLANNED ASSET		
	As at March 31, 2026	**As at March 31, 2025**
Defined Benefit obligation at the end of the year	4052.49	5942.67
Fair value of plan assets at the end of the year	8870.03	6539.29

IX. EXPERIENCE ADJUSTMENTS	As at March 31, 2026	As at March 31, 2025
Status of plan	Funded	Funded
On Plan Liability (Gains)/Losses	.00	.00
Actuarial (Gains)/Losses on Obligations - Due to Change in Financial assumptior	-264.64	-835.41
On Plan Asset (Gains)/Losses	-575.69	68.11

X. The estimates of rate of salary increase considered in the actuarial valuation takes into account inflation, seniority, promotion and all other relevant factors including supply and demand in the employment market. During the year company have revise/rectify basic salary structure as per the law, and as per revise structure liability calculation also revised and as per the calculation there is excess provision of gratuity which was credited to the profit and loss accounts.

XI. The company operates an Funded gratuity plan wherein employees are entitled to the benefit as per scheme of the company for each completed year of service. The same is payable on retirement or termination whichever is earlier. The benefit vests only after five years of continuous service.

31.08 **Taxation:**

Company has followed accounting standard AS 22 for determination of tax expense in the accounts. Tax provision for current tax is made for income tax, based on the tax liability computed, after considering tax allowances and exemptions. For defer tax the relevant information is stated at note no. 4 to balance sheet.

31.09 **Related Party Disclosures (AS-18):**

Disclosers required by accounting standard 18 regarding related party transactions are as under.

Name of related parties and description of relationship.

Description of Relationship	Name of the related party
Key Managerial Personal	Pranav Rohitbhai Thaker
	Vimalkumar Natverlal Patel
	Narendra Singh Tanwar
	Purvesh Harshadbhai Mali
	Jayesh S Patel
	Parimal Arvindbhai Desai
	Girish Surajmal Pokharna
Wholly Owned Susidiary	Maitreya Lifescience Private Limited
Susidiary	Maitreya Hospital Private Limited
Associate concern of Company	OHM MRI Private Limited
	Tulip Agility Private Limited
Associate concern of key managerial person	Maitreya Heart and Vascular Care Private Limited
	Torin Pharmaceuticles Private Limited
Raltives/Related party of Key Managerial Presonal	Puspdant Parantapbhai Pandit
	Jyotikaben Parantapbhai Pandit
	Darshana Pranav Thaker
	Binti Singh
	Yamini Vimalkumar Patel
	Shiv Consulatancy Prop Yamini Vimalkumar Patel
	Dr. Vibha Singh Tanwar

Details of transaction with related party

Name of the party	Nature of relation	Nature of transaction	For the period ended 31.03.2026	For the period ended 31.03.2025
Pranav Rohitbhai Thaker	Whole Time Director	Loan received	.00	.00
		Loan repaid	.00	1146.60
		Sale of Pharmacy	3.16	.38
		Travelling Expenses	71.02	169.27
		Professional Fees paid	4937.36	4104.46
Vimalkumar Natverlal Patel	Whole Time Director	Loan received	.00	.00
		Loan repaid	.00	1033.00
		Sale of Pharmacy	.00	5.22
		Marketing Expenses	.00	.00
		Travelling Expenses	498.34	206.01
		Professional Fees paid	1281.27	212.01
		Amount receivable for Sale of Pharmacy	.00	.00
Narendra Singh Tanwar	Managing Director-CFO	Loan received	.00	.00
		Loan repaid	.00	3720.00
		Sale of Pharmacy	3.47	.00
		Professional Fees paid	12979.80	12784.29
Purvesh Harshadbhai Mali	Director	Professional Fees paid	600.00	1098.06

Jayesh S Patel	Director	Professional Fees paid	5.69	7.88
Parimal Arvindbhai Desai	Director	Professional Fees paid	24.73	646.55
Girish Surajmal Pokharna	Director	Professional Fees paid	2057.09	2492.48
Maitreya Lifescience Private Limited	Wholly Owned Subsidiary	Amount of loan given	400.00	.00
		Amount received agaisnt loan given	5300.00	
		Professional Fees Received	.00	6270.93
Maitreya Hospital Private Limited	Subsidiary	Loan given	5000.00	.00
		Investment in Equity shares Capital During the year	.00	75000.00
		Loan received	30970.80	
		Amount received agaisnt loan given	11029.20	2620.80
Tulip Agility Private Limited	Subsidiary	Laboratory Charges	37.98	34.56
		Deposit Given	.00	.00
		Loan given	7500.00	1500.00
		Investment in Capital Account	.00	.00
		Sale of Pharmacy	.00	436.54
		Professional Fees received	.00	1858.37
		Machinery Rent	.00	.00
		Professional Fees paid	.00	.00
Puspdant Parantapbhai Pandit	Raltives of Key Managerial Presonal	Hospital Equipments	200.00	.00
Darshana Pranav Thaker	Raltives of Key Managerial Presonal	Professional Fees paid	1800.00	1755.00
Yamini Vimalkumar Patel	Raltives of Key Managerial Presonal	Professional Fees paid	1800.00	1755.00
OHM MRI Pvt Limited	**Associate concern of Company**	Laboratory Charges	301.10	276.30
Dr. Vibha Singh Tanwar	Raltives of Key Managerial Presonal	Professional Fees paid	4800.00	4500.00
		Pharmacy Sales	33.57	400.57
		Amount receivable for Sale of Pharmacy	174.12	155.16
Big Xreay Dignostic Pvt Limited	Related party of Key Managerial Presonal	Professional Fees paid	1449.72	.00
Pranav Rohitbhai Thaker	Whole Time Director	Closing Balance of Loan	.00	.00
		Amount receivable for Sale of Pharmacy	17.13	.00
Vimalkumar Natverlal Patel	Whole Time Director	Closing Balance of Loan	.00	.00

Narendra Singh Tanwar	Managing Director-CFO	Closing Balance of Loan	.00	.00
		Amount receivable for Sale of Pharmacy	46.62	.00
Maitreya Lifescience Private Limited	Wholly Owned Subsidiary	Investment in Equity shares at the year end	100.00	100.00
Maitreya Hospital Private Limited	Subsidiary	Investment in Equity shares at the year end	75100.00	75100.00
		Closing Balance of Loan Receivable	.00	6029.20
		Closing Balance of Loan Payable	30970.80	.00
Maitreya Hospital Private Limited	Subsidiary	Investment in Sahre Application for Equity shares pending for allotment by Company at the year end	.00	100.00
Tulip Agility Private Limited	Subsidiary	Closing Balance of Loan	29774.10	22274.10
OHM MRI Pvt Limited	**Associate concern of Company**	Investment in Equity shares at the year end	10.00	10.00

31.10 **SEGMENT REPORTING:**

In view of the Accounting Standard 17 “Segment Reporting” issued by the Institute of Chartered Accountants of India the disclosures in respect of segment information for the year ended 31st March 2024 is not applicable to the Company as the Company does not deal in varied products / services and hence not exposed to different risks and returns. Further the Company operates in only one geographical area and does not having any branches or any other outlets and hence not exposed to different risks and returns of geographical segmentation.

31.11 As certified by the management, no transactions has been entered in to by the Company during the year ended 31.03.2026 with any stuck off companies u/s. 248 of the Companies Act, 2013 or u/s. 560 of the Companies Act, 1956.

31.12 All the charges which are subject to register with the Ministry of Corporate Affairs has been duly registered. Bank Guaratnee for MAYOJANA of Rs. 2963.97 (Thousands), Bank Guarantee for ESIC of Rs. 644.41(Thousands) agaisnt fixed deposit for which charge to be created on Fixed Deposits with ROC Ahmedabad with thirty days of sanctioned, is inadvetently missed and not registered with ROC,Ahemedabad. The charges which are needs to be satisfied has also been duly field with MCA wherever applicable.

31.13 During the period under consideration , the Company has not required to comply with the provisions of section 135 (Corporate Social Responsibility) of the Companies Act, 2013 .

31.14 The Company has not sanctioned working capital limit in excess of Rs. 5 Crore by Bank/ Financial Institution on the basis of security of current assets and therefore no disclosure is applicable.

31.15 The Company has complied with clause (87) of section 2 of the Act read with the Companies (Restriction on number of Layers) Rules, 2017.

31.16 The Company has made Loan and advances in the nature of loans to promoters, directors, KMPs and the related parties in the during the year to the tune of Rs. 34274 , which is reported under related party transaction as per AS 18.

31.17 The Company does not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property.

31.18 The Group is not declared a wilfull defaulter by any Bank or Financial institution or any other lender.

31.19 During the year no Scheme of Arrangement has been formulated by the Group/pending with competent authority.

31.2 No funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries") with the understanding, whether recorded in writing or otherwise, that the Intermediary shall lend or invest in party identified by or on behalf of the Company (Ultimate Beneficiaries). The Company has not received any fund from any party(s) (Funding Party) with the understanding that the Company shall whether, directly or indirectly lend or invest in other persons or entities identified by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

31.21 The Company has not surrendered or disclosed any transactions, previously unrecorded as income in the books of account, in the tax assessments under the Income Tax Act, 1961 as income during the year.

31.22 The Company has not traded or invested in Crypto Currency or Virtual Currency during the half year ended.

31.23 In the opinion of the Board of Directors of the Company, the Current Assets, Loans and Advances are approximately of the value stated, if realized in the ordinary course of business, except for which provision has been made in the accounts. The Company has requested account confirmation from Debotrs and Creditors as at the end of the year but till date there is no such confirmation have been received from the Debtors and Creditors, therefore what ever balance outstanding is subject to confirmation as well as reconciliation.

31.24 In the opinion of The Board of Directors, there were no contingent liabilities on the date of Balance Sheet, except as mentioned in below table regarding legal consumenr court cases against the Company.

A. Civil Proceedings againts Maitreya Medicare Limited

Parties to the Proceedings Suit etc. Name	Forum	Details of the relief / prayers / claims along with details of any orders / decrees / directi / ons passed in the matter, (including any interim relief granted and / or applied for)	Amount involved	Current Status of the Matter
United India Insurance Co. Ltd. - Surat Branch Mahager – Surat Paramount Health Services and Insurance Tpa Pvt. Ltd.- Surat Maitreya Hospital – Surat	Consumer		388617/-	Active
The New India Insurance Co. Ltd. - Surat Health India Insurance TPA Services Pvt. Ltd – Surat Aadhya Hospital – Surat Maitreya Multi Superspeciality Hospital & Research Centre – Surat	Consumer		361727/-	Active
The New India Insurance Co. Ltd. - Surat Branch Mahager – Surat Ericson Insurance TPA Pvt Ltd Maitreya Hospital – Surat	Consumer		186514/-	Active
SBI General Insurance Co Ltd – Surat Branch Manager – Surat Paramount Health Services and Insurance Tpa Pvt. Ltd.- Surat Maitreya Hospital – Surat	Consumer		291799/-	Active
The New India Insurance Co. Ltd. - Surat				

Heritage Health Tpa Private Limited – Surat Maitreya Multi Superspeciality Hospital & Research Centre – Surat	Consumer		61087/-	Active
The New India Insurance Co. Ltd. - Surat Divisional Manaer – Surat Health India Insurance TPA Services Pvt. Ltd Maitreya Hospital – Surat	Consumer		327694/-	Active
The New India Insurance Co. Ltd. - Surat Branch Mahager Heritage Health Tpa Private Limited – Surat Maitreya Hospital	Consumer		448116/-	Active
The Oriental Insurance co ltd – Surat Sr. Divisional Manager Vipul Medcorp Insurance TPA Pvt Ltd Maitreya Hospital	Consumer		245091/-	Active
Star Health and allied insurance company limited – Surat Maitreya Hospital – Surat	Consumer		200487/-	Active
Maitreya Multi Superspeciality Hospital & Research Centre – Surat Dr. Pranav Thaker – Surat Vimal Patel – Surat Dr. Narendra Singh Tanwar – Surat Dr. Suchay Parikh – Surat Dr. Ronak Nagoria – Surat	Consumer		470437/-	Active

31.25 The provision for depreciation and for all the known liabilities are adequate and not in excess of the amount reasonably necessary. However there is pending court litigation against the Company in the Consumer Court as per as per above table, all these case filed by patients against various insurance companies in which company is co-accuse. As per previous experiences Company Management are opinion that there will not be any liability on the Company and therefore no provisions for the same has been made in the books of accounts during the year.

31.26 All the balances of parties’ accounts are subject to confirmation.

31.28 **Financial Ratio:-**

PARTICULAR			FY 2025-26	FY 2024-25	CHANGE
Current Ratio	Current Assets	Current Liabilities	1.51	1.90	-0.38
Debt-equity ratio	Total Debt	Shareholder's Equity	1.98	0.29	1.69
Debt service coverage ratio	Earnings available for debt service	Debt Service	0.04	6.75	-6.71
Return on equity ratio	Net Profits after taxes – Preference Dividend (if any)	Average Shareholder's Equity	-0.30	0.24	-0.55
Inventory turnover ratio	Cost of goods sold OR sales	Average Inventory	24.46	11.76	12.71
Trade receivables turnover ratio	Net Credit Sales	Average Accounts Receivable	0.00	0.00	0.00
Trade payables turnover ratio	Net Credit Purchases	Average Trade Payables	0.00	0.00	0.00
Net capital turnover ratio	Net Sales	Average Working Capital	6.25	7.87	-1.61
Return on capital employed	Earning before interest and taxes	Capital Employed	-0.02	0.11	-0.13
Return on investment	Income generated from investments	Time weighted average investment	0.00	0.00	0.00

As Per Our Report of Even Dated Annexed
Saherwala & Co.
FRN 108969W

For MAITREYA MEDICARE LIMITED

(ESMAYEEL O. SAHERWALA)
Chartered Accountant
M. NO. 122386
29th May 2026, Surat.
UDIN :

VIMAL PATEL
DIN- 08458999
Wholetime Director

NARENDRA TANWAR
DIN - 0008459007
MD AND CFO

INDEPENDENT AUDITOR'S REPORT

To the Members of MAITREYA MEDICARE LIMITED

Formerly known as MAITREYA MEDICARE PRIVATE LIMITED

Report on the Audit of the Consolidated Financial Statements

1. We have audited the financial statements of Maitreya Medicare Limited (*Formerly known as Maitreya Medicare Private Limited)* and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), which comprise the Consolidated balance sheet as at 31st March 2026, and the Consolidated statement of profit and loss, the Consolidated Statement of Changes in Equity, Consolidated statement of cash flows for the period then ended, and notes to the Consolidated financial statements, including a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

2. The Holding Company's Board of Directors are responsible for the preparation of these consolidated financial statements in terms of the requirements of the Companies Act, ('the act') that give a true and fair view of the consolidated financial position, consolidated financial performance and consolidated cash flows of the Group in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; the selection and application of appropriate accounting policies; making judgments and estimates that are

reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial statements by the Directors of the Holding Company, as aforesaid;

Auditor's Responsibility

3. Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder.

   We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

4. An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the consolidated financial statements, that give a true and fair view, in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on whether the Company has in place an adequate internal financial controls system over financial reporting and the operating effectiveness of such controls. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness

of the accounting estimates made by the Company's management and Board of Directors, as well as evaluating the overall presentation of the consolidated financial statements.

5. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the consolidated financial statements.

Opinion

6. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid consolidated financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the consolidated state of affairs of the Group as at 31st March 2026, and their consolidated ~~profit~~/loss and their consolidated cash flows for the period ended on that date.

7. As described in the notes no 1.13 to the financial statements statutory auditor of WOS Maitrya Lifescience Private Limited has qualified his report that, the MLPL Company has not complied with the requirements of Section 55 of the Companies Act, 2013 and the accounting principles generally accepted in India in the preparation and presentation of these financial statements, resulting in material misstatements whose effects are material but not pervasive to the financial statements. These matters collectively form the basis for our Qualified Opinion in accordance with SA 705 (Revised).

Report on Other Legal and Regulatory Requirements

7. According to the information and explanations given to us, and based on the reports, issued by the auditors of the subsidiaries included in the consolidated financial statements of the Company, to which reporting on matters specified in paragraph 3 and 4 of the Order is applicable, provided to us by the Management of the Company and based on the identification of matters of qualifications or adverse remarks in their Companies (Auditor’s Report) Order, 2020 reports by

the respective component auditors and provided to us, we report that the auditors of such companies have not reported any qualifications or adverse remarks in their CARO reports.

8. As required by section 143(3) of the Act, we further report that:

a) we have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;

b) in our opinion proper books of account as required by law have been kept by the Company so far as appears from our examination of those books;

c) the Consolidated Balance Sheet, Consolidated Statement of Profit and Loss, and Consolidated Cash Flow Statement dealt with by this Report are in agreement with the relevant books of account maintained for the purpose of preparation of the consolidated financial statements;

d) in our opinion, the aforesaid financial statements comply with the applicable Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules 2014.

e) on the basis of written representations received from the directors of the Holding Company as on 31st March, 2026 taken on record by the Board of Directors of the Holding Company and the reports of the statutory auditors of its subsidiary companies, incorporated in India, none of the directors of the Group companies, incorporated in India is disqualified as on 31st March, 2026 from being appointed as a director in terms of Section 164 (2) of the Act.

f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in “Annexure A”.

g) In our opinion and to the best of our information and according to the explanations given to us, we report as under with respect to other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014:

i. The Company does not have any legal pending court litigations which would impact its financial position of the Group; except cases under the consumer court filed by patients against various insurance companies in which company is co-respondent. (Please see Notes No. 32.24 to the Balance Sheet)

ii. The Company did not have any long-term contracts including derivative contracts; as such the question of commenting on any material foreseeable losses thereon does not arise;

iii. There has not been an occasion in case of the Company during the period under report to transfer any sums to the Investor Education and Protection Fund. The question of delay in transferring such sums does not arise.

h) The company, has used such accounting software for maintaining its books of account which:

i. Has a built-in Feature of recording audit trail (edit log) facility and

ii. The audit trail has operated throughout the year for all transactions recorded in the software and

iii. The audit trail feature has not been tampered with.

iv. The audit trail has been preserved by the company as per the statutory requirements for record retention.

FOR SAHERWALA & CO
CHARTERED ACCOUNTANTS
FRN 108969W

PLACE: SURAT
DATE: 29/05/2026

ESMAYEEL O. SAHERWALA
PARTNER
M. No. 122386
UDIN: 26122386UPBQFR5710

ANNEXURE "A" TO THE INDEPENDENT AUDITOR'S REPORT OF EVEN DATE ON THE CONSOLIDATED FINANCIAL STATEMENTS OF MAITREYA MEDICARE LIMITED *Formerly known as MAITREYA MEDICARE PRIVATE LIMITED*

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of **MAITREYA MEDICARE LIMITED** *(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)* and its subsidiaries (the Holding Company and its subsidiaries together referred to as the "Group") as of 31-Mar-2026 in conjunction with our audit of the consolidated financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Group's management is responsible for establishing and maintaining internal financial controls. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to Group's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Group's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects. Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness.

Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Group's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls Over Financial Reporting

A Group's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A Group's internal financial control over financial reporting includes those policies and procedures that

(1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Group;

(2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Group are being made only in accordance with authorisations of management and directors of the Group; and

(3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the Group's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Group has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31-Mar-2026.

FOR SAHERWALA & CO
CHARTERED ACCOUNTANTS
FRN 108969W

PLACE: SURAT
DATE: 29/05/2026

(ESMAYEEL O SAHERWALA)
PARTNER
M. No. 122386
UDIN: 26122386UPBQFR5710

MAITREYA MEDICARE LIMITED
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)
CONSOLIDATED AUDITED BALANCE SHEET AS ON 31st March 2026
CIN No. - U24290GJ2019PTC107298
(Currency: Rs in '000')

Particulars	Note No.	CONSOLIDATED AMOUNT As at 31st March 2026	CONSOLIDATED AMOUNT As at 31st March 2025
I. EQUITY & LIABILITIES			
(1) Shareholders"s Funds			
a) Share capital	1	**115523**	120923
b) Reserve & Surplus	2	**174775**	199428
c) Money received against share warrants	3		
d) Minorities Interest / Capital Reserve	3.1	**7480**	8227
(2) Share application money pending allotment			
(3) Non-Current Liabilities			
a) Long-term Borrowings	4	**219396**	36348
b)Deffered tax liability (Net)	5	**8064**	7034
c)Other long term Liabilities			
d)Long term Provisions			
(4) Current Liabilities			
a) Short-term Borrowings	6	**11786**	15744
b) Trade payables			
(A) total outstanding dues of micro enterprises and small enterprises; and small enterprises.	7		3295
(B) total outstanding dues of creditors other than micro enterprises and small enterprises.	7	**40110**	28867
c) Other curent Liabilites	8	**107260**	51805
d) Short term Provisions	9		8272
Total		**684395**	**479943**
II. Assets			
(1) Non-current assets			
(a) Property, Plant and Equipment			
(i) Gross Block	10	**490270**	219621
(ii) Depreciation	10	**82128**	67024
(iii) Net Block	10	**408142**	152597
b) Non Current Investments	11	**10**	10
c) Deffered tax asset (net)			
d) Long term loans and advances	12	**29622**	30489
e) Other Non current assets	13	**12946**	18442
(2) Current assets			
a) Current Investments	14	**522**	422
b) Inventories	15	**8436**	5923
c) Trade receivables	16	**110212**	149565
d) Cash & Cash equivalents	17	**86696**	79163
e) Short-term loans and advances	18	**23429**	39789
f) Other current assets	19	**4379**	3542
Total		**684395**	**479943**

As Per Our Report of Even Dated Annexed
Saherwala & Co.
FRN 108969W

For MAITREYA MEDICARE LIMITED

(ESMAYEEL O. SAHERWALA)
Chartered Accountant
M. NO. 122386
29th May 2026, Surat.
UDIN :

VIMAL PATEL
DIN- 08458999
Wholetime Director

NARENDRA TANWAR
DIN - 0008459007
MD AND CFO

MAITREYA MEDICARE LIMITED
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)
Statement of Consolidated Audited Profit & Loss for the year ended 31st March 2026
CIN No. - U24290GJ2019PTC107298
(Currency: Rs in '000')

Particulars	Note No.	CONSOLIDATED AMOUNT As at 31st March 2026	CONSOLIDATED AMOUNT As at 31st March 2025
I. Revenue from operations	20	448499	466620
II. Other Income	21	9871	5722
III. Total Revenue (I+II)		458370	472342
IV, Expenses:			
Cost of materials consumed	22	47311	28717
Purchase of stock-in-Trade	23	47846	59139
Changes in inventories of finished goods, work-in-progress and stock-in-Trade	24	485	-248
Employee benefit expense	25	55649	61278
Financial Costs	26	14840	8020
Depreciation and amortization expense	27	15220	14964
Other expense	28	300551	268912
Total Expense		481902	440783
V.Profit Before exceptional and extradinary items and tax	(III-IV)	-23533	31559
VI. Exceptional Items			
Adjustment of GST Liability			
Reversal of Previous Year Income Tax/TCS		-634	
Rectification of Previous Year Mutual Fund Value			
Rectification of Depreciation			
Prior Period Adjustment		1179	
Operating lease Prior Period Adjustment			
VII. Profit Before extraorinary items and tax (V-VI)		-24077	31559
VIII. Extraordinary Items			
IX. Profit before tax (VII-VIII)		-24077	31559
X. Tax expense:			
(1) Current Tax	29		8272
(2) Deferred Tax	30	576	63
(3) MAT Credit Entitlement			
(4) Incpme Tax Paid 2023-2024			5042
XI. Profit(Loss) from the period from continuing operations		-24653	18181
XII. Profit/(Loss) from discontinuing operations			
XIII. Tax expense of discontinuing operations			
XIV. Profit/(Loss) from discountinuing operations (XII- XIII)			
XV. Profit/Loss for the period (XI+XIV)		-24653	18181
XVI. Earning per equity share:	31		
Basic		(3.64)	2.68
Diluted		(3.64)	2.68

As Per Our Report of Even Dated Annexed
Saherwala & Co.
FRN 108969W

For MAITREYA MEDICARE LIMITED

VIMAL PATEL
DIN- 08458999
Wholetime Director

NARENDRA TANWAR
DIN - 0008459007
MD AND CFO

(ESMAYEEL O. SAHERWALA)
Chartered Accountant
M. NO. 122386
29th May 2026, Surat.
UDIN :

MAITREYA MEDICARE LIMITED
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)
Statement of Consolidated Audited Cash Flow Statement for the year ended 31st March 2026
CIN No. - U24290GJ2019PTC107298
(Currency: Rs in '000')

PARTICULARS		CONSOLIDATED AMOUNT As at 31st March 2026	CONSOLIDATED AMOUNT As at 31st March 2025
A. Cash Flow from Operating Activities:			
Net Profit before tax		-23533	32102
Adjustments for :			
Depreciation		15220	14421
Interest Income		-4864	-2154
Interest & Finance Charges Paid		13630	7984
Gratuity			1677
Profit on sale of Investment			225
Prior Period Adjustment - gst		-725	
Reversal of Previous Year Income Tax		634	
Profit on sale of Fixed Assets		-20	
Sub Total		23876	22153
Operating Profit before Working Capital Changes		343	54255
Adjustments for :			
Increase / Decrease in Inventories		-2513	147
Increase / Decrease in Short-term loans and advances		1225	-3478
Increase / Decrease in Trade Receivables		44129	-18444
Increase / Decrease in Trade Payables		-785	6571
Increase / Decrease in Other Current Assets		11109	-619
Increase / Decrease in Other Non Current Assets		342	4174
Increase / Decrease in Long-term loans and advances		-19246	145
Increase/Decrease in Provision		-8300	-3918
Increase/Decrease in short term liabilites		-3957	2143
Increase/Decrease in Current Liability		59438	24289
Sub Total		81444	11009
Cash Generated from Operations		81788	65264
Direct Taxes Paid (Net)		1203	14695
Net Cash inflow in Operating Activities Total A		**80584**	**50568**
B. Cash Flow from Investing Activities:			
Purchases of Property, Plant and Equipment		-272483	-23813
Purchase of Investment		-100	-44656
Depreciation reveresed back on sale of fixed assets			
Capital Government Grant of Property, Plant and Equipment			
Loans given to Associates and Subsidiaries		-1471	-9073
Loans given to Others			
Loans received from Holding compnay			-2621
Interest Income		4864	2154
Sale of Fixed Assets		1738	
Sale of Investment		100	4300
		-267351	-73709
Net Cash used in Investing Activities Total B		**-267351**	**-73709**
C. Cash Flow from Financing Activities:			
Issue of Equity Capital		3900	
Share application Money		-100	51600
Share Premium			
Dividend			
Proceed of Borrowing		12895	4783
issue of Preference Shares			
Redemption of Preference shares		-10047	-2000
Repayment of Borrowing		197383	-9665
Interest & Finance Charges Paid		-13630	-7984
		190401	36735
Net Cash from Financing Activities Total C		**190401**	**36735**
Net increase /(decrease) in cash and cash equivalents (A+B+C)		**3634**	**13594**
Opening Cash and Cash equivalents		79163	65569
Closing Cash and Cash equivalents		**82796**	**79163**

Notes :

(i) Figures in brackets represent outflow.

(ii) The above Cash Flow statement has been prepared under the indirect method set out in AS-3 notified under Section 133 of the Companies Act,2013

(iii) Cash and Cash Equivalents represent cash and bank balances.

As Per Our Report of Even Dated Annexed
Saherwala & Co.
FRN 108969W

For MAITREYA MEDICARE LIMITED

(ESMAYEEL O. SAHERWALA)
Chartered Accountant
M. NO. 122386
29th May 2026, Surat.
UDIN :

VIMAL PATEL
DIN- 08458999
Wholetime Director

NARENDRA TANWAR
DIN - 0008459007
MD AND CFO

MAITREYA MEDICARE LIMITED
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)
CIN No. - U24290GJ2019PTC107298
Notes to the financial statements for the Year ended March 31,2026
(Currency: Rs in '000')

Note No. 1

Share Capital	**CONSOLIDATED AMOUNT**	**CONSOLIDATED AMOUNT**
Particulars	**As at 31st March 2026**	**As at 31st March 2025**
Authorized Share capital;		
15870000 Equity shares of Rs. 10/- each	158700	153700
(Previous year 8650000 equity shares of Rs. 10 each)		
(7940000) 6% Preferrence Shares of Rs. 10/- each.	79400	79400
(Previous year 7940000 equity shares of Rs. 10 each)		
Issued & Subscibed & fully paid up capital;		
EQUITY SHARES	67760	67760
(6776000) Equity Shares of Rs. 10/- each.		
(Previous year 6776000 equity shares of Rs. 10 each fully paid up)		
Share Application Money received from Maitreya Medicare Limited		
Capital Account in Tulip Health Check		
REEDEEMABLE NON COVERTIBLE NON CUMULATIVE PREFERENCE SHARES	47763	53163
(4776300) 6% Preference Shares of Rs. 10/- each.		
(Previous year 5316300 Preference shares of Rs. 10 each fully paid up)		
Other Partners Capital Account in Tulip Health Check		
TOTAL	**115523**	**120923**

Note No. 1.1 Terms attached to Equity Shares

The Company has only one class of equity shares referred to as equity shares having a par value of Rs. 10/- each. Each holder of Equity Share is entitled to one vote per share. In the event of liquidation of the company, the holders of equity shares will be entitled to receive the remaining assets of the company in proportion to the number of equity shares held.

The Company had allotted 4950000 number of fully paid Bonus shares on 17/03/2023 in the ratio of Four Ninety Five equity share of Rs 10 each fully paid up for every One existing equity shares of Rs 10 each fully paid up.

The Subsidiary of the company namely Maitray Hospital Private Limited has alloted 390000.00 share of Rs. 10 face value as private placement during the year.

Note No. 1.2 Terms attached to Preference Shares

The Company has only one class of preference shares referred to as Redeemable Non Convertible Non Cumulative Preference shares having a par value of Rs. 10/- each.

Preference shares issued by the Company shall be redeemable at any time in one or more tranches at the dicretion of the Company or share holder after allotment of shares but not later than 10 years from the date of allotment of the preference shares.

Dividend on Preference shares issued by the Company shall be 6% p.a. on face value which will remain fixed over the tenure of preference shares and shall have priority with respect to payment of dividend or repayment of capital over equity shares.

Note No. 1.2 Reconciliation of Number of Equity Shares	CONSOLIDATED AMOUNT	CONSOLIDATED AMOUNT
Particulars	As at 31st March 2026	As at 31st March 2025
	Number	Number
Shares outstanding at the beginning of the year	6776	6776
Shares issued during the Year		
Shares outstanding at the end of the year	6776	6776

Note No. 1.3 Reconciliation of Number of Preference Shares	CONSOLIDATED AMOUNT	CONSOLIDATED AMOUNT
Particulars	As at 31st March 2026	As at 31st March 2025
	Number	Number
Shares outstanding at the beginning of the year	5316	5396
Shares issued during the Year		
Shares Redemption During the year	540	80
Shares outstanding at the end of the year	4776	5316

Note No. 1.4 Details of shares held by each shareholder holding more than 5%	CONSOLIDATED AMOUNT	CONSOLIDATED AMOUNT
Name of Shareholder	As at 31st March 2026	As at 31st March 2025
	No. of Equity Share held	No. of Equity Share held
Narendra Singh Prem Singh Tanwar	3186	3186
Vimalkumar Natverlal Patel	707	707
Pranav Rohitbhai Thaker	1061	1061
Maitreya Medicare Private Limited		
Total	**4954**	**4954**

Note No. 1.5 Shares held by promotors at 31st March 2025 is set out below:-	CONSOLIDATED AMOUNT	
Name of Shareholder	No. of Shares (%)	% change during the year
Narendra Singh Prem Singh Tanwar	3185808 (64.307%)	
Vimalkumar Natverlal Patel	706800 (14.267%)	
Pranav Rohitbhai Thaker	1061440 (21.426%)	
Maitreya Medicare Private Limited		
Total	**4954048(100%)**	

Note No. 1.7

All share are ranking pari-passu in all respects.

Note No. 1.8

The company does not have reserved any shares for issue under options and

Note No. 1.9

As the company does not have issued any securities convertible into equity/preference shares hence the details regarding Terms of any securities convertible into equity/preference shares issued (along with the earliest date of conversion in descending order starting from the farthest such date) are not applicable.

Note No. 1.10

The company has not forfeited any shares at any time.

Note No. 1.11

Disclosure pursuant to unpaid Call

Unpaid Calls

By Directors

By Officers

Note No. 1.12

held by or by subsidiaries or associates of the holding company or the ultimate holding company in aggregate.

Note No. 1.13

The WOS Company namely Maitrya Life Science Private Limited has redeemed 8,84,700 preference shares of ₹10 each aggregating to ₹88,47,000 over FY 2022–23 to the current year, comprising 2,30,000 shares in FY 2022–23, 1,20,000 shares in FY 2023–24, 1,20,000 shares in FY 2024–25 and 4,14,700 shares during the current year. As per section 55 of Companies Act, 2013, an equivalent amount was required to be transferred to Capital Redemption Reserve if redemption was out of profit or have to redem out of fresh issue of share. Accordingly WOS of company has violated provision of secton 55 of the Companies ACt, 2013.

Note No. 2

Reserve & Surplus	**CONSOLIDATED AMOUNT**	**CONSOLIDATED AMOUNT**
Particulars	**As at 31st March 2026**	**As at 31st March 2025**
Surplus:		
Opening Balance	75483	60959
Add: Profit/(Loss) for the year	-24653	18724
Add: Income Tax Expenses for earliyer year		
Less: Capital redemption reserve	-5600	-4200
Less: Preference Share Dividend		
Less: Preference Share Dividend of earlier year		
Less: Bonus Share issued		
Closing Balance	**45230**	**75483**
Other Reserves:		
Capital Redemption Reserves	15100	9500
Share Premium	114445	114445
TOTAL	**174775**	**199428**

The subsidiaryof the company namely Maitrya Hospital Private Limited has created part amount of capital redemption reserve for the year 2024 during the year under cosnideration.

Note No. 3

Money received against share warrants	**CONSOLIDATED AMOUNT**	**CONSOLIDATED AMOUNT**
Particulars	**As at 31st March 2026**	**As at 31st March 2025**
TOTAL		

Note No. 3.1

Minorities Interest / Capital Reserve	**CONSOLIDATED AMOUNT**	**CONSOLIDATED AMOUNT**
Particulars	**As at 31st March 2026**	**As at 31st March 2025**
Minoritiest Interest in Equity Share	4380	480
Minoritiest Interest in Preference Share	3100	7747
Minoritiest Interest in Capital Profit		
Minoritiest Interest in Revenue Profit		
TOTAL	**7480**	**8227**

Note No. 4

Long Term Borrowings	**CONSOLIDATED AMOUNT**	**CONSOLIDATED AMOUNT**
Particulars	**As at 31st March 2026**	**As at 31st March 2025**
Secured Loans		
(A) Term Loan From Banks	210090	26542
Unsecured Loans		
(A) Loan & Advances from Related Party		
Maitreya Hospital Pvt Ltd (Sbsidery)		
Loan and Advances from Associat Concern	6100	9806
Loan and Advances from - Others	3206	
TOTAL	**219396**	**36348**

Note No. 4.1

1) 10.65% Healtcare Equipments/Infra Loan A/c. No. 84007783 is repayable in 84 EMI of Rs. 441374/- with HDFC Bank is secured agaisnt hypothication of Fixed Deposit of Rs. 60,00,000/- with HDFC Bank,All the stock in trade both present and future consisiting of raw materials, finished goods, goods in process of manufacturing and any other goods, All the book debts, amounts outstanding, monies receivable, claims, bills, which are now due and owing or which may at any time, All the plant and machinery both present and future consisting of as mentioned in Deed of Hypothecation which is executed with the Bank by the Company. These all loans are also secured by personal gaurantee of the Directors of the Company.

2) 12.05% Healtcare Equipments/Infra Loan A/c. No. 84145456 is repayable in 84 EMI of Rs. 560439/- with HDFC Bank is secured agaisnt hypothication of Fixed Deposit of Rs. 60,00,000/- with HDFC Bank,All the stock in trade both present and future consisiting of raw materials, finished goods, goods in process of manufacturing and any other goods, All the book debts, amounts outstanding, monies receivable, claims, bills, which are now due and owing or which may at any time, All the plant and machinery both present and future consisting of as mentioned in Deed of Hypothecation which is executed with the Bank by the Company. These all loans are also secured by personal gaurantee of the Directors of the Company.

3) 11.30% Healtcare Equipments/Infra Loan A/c. No. 84702766 is repayable in 60 EMI of Rs. 402584/- with HDFC Bank is secured agaisnt hypothication of Fixed Deposit of Rs. 60,00,000/- with HDFC Bank,All the stock in trade both present and future consisiting of raw materials, finished goods, goods in process of manufacturing and any other goods, All the book debts, amounts outstanding, monies receivable, claims, bills, which are now due and owing or which may at any time, All the plant and machinery both present and future consisting of as mentioned in Deed of Hypothecation which is executed with the Bank by the Company. These all loans are also secured by personal gaurantee of the Directors of the Company.

4) 9.04% Healtcare Equipments/Infra Loan A/c. No. 732000016070 is repayable in 60 EMI of Rs. 124149/- with Indusind Bank is secured agaisnt hypothication of All the stock in trade both present and future consisiting of raw materials, finished goods, goods in process of manufacturing and any other goods, All the book debts, amounts outstanding, monies receivable, claims, bills, which are now due and owing or which may at any time, All the plant and machinery both present and future consisting of as mentioned in Deed of Hypothecation which is executed with the Bank by the Company. These all loans are also secured by personal gaurantee of the Directors of the Company.

5) 8.80% Healtcare Equipments/Infra Loan A/c. No. 0871TL0100000759 is repayable in 60 EMI of Rs. 88342/- with Kotak Mahindra Bank Limited is secured agaisnt hypothication of All the stock in trade both present and future consisiting of raw materials, finished goods, goods in process of manufacturing and any other goods, All the book debts, amounts outstanding, monies receivable, claims, bills, which are now due and owing or which may at any time, All the plant and machinery both present and future consisting of as mentioned in Deed of Hypothecation which is executed with the Bank by the Company. These all loans are also secured by personal gaurantee of the Directors of the Company.

6) 8.00 % Healthcare Project Finance Loan A/c. No. 802707696 is repayable in 177 EMI of Rs. 1699067/- with HDFC Bank Limited is secured agaisnt hypothication of immovable Property owned by Company as mentioned in Deed of Hypothecation which is executed with the Bank by the Company. These all loans are also secured by personal gaurantee of the Directors of the Company.

7) 7.75% HEALTH CARE INFRA FINANCE Loan A/c. No. 802841943 is repayable in 180 EMI of Rs. 27925/- with HDFC Bank Limited is secured agaisnt hypothication of All the stock in trade both present and future consisiting of raw materials, finished goods, goods in process of manufacturing and any other goods, All the book debts, amounts outstanding, monies receivable, claims, bills, which are now due and owing or which may at any time, All the plant and machinery both present and future consisting of as mentioned in Deed of Hypothecation which is executed with the Bank by the Company. These all loans are also secured by personal gaurantee of the Directors of the Company.

8) During the year, the MHPL Company has been sanctioned aggregate credit facilities of ₹3,45,00,000 by HDFC Bank Limited under its Healthcare Finance segment for the purpose of funding its healthcare project. The sanctioned facilities comprise Equipment Loan (HCEQ) of ₹1,45,00,000 and Infrastructure Finance (HCIF) of ₹2,00,00,000, with a tenure of 60 months.Out of the above sanctioned limit, an amount of ₹1,89,24,425 has been disbursed during the financial year. The loan carries interest at applicable rates (floating) and is repayable in equated monthly instalments as per the agreed repayment schedule.The credit facilities are secured/supported by personal guarantees of the directors, namely Dr. Pranav Thaker, Dr. Vimal Patel, and Dr. Narendra Tanwar, along with a corporate guarantee from Maitreya Medicare Limited. The Company is required to comply with all covenants and conditions stipulated by the lender from time to time. Since only part of the sanctioned facilities has been disbursed during the year and no revised repayment schedule has been provided by the bank or the Company as at the reporting date, the disbursed amount has been considered and classified as long-term borrowings in the financial statements.

Note No. 5

Deffered Tax Liability	**CONSOLIDATED AMOUNT**	**CONSOLIDATED AMOUNT**
Particulars	**As at 31st March 2026**	**As at 31st March 2025**
Deferred Tax Liability	8063.65	7033.72
TOTAL	**8064**	**7034**

Note No. 5.1

As required by the Accounting Standard AS 22 Accounting for Taxes on Income issued by Institute of Chartered Accountants of India, the relevant details are as under.

i) The opening balance of DTL is Rs. 7033.72 and the balance amount Rs. 1029.93 is created for the period ended 31-03-2026.

ii) During the year DTL of Rs. 1029.93 is created due to originating of Timing difference between accounting and Tax Depreciation.

ii) Net deferred Tax liability as on 31-03-2026 works out to Rs. 8063.65

The DTL of Rs. 8063.65 comprises DTL of Rs. 8063.65 and DTA of Rs. 0 on account of difference between accounting and tax depreciation.

Note No. 6

Short Term Borrowings	**CONSOLIDATED AMOUNT**	**CONSOLIDATED AMOUNT**
Particulars	**As at 31st March 2026**	**As at 31st March 2025**
Secured Loans		
(A) Equipments and Infrastructure Loan	11786	15744
(B) Vehicle Loan From Banks:		
TOTAL	11786	15744

Note No. 6.1

1) 9.40% Healtcare Equipments/Infra Loan A/c. No. 84007783 is repayable in 84 EMI of Rs. 441374/- with HDFC Bank is secured agaisnt hypothication of Fixed Deposit of Rs. 60,00,000/- with HDFC Bank,All the stock in trade both present and future consisiting of raw materials, finished goods, goods in process of manufacturing and any other goods, All the book debts, amounts outstanding, monies receivable, claims, bills, which are now due and owing or which may at any time, All the plant and machinery both present and future consisting of as mentioned in Deed of Hypothecation which is executed with the Bank by the Company. These all loans are also secured by personal gaurantee of the Directors of the Company.

2) 11.80% Healtcare Equipments/Infra Loan A/c. No. 84145456 is repayable in 84 EMI of Rs. 560439/- with HDFC Bank is secured agaisnt hypothication of Fixed Deposit of Rs. 60,00,000/- with HDFC Bank,All the stock in trade both present and future consisiting of raw materials, finished goods, goods in process of manufacturing and any other goods, All the book debts, amounts outstanding, monies receivable, claims, bills, which are now due and owing or which may at any time, All the plant and machinery both present and future consisting of as mentioned in Deed of Hypothecation which is executed with the Bank by the Company. These all loans are also secured by personal gaurantee of the Directors of the Company.

3) 11.05% Healtcare Equipments/Infra Loan A/c. No. 84702766 is repayable in 60 EMI of Rs. 402584/- with HDFC Bank is secured agaisnt hypothication of Fixed Deposit of Rs. 60,00,000/- with HDFC Bank,All the stock in trade both present and future consisiting of raw materials, finished goods, goods in process of manufacturing and any other goods, All the book debts, amounts outstanding, monies receivable, claims, bills, which are now due and owing or which may at any time, All the plant and machinery both present and future consisting of as mentioned in Deed of Hypothecation which is executed with the Bank by the Company. These all loans are also secured by personal gaurantee of the Directors of the Company.

Note No. 7

Trade payables	CONSOLIDATED AMOUNT	CONSOLIDATED AMOUNT
Particulars	As at 31st March 2026	As at 31st March 2025
Unsecured, Considered Good:		
Sundry Creditors for Doctor	4398	3578
Sundry Creditors for Purchase	35712	28584
TOTAL	**40110**	**32162**

Note No. 7.1

	CONSOLIDATED AMOUNT	CONSOLIDATED AMOUNT
Particulars	As at 31st March 2026	As at 31st March 2025
Micro, Small and Medium Enterprises		3295
Others	40110	28867
Total	**40110**	**32162**

Note No. 7.2

Dues of small enterprises and micro enterprises

	CONSOLIDATED AMOUNT	CONSOLIDATED AMOUNT
Particulars	As at 31st March 2026	As at 31st March 2025
(a) Dues remaining unpaid to any supplier at the end of each accounting year		
- Principal		
- Interest on the above		
(b) the amount of interest paid by the buyer in terms of section 16 of the Micro, Small and Medium Enterprises Development Act, 2006, along with the amount of the payment made to the supplier beyond the appointed day during each accounting year;		
(c) the amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the Micro, Small and Medium Enterprises Development Act, 2006;		
(d) the amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues above are actually paid to the small enterprise, for the purpose of disallowance of a deductible expenditure under section 23 of the Micro, Small and Medium Enterprises Development Act, 200		

Note No. 8

Other curent Liabilites	CONSOLIDATED AMOUNT	CONSOLIDATED AMOUNT
Particulars	**As at 31st March 2026**	**As at 31st March 2025**
PF Payable	305	335
Professional Tax Payable	34	25
CGST Sales Pharmacy	222	180
SGST Sales Pharmacy	222	180
Tax Deducted At Sources for Contractor	85	31
Tax Deducted At Sources for Professional Fees Non Company	1402	1669
SHIV JYOTI HOSPITAL (RENT)		225
Tds	220	473
IGST	40	77
RCM Payble	190	
Salary Payable	4538	4679
Retention	3283	3048
Advance From Customer	36	4008
Book Overdraft HDFC Bank	95889	35954
Electricity Bill Payable	19	72
Preference Share dividend payable earliyer years	663	672
Audit Payable	110	177
TOTAL		
	107260	**51805**

1) 09.15% Book Overdraft A/c. No. 50200088059300 is repayable in on demand for the tenure of 60 months with annual renewal with HDFC Bank is secured agaisnt First and exclusive charge on the entire current assets including stocks and book debts, present and future, First and exclusive charge on entire immovable fixed assets of company including various medical equipment, CGTMSE guarantee, Personal Guarantee of Promoter Directors 1. Dr Pranav Thaker, 2. Dr. Narendra Tanwar and 3. Mr. Vimal Patel.

2) During the course of our audit, the MHPL Company has not provided the sanction letter and related loan documentation pertaining to the credit facilities availed from HDFC Bank Limited for our verification. Accordingly, the terms and conditions of the sanction, including the nature of security, rate of interest, repayment schedule, covenants and other related matters, have been considered based on the information and explanations (loan account statement) provided by the management. Further, we have been informed that the said facilities are secured by way of lien on hdfc bank's fixed deposits with the bank; however, no charge has been created or registered in favour of the bank with the Registrar of Companies in this regard.

Note No. 9

Short Term Provisions		
Particulars	**CONSOLIDATED AMOUNT**	**CONSOLIDATED AMOUNT**
	As at 31st March 2026	**As at 31st March 2025**
Provision for Tax (FY 2024-2025)		8272
Provision for Current Tax (FY 2025-2026)		
TOTAL		
		8272

MAITREYA MEDICARE LIMITED
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)
CIN No. - U24290GJ2019PTC107298
Notes to the financial statements for the Year ended March 31,2026
(Currency: Rs in '000')

Note No.11

Non Current Investments	**CONSOLIDATED AMOUNT**	**CONSOLIDATED AMOUNT**
Particulars	**As at 31st March 2026**	**As at 31st March 2025**
Quoted Investment		
<u>Unquoted Investment:</u>		
<u>Unquoted Investment:</u>		
7510000 Equity Shares (Previous Year 10000) of Maitreya Hospital Private Limited having face value of Rs. 10 each.		
10000 Equity Shares (Previous Year 10000) of Maitreya Lifescience Private Limited having face value of Rs. 10 each.		
1000 Equity Shares (Previous Year 451000) OHM MRI PVT LTD having face value of Rs. 10 each.	10	10
Share Application Money for 2350000 Equity Shares (Previous Year Nil) of Maitreya Hospital Private Limited having face value of Rs. 10 each pending for allotment.		
52000 Equity Shares of Tulip Agility Private Limited (Previous year Investment in Tulip Health Check Partnership Firm as Capital Introduction and having 52 % share in Capital of the Firm)		
TOTAL	**10**	**10**

Note No.11.1

Maitreya Hospital Private Limited shares are not tradeable or listed therefore market value can not be deternined and therefore not reported herein.

Maitreya Lifeschience Private Limited. Shares are not tradeable or listed therefore market value can not be deternined and therefore not reported herein.

OHM MRI Private Limited. Shares are not tradeable or listed therefore market value can not be deternined and therefore not reported herein.

Maitreya Hospital Private Limited has not issued shares agaisnt the share application money and that are not tradeable or listed therefore market value can not be deternined and therefore not reported herein.

Tulip Agility Private Limited. Shares are not tradeable or listed therefore market value can not be deternined and therefore not reported herein.

Note No.12

Long term loans and advances	**CONSOLIDATED AMOUNT**	**CONSOLIDATED AMOUNT**
Particulars	**As at 31st March 2026**	**As at 31st March 2025**
<u>Loans to others:</u>		
<u>Unsecured and Considered Good</u>		
Tax Deducted At Source On Income	21092	**21959**
SHIV JYOTI HOSPITAL	4000	**4000**
USHABEN M RATHOD	30	**30**
<u>Loan to Related parties</u>		
<u>Unsecured and Considered Good</u>	4500	4500
TOTAL	**29622**	**30489**

Note No 12.1

Company has granted loan to Wholly owned Subsidiary and Related party entity for which no terms have been agreed regarding tenure/ repayment shedule of the loan as well as interest rate on it.

Note No. 13

Other Non Current Investments	**CONSOLIDATED AMOUNT**	**CONSOLIDATED AMOUNT**
Particulars	**As at 31st March 2026**	**As at 31st March 2025**
Rent Deposit (including machinery rent deposit)	**7500**	**11020**
Fixed Deposit with HDFC Bank 50300678347925 (Lien Machine/Infra Loan)		**4597**
Deposit	**53**	11
Telephone Deposit	**10**	10
Sidni Earth Protectors(Deposit)	**12**	
NSE Deposit		1489
NSDL Deposit	**53**	18
Neel Jagdishbhai Desai - Rent Deposit		
Gratuity Planed Assets	**4818**	597
Saral Healthcare Deposit		**200**
ESIC Deposit	**500**	**500**
	12946	**18442**

Fixed Deposit with HDFC Bank is under lien against the Loan for Equipment and Infrastructure loans taken from HDFC Bank

Fixed Deposit with HDFC Bank reported above is Principal Amount of Fixed deposit and it also includes accrued interest on it up to 31.03.2025

In the Opinion of the Board of Directors Current Assets, Loans and Advances (including capital Advances) have a value on realisation in the ordinary course of business, at least equal to the amount which they are stated herein Balance Sheet.

Note No. 14

Current Investments	**CONSOLIDATED AMOUNT**	**CONSOLIDATED AMOUNT**
Particulars	**As at 31st March 2026**	**As at 31st March 2025**
<u>Quoted Investment;</u>		
Unquoted Investment;		
Axis Ultra Short Term Mutual Fund	**134**	134
ICICI Prudential Ultra Short Term Fund	**288**	288
Bandhan Small Cap Fund	**25**	
Motilal Oswal Nifty Microcap 250 Index Fund	**25**	
HDFC Diversified Equity All Cap Active FOF	**25**	
ICICI Prudential Thematic Advantage Fund (FOF)	**25**	
Total	**522**	**422**
Aggregate amount of quoted investments		
Aggregate market value thereof		
Aggregate amount of unquoted investments	**522**	**422**
Aggregate provision for diminution in value of investments		

Company is holding 10060.196 (Previous year 10060.196) unit of Axis Ultra Short Term Mutual Fund, NAV of the same as on 31.03.2026 is Rs. 15.3373 (Previous Year 14.4696) accordingly it market value as on 31.03.2026 is Rs. 154.296 (Previous Year 145.567)

Company is holding 11557.3620 (Previous year 11557.3620) unit of ICICI Prudential Ultra short Term Fund, NAV of the same as on 31.03.2026 is Rs. 28.9546 (Previous Year 27.1758) accordingly it market value as on 31.03.2026 is Rs. 334.638 (Previous Year 314.081)

Company is holding 527.6670 unit of Bandhan Small Cap Fund Growth, NAV of the same as on 31.03.2026 is Rs.40.5640 accordingly it market value as on 31.03.2026 is Rs. 21.404

Company is holding 2417.44 unit of HDFC Diversified Equity All Cap Active FOF Growth, NAV of the same as on 31.03.2026 is Rs.8.9549 accordingly it market value as on 31.03.2026 is Rs. 21.647

Company is holding 107.281 unit of ICICI Prudential Aggressive Hybrid Active FOF, NAV of the same as on 31.03.2026 is Rs.203.4921 accordingly it market value as on 31.03.2026 is Rs. 21.831

Company is holding 1475.444 unit of Motilal Oswal Nifty Microcap 250 Index Fund Growth, NAV of the same as on 31.03.2026 is Rs.13.5647 accordingly it market value as on 31.03.2026 is Rs. 20.014

Note No. 15

Inventories	**CONSOLIDATED AMOUNT**	**CONSOLIDATED AMOUNT**
Particulars	**As at 31st March 2026**	**As at 31st March 2025**
Closing Stock Pharmacy	5322	5808
Closing Stock Store	3114	116
Total	**8436**	**5923**

Note No. 16

Trade receivables	**CONSOLIDATED AMOUNT**	**CONSOLIDATED AMOUNT**
Particulars	**As at 31st March 2026**	**As at 31st March 2025**
Unsecured, Considered Good		
Centre Debtors	4485	22270
IPD Debtors	86752	107464
Pharmacy Debtors	15698	16190
OPD Debtors	3269	3314
Sponsorship Debtor	9	327
Total	**110212**	**149565**

MAITREYA MEDICARE LIMITED
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)
CIN No. - U24290GJ2019PTC107298
Notes to the financial statements for the Year ended March 31,2026
(Currency: Rs in '000')

Note No. 7.3

Ageing of Trade Payables	As at 31st March 2026				
Particulars	**Less than 1 year**	**1-2 years**	**2-3 years**	**More than 3 years**	**Total**
Undisputed Trade Payables					
MSME	4637	60			**4696**
Other Creditors	33228	2187			**35414**
Disputed Trade Payables					
MSME					
Other Creditors					
Total	**37864**	**2246**			**40110**

Note No. 7.3

Ageing of Trade Payables	As at 31st March 2025				
Particulars	**Less than 1 year**	**1-2 years**	**2-3 years**	**More than 3 years**	**Total**
Undisputed Trade Payables					
MSME	3295				**3295**
Other Creditors	26967	1869	32		**28867**
Disputed Trade Payables					
MSME					
Other Creditors					
Total	**30262**	**1869**	**32**		**32162**

Note No. 16.1

Ageing of Trade Receivables	As at 31st March 2026						
		Outstanding for following periods from due date of Payments					
Particulars	**Not due**	**Less than 6 months**	**6 months - 1 year**	**1-2 years**	**2-3 years**	**More than 3 years**	**Total**
Undisputed Trade Receivables							
Considered good	-	46738	29467	6460	8988	18560	**110212**
	-	-		-	-	-	
Disputed Trade Receivables							
Considered good	-	-	-	-	-	-	
	-	-	-	-	-	-	
Gross Total	-	46738	29467	6460	8988	18560	**110212**
Less : Impairment for doubtful receivables	-	-	-	-	-	-	-
Net Total	-	**46738**	29467	6460	8988	18560	**110212**

Ageing of Trade Receivables	As on 31st March, 2025						
		Outstanding for following periods from due date of Payments					
Particulars	**Not due**	**Less than 6 months**	**6 months - 1 year**	**1-2 years**	**2-3 years**	**More than 3 years**	**Total**
Undisputed Trade Receivables							
Considered good	-						
	-	73492	21306	36624	13660	4482	**149565**
Disputed Trade Receivables							
Considered good	-	-	-	-	-	-	
	-	-	-	-	-	-	
Gross Total	-	73492	21306	36624	13660	4482	**149565**
Less : Impairment for doubtful receivables	-	-	-	-	-	-	
Net Total	-	**73492**	**21306**	**36624**	**13660**	**4482**	**149565**

MAITREYA MEDICARE LIMITED
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)
CIN No. - U24290GJ2019PTC107298
Notes to the financial statements for the Year ended March 31,2026
(Currency: Rs in '000')

Note No.17

Cash and Bank Balances	**CONSOLIDATED AMOUNT**	**CONSOLIDATED AMOUNT**
Particulars	**As at 31st March 2026**	**As at 31st March 2025**
Cash and Cash Equivalents		
a) Cash-in-Hand		
Cash in Hand	1065	751
	1065	751
a)Bank Balance with Scheduled Bank		
a) Current Account		
HDFC Bank	10931	8573
ICICIC Bank	16	7897
Bank of India	1607	1473
IDFC FIRST BANK (A/C NO. 10085723266)		114
YES BANK (C/A)	285	759
YES BANK LTD (A/C.001163400004888)	453	931
b) Other Bank Balance		
Fixed Deposit with HDFC Bank 50300383852597 (Lien Machine/Infra Loan	5609	5294
Fixed Deposit with HDFC Bank 50300426670211 (Lien MA Yojana)	1356	1278
Fixed Deposit with HDFC Bank 50300522850081 (Lien ESIC Deposit)	644	609
Fixed Deposit 50300962911096 - MA	2958	2789
Fixed Deposit 50301218349170		4143
Fixed Deposit 50300966788542 MA	6	5
Fixed Deposit with HDFC Bank 50301304559541	1508	
Fixed Deposit with HDFC Bank 50301324437709	4356	
Fixed Deposit - 138813009908		44548
Fixed Deposit - 138810004114		
Fixed Deposit with HDFC Bank 50300678347925 (Lien Machine/Infra Loan	4855	
Fixed Deposit 50301249878568 lien marked with HDFC Loan	25535	
Fixed Deposit 50301252203905 lien marked with HDFC Loan	25511	
	85632	78412
Total cash and cash equivalents (as per AS 3 Cash flow statement)(A)	86696	79163
TOTAL	**86696**	**79163**

Fixed Deposit with HDFC Bank 50300383852597 is under lien against the Loan for Equipment and Infrastructure loans taken from HDFC Bank.

Fixed Deposit with HDFC Bank 50300522850081 is under lien against the Bank Guarantee issued by HDFC Bank to Nodal Office of ESIC.

Fixed Deposit with HDFC Bank 50300962911096 is under lien against the Bank Guarantee issued by HDFC Bank to State Nodal Office of MA & PMJAY Yojana.

Fixed Deposit with HDFC Bank 50300966788542 is under lien against the Bank Guarantee issued by HDFC Bank to State Nodal Office of MA & PMJAY Yojana.

Fixed Deposit with HDFC Bank 50300678347925 is under lien against the Loan for Equipment and Infrastructure loans taken from HDFC Bank.

Fixed Deposit with HDFC Bank reported above is Principal Amount of Fixed deposit and it also includes accrued interest on it up to 31.03.2026

Note No. 18

Short Term Loans & Advances	**CONSOLIDATED AMOUNT**	**CONSOLIDATED AMOUNT**
Particulars	**As at 31st March 2026**	**As at 31st March 2025**
Unsecured, consider good(unless otherwise stated):		
Loan to Related Parties		
Loan to Other		
Advances to Related Parties		
Advances to Sundry Creditors	22456	15669
Advances to Staff	973	3243
Advacnes to Other		20877
TOTAL	**23429**	**39789**

Note No. 19

Other Current Assets	**CONSOLIDATED AMOUNT**	**CONSOLIDATED AMOUNT**
Particulars	**As at 31st March 2026**	**As at 31st March 2025**
Prepaid Expenses	3392	2564
Increased in Authorised Capital Expenditure	914	914
Gst Receivable	73	64
Total	**4379**	**3542**

In the Opinion of the Board of Directors Current Assets, Loans and Advances (including capital Advances) have a value on realisation in the ordinary course of business, at least equal to the amount which they are stated herein Balance Sheet.

MAITREYA MEDICARE LIMITED
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)
CIN No. - U24290GJ2019PTC107298
Notes to the financial statements for the Year ended March 31,2026
(Currency: Rs in '000')
Note No. 10
Property, Plant and Equipment

Sr. No.	Particulars	Gross Block				Depreciaton				Net Block	
		Value at the beginning as on 01.04.2025	Addition during the year	Deduction during the year	Value at the end as on 31.03.2026	Value at the beginning as on 01.04.2025	Addition during the year	Deduction during the year	Value at the end as on 31.03.2026	WDV as on 31.03.2026	WDV as on 31.03.2025
I	Property										
	BUILDINGS	18456	212093		230549	5369	1117		6486	224063	13087
II	Tangible Assets										
	Plant and Machinery										
	PLANT AND MACHINERY	137141	11570		148711	44343	10141		54485	94226	92798
	PLANT AND MACHINERY	1448			1448	551	53		604	844	897
	PLANT AND MACHINERY	8831	46279	1048	54063					54063	8831
	ELECTRICAL INSTALLATIONS AND EQUIPMENT	2363	961		3324	1154	225		1378	1946	1210
	PLANT AND MACHINERY-tulip	22877	600		23477	557	1086		1643	21834	22320
	Office Equipments										
	COMPUTERS AND DATA PROCESSING UNITS	4353			4353	3496	304		3800	553	857
	OFFICE EQUIPMENT	6821			6821	6166	200		6367	454	654
	COMPUTERS EQUIPMENT	18			18	3	2	2	3	15	
	OFFICE EQUIPMENT-tulip	654	107	138	623	221	245	21	444	179	433
	Furniture & Fixtures										
	FURNITURE AND FITTINGS	9574	573	131	10016	2381	948	20	3309	6707	7194
	FURNITURE AND FITTINGS-tulip	518		518		76		76			443
	FURNITURE AND FITTINGS		300		300		27		27	273	
	Vehicles:										
	MOTOR VEHICLES	4870			4870	2457	579		3036	1834	2413
	SUB TOTAL (A)	**217926**	**272483**	**1835**	**488574**	**66773**	**14926**	**118**	**81582**	**406993**	**151138**
II	Intangible Assets										
	INTANGIBLE ASSETS	1695			1695	251	296		546	1149	1445
	SUB TOTAL (B)	**1695**			**1695**	**251**	**296**		**546**	**1149**	**1445**
III	Intangible Assets Under Development										
	SUB TOTAL (C)										
	Total [A + B + C] (Current Year)	**219621**	**272483**	**1835**	**490270**	**67024**	**15222**	**118**	**82128**	**408142**	**152582**
	(Previous Year)	**195809**	**24138**	**325**	**219621**	**52603**	**14421**		**67024**	**152597**	**143206**

During the year there is addition in Plant and Machinery in WOS Maitreya Hospital Private Limited, but the same has not been put to use till date on balance sheet and therefore depreciation has not provided on the same herein above.

During the year there is addition in Plant and Machinery in WOS Tulip Agility Private Limited, but the same has not been put to use till date on balance sheet and therefore depreciation has not provided on the same herein above.

MAITREYA MEDICARE LIMITED
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)
CIN No. - U24290GJ2019PTC107298
Notes to the financial statements for the Year ended March 31,2026
(Currency: Rs in '000')

Note No. 20

Revenue From Operation	CONSOLIDATED AMOUNT	CONSOLIDATED AMOUNT
Particulars	As at 31st March 2026	As at 31st March 2025
Centre Income	23433	27677
IPD Income	293413	293354
OPD Income	21344	16541
Pharmacy Income	104906	123260
HEALTH PACKAGE INCOME	2263	1647
LABORATORY INCOME	2113	2412
IVF INCOME		220
DOCTOR CONSULTING INCOME	1027	1508
	448499	466620
TOTAL	**448499**	**466620**

Note No. 20.1

Revenue from Operation of the Company are exclusive of any Duty, GST, VAT or other refund/ Tax

Note No. 21

Other Income	CONSOLIDATED AMOUNT	CONSOLIDATED AMOUNT
Particulars	As at 31st March 2026	As at 31st March 2025
Interest on Fixed Deposit	3594	2505
Business Development Fees	600	175
Interest on Income Tax Refund	715	49
Profit on Sale of Fixed Assets	20	
Profit on Sale of Investment		225
Interest Income	579	401
Round Off		
Sponsorship Income	1143	2015
Sundry Balance Write Off		235
Vatav Kasar	3	43
Notice Pay	50	74
INSURANCE CLAIM RECD	46	
Gratuity Exess Provision Writen back	3121	
TOTAL	**9871**	**5722**

Note No. 22

Consumption of Stores and Pharmacy	CONSOLIDATED AMOUNT	CONSOLIDATED AMOUNT
Particulars	**As at 31st March 2026**	**As at 31st March 2025**
Consumption of Stores:		
Opening Stock	116	106
Purchase Store	38126	6311
Closing Stock	3114	116
Total Consumption of Stores	35128	6301
Consumption of Pharmacy	12184	22416
TOTAL	**47311**	**28717**

Note No. 23

Purchase of stock-in-Trade	CONSOLIDATED AMOUNT	CONSOLIDATED AMOUNT
Particulars	**As at 31st March 2026**	**As at 31st March 2025**
Purchase Pharmacy	60030	81555
Less : Consumption of Pharmacy	12184	22416
TOTAL	**47846**	**59139**

Note No. 24

Changes in stock-in-Trade	CONSOLIDATED AMOUNT	CONSOLIDATED AMOUNT
Particulars	**As at 31st March 2026**	**As at 31st March 2025**
Opening Stock		
Opening Stock Pharmacy	5808	5560
Less: Closing Stock		
Closing Stock Pharmacy	5322	5808
Increase/Decrease	485	-248
TOTAL	**485**	**-248**

Note No.25

Employee benefit expense	**CONSOLIDATED AMOUNT**	**CONSOLIDATED AMOUNT**
Particulars	**As at 31st March 2026**	**As at 31st March 2025**
Bonus		1104
EDLI	98	104
Gratuity Expenses		1677
Employer Contribution to PF	1252	1293
Overtime Expenses	1271	1119
Salary	52258	55538
Staffwellfare Expenses	692	186
Staff Quarter	20	45
Stipend Exp		212
Employer Contribution to ESIC	59	
TOTAL	**55649**	**61278**

Note No.26

Finance Cost	**CONSOLIDATED AMOUNT**	**CONSOLIDATED AMOUNT**
Particulars	**As at 31st March 2026**	**As at 31st March 2025**
Bank Charges	255	361
Bank Charges Credit Card	305	269
Bank Charges Credit Card (Pharmacy)	52	57
Interest Expense		51
Loan Stamp Duty / Franking	1618	152
Loan Interest	7135	4176
Loan Interest Overdraft	4944	2561
Overdraft Expense	162	
Overdraft Proposal Charges		
Preclose Charges		357
Processing Fees	336	
Interest on TDS	25	34
Interest on Income Tax	7	
MSME Interest		
Gst late Fees & Interest	1	2
TOTAL	**14840**	**8020**

Note No.27

Depreciation and amortization expense	CONSOLIDATED AMOUNT	CONSOLIDATED AMOUNT
Particulars	**As at 31st March 2026**	**As at 31st March 2025**
ACT Machine	25	25
AQUA GUARD		2
AUTOCLAVE MACHINE DOUBLE DRUM		
AIR CONDITIONER	156	693
AMBULANCE FABRICATION	38	38
ARTIS ONE CARD CATHLAB	1491	1491
ARTIS ZEE FLOOR COMBO CATHLAB	2010	2010
ATTENDENCE MACHINE		3
BOLERO AMBULANCE	92	92
BORWELL	3	3
CAPEX	1114	1083
Cardiac Probe	39	39
CARL ZEISS VARIO MICROSCOPE	256	256
CIAZ BS VI DELTA	112	111
COLOUR DOPPLER MACHINE [ULTRASOUND]	83	83
CC TV CAMERA		29
COMPUTER		
COMPUTER EQUIPMENT	184	185
DATASCOPE CS 100 IABP MACHINE	55	55
DG SET [GENERATOR]	123	125
DRAGER EVITA XL VENTILATOR	445	445
ECG ANALYSIS SOFTWARE	13	13
ECG RECODER MACHINE	36	36
ECHO MACHINE	51	43
EECO AMBULANCE	78	78
ELECTRIC OWN	1	100
ELECTRICAL FITTING	100	22
ELECTRIC APPLIANCE	4	23
ERTIGA MOTOR CAR	135	135
ETO STERILIZER MACHINE	25	25
FAN	4	38
FIRE SYSTEM	15	60
FORCE AMBULANCE	160	160
FURNITURE	975	858
FURNITURE FIXTURE		76
GE Healthcare Innova 2100 Angiography System (Cath)	958	543
Gear Less Motor	3	543
HMS SOFTWARE	7	7
HOSPITAL EQUIPMENT	2153	954
IABP Machine	53	18
IND. WATER HEATING MACHINE	1	1
LG REFRIGATOR		9
LOGO	7	7
MACHINERY EQUIPMENT	233	214
MOBILE PHONE	6	2
MACQUET ECMO PUMP	84	84
MEDIAN INFUSION PUMP IP100	8	8
Medical Equipment	1380	1802
MEDION ASTEROS 9000	6	6
MEDRED MARK V PROVIS CATHLAB DYE INJECTOR	29	29
MOTORISED INSTRUMENTS TABLE		
MEDTRONICS PACEMAKER	11	11
MIS MEDICAL EQUIPMENT	92	92
NETWORKING EQUIPMENT	219	383
OXYGEN PLANT	663	663
PHILLIPS ETCO2 MAINSTREAM CABLE CMOP	11	11
PHILLIPS HEARTSTART XL DEFIB-9018	35	35
PHILLIPS MP 70 MULTIPARA MONITER	157	157
Refrigreator		
RO SYSTEM		17

SARNS STERNAL SAW5590	18	18
SARNS SYSTEM 1HLM	219	219
SCHILLER SPANDAN PC BASED CARDIAC WORK STATION	16	16
SECURITY SOFTWARE	4	4
SOFTWARE	272	102
SURGICAL DRILL	12	12
SYRINGE INFUSION PUMP 101P	69	69
TALLY SOFTWARE	6	6
TELEVISION	26	108
ULTRASOUND MACHINE RS ACUSON S2000	278	278
VACUUM CLEANER MACHINE		6
VEHICLE EQUIPMENT	1	1
Vela Vantilator	351	82
WARMTOUCH PATENT WARMING SYSTEM	12	12
TOTAL	**15220**	**14964**

During the year under consideration one of the WOS Maitreya Life Science Private Limited has change it's depreciation method from WDV to SLM in line with Parent Company, what ever difference arises due to change in depreciation method has been shown as deduction from depreciation in the Schedule 10 and same has been charged to profit and loss account as exceptional items.

Notes No. 28

Other expenses	**CONSOLIDATED AMOUNT**	**CONSOLIDATED AMOUNT**
Particulars	**As at 31st March 2026**	**As at 31st March 2025**
Administrative Expenses	25	258
ACCOUNTING FEES	60	196
Advertisement Exp	714	295
AMC Charges	5133	2660
Audit Fees	961	864
Listing Annual Fees	489	
CGTMSE Fee	1451	58
Blood Charges	152	358
Cables Connection Charges	53	127
Canteen Exp	8665	8523
Computer Exp	280	133
Consulting Fee	171	
Conveyance Exp	132	57
Annual Subscription Fee		178
CMC Charges	1694	1156
Tally Software Services	26	
Dialysis Charges Exp		67
Diesel Exp	823	819
Discount IPD	28109	16693
Discount Pharmacy		
Donation	31	
Applicaion Fee	179	12
Electrical Exp	35	40
Electricity Exp	6134	6426
Fire Equipment Expenses	5	
Freight & Octroi	1	
Gardening Exp	20	26
Gas Expenses	234	153
Brokarage Comossion (IPO)		
Hospital Expenses	1894	1586
Waiver Fees		12
Hospitality Expenses	536	169
Housekeeping Exp	8268	6917
Insurance	2976	6701
Internal Auditor Fees	245	530
Internet Exp	102	22
Interset On TDS		
IP Refund	6321	3903

IPO Expenses		165
Laboratory Charges	3205	4486
Laundry Charges	1644	1573
Legal Charges	43	24
Licenes Fees	238	
Market Making Fees	1416	1180
MA Conveyance	140	143
Marketing Exp		
Membership Fee	390	390
NABH Annual Fees	472	168
NABL Fees	18	71
Penal Charge	80	8
Consumable Expenses		60
Postage & Telegrame Exp	139	157
Printing & Stationery	295	253
Professional Fees Outside	140207	139278
Professional Fees Salary	34899	28626
Professional Tax Yearly	19	5
Property Tax	1558	1559
Rent Exp	26227	23807
Rent,Rates & Taxes	278	317
Repairs & Maintenance Charges	2510	1556
Reparing Expenses	116	310
RCM Paid	366	
ROC & Legal Charges	89	30
Round Off	8	4
Security Expenses	1145	
LEL Charges		16
SMS Charges	60	37
Telephone Expenses	149	124
Travelling Expenses	3260	3707
Vatav Kasar	771	74
Vehicle Expenses	418	374
Water Expenses	1207	1470
Dismantling & Re-Installation Services	1501	
Sundry Balance Write Off	1352	
Gst late Fee		
Loss On Sale Of Fixed Assets	409	
TOTAL	**300551**	**268912**

Note No. 29

Provision for Income tax	**CONSOLIDATED AMOUNT**	**CONSOLIDATED AMOUNT**
Particulars	**As at 31st March 2026**	**As at 31st March 2025**
Current Year Tax		8272
Income Tax Previous year		
		8272

Note No. 30

Deffered Tax	**CONSOLIDATED AMOUNT**	**CONSOLIDATED AMOUNT**
Particulars	**As at 31st March 2026**	**As at 31st March 2025**
Deffered Tax Expenses	576	63
	576	**63**

Note No.31

Earning Per Share	**CONSOLIDATED AMOUNT**	**CONSOLIDATED AMOUNT**
Particulars	**As at 31st March 2026**	**As at 31st March 2025**
(A) Profit attributable to Equity Shareholders (Rs.)		
Profit as per Profit & Loss Account	-24653	18181
Less: Dividend on Preference Shares for the Year		
Net Profit attributable to Equity Shareholders (Rs.)	-24653	18181
(B) Weighted average No. of Equity Share outstanding during the year.	6776	6776
(C) Face Value of each Equity Share (Rs.)		
(D) Basic earning per Share (Rs.)		
(E) Diluted earning per Share (Rs.)		

	As at 31st March 2026	**As at 31st March 2025**
Details of Weighted average no. of shares		
No. of Shares outstanding at the beginning of the year	6776	6776
Add: Issued during the previous year		
Less: Buyback of Shares		
Total Weighted Average No. of Shares	6776	6776

MAITREYA MEDICARE LIMITED
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)
CIN No. - U24290GJ2019PTC107298
Notes to the financial statements for the Year ended March 31,2026
(Currency: Rs in '000')

Note No 32

Significant Accounting Policies

Additional Regulatory Information pursuant to Clause 6L of General Instructions for preparation of Balance Sheet as given in Part I of Division II of Schedule III to the Companies Act, 2013, are given hereunder to the extent relevant and other than those given elsewhere in any other notes to the Financial Statements.

32.01 **Basis of preparation of financial statement:**

These financial statements have been prepared in accordance with the generally accepted accounting principles in India under the historical cost convention on an accrual basis. Pursuant to section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (accounts) Rule, 2014, till the Standards of Accounting or any addendum thereto are prescribed by Central Government in consultation and recommendation of the National Financial Reporting Authority, the existing Accounting Standards notified under the Companies Act, 1956 shall continue to apply. Consequently, these financial statements have been prepared to comply in all material aspect with the accounting standards notified under section 211(3C) Companies (Accounting Standards), 2006 as amended and other relevant provisions of the Companies Act, 2013.

32.02 Revenue/incomes and costs/expenditures are generally accounted on accrual, as they are earned and incurred. Sales of Pharmacy accounted as and when delivery has been completed. Income of IPD has been accounted for at the time of discharge of patient.

32.03 **Property, Plant and Equipment (AS-10):**

Tangible Fixed assets are comprises of Building on rented land are stated at cost of construction less accumulated depreciation (except land). Cost comprises of the purchase price and attributed cost of bringing the asset to working condition for its interned use. Company has invested in Hospital Building on the rented land, there are no other investment in properties. There are no Capital Work in Progress and Intangible assets under development.

An item of Property, Plant and Equipment (PPE) is recognized as an asset when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. The carrying amount of PPE will be depreciated over the remaining useful lives on written down value method as prescribed in the Schedule II of the Companies Act, 2013. Assets which are added during the year will be amortized over useful lives on written down value method prescribed in Schedule II of the Companies Act. Depreciation on assets added / disposed off during the year has been provided on prorate basis from the date of additions. The carrying amount of an item of PPE is derecognized upon disposal or when no future economic benefit is expected to arise from its continued use. Any gain or loss arising on the de recognition of an item of PPE is determined as the difference between the net disposal proceeds and the carrying amount of the item and is recognized in Statement of Profit and Loss. However during the year there is addition in Furniture and Fixture / Plant and Machinery which are not put to use and therefore no depreciation has been provided during the year.

The Company has not revalued its Property, Plant and Equipment and intangible assets during the year.

32.04 **Depreciation:**

The depreciation on fixed asset is provided on S.L.M in the books of accounts at the rates based on the on useful life prescribed as per Sch. II to the companies act, 2013.

32.05 **Investments:**

Investments that are readily realizable and are intended to be not held for more than one year from the date, on which such investments are made, are classified as current investments. All the other investments are classified as Long Term Investment. Long Term Investments are carried at cost.

32.06 **Inventories (AS-2):**

Inventories are valued at cost or Net Realizable Value whichever is lower.

32.07 **Employee Benefits (AS-15):**

Short Term Employee Benefits

All the employee benefits payable wholly within twelve months of rendering the services are classified as short – term employee benefits and they are recognized in the period in which the employee renders the related services.

The benefit in the form of Leave Encashment is a non-accumulating short term compensated absences. It is accounted in the year when absences occur and charged to Statement of Profit & Loss of the year.

Post-Employment Benefits

Defined Contribution Plans

Defined contribution plans are employee and Government administrated provident fund scheme and ESI scheme for all the applicable employees. The Company makes specified monthly contribution towards Employee Provident Fund scheme as per the norms prescribed by the Central Government. The Company’s contribution to defined contribution plans are recognized in the Statement of Profit and Loss accounts in the reporting period to which they relate.

Defined Benefits Plans

Gratuity Scheme

The Company operates a defined benefit gratuity plan for employees with Life Insurance Corporation, and accordingly, the Company pays the gratuity to the employee whoever has completed five year of service with the Company at the time of resignation or superannuation. The Gratuity is calculated as required under payment of Gratuity Act, 1972.

Contributions are made to Group Gratuity Fund scheme, administered by Life Insurance Corporation of India (LIC), in respect of gratuity based upon demand as raised by the LIC. Provision for liability as at the year end is based on actuarial valuation done by an independent actuary using the 'Projected Unit Credit' method. Major drivers in actuarial assumptions, typically, are years of service and employee compensation. Gains and losses on changes in actuarial assumptions are accounted for in the Statement of Profit and Loss. The Company has considered Actuarial Valuation performed by LIC for Policy -1 & Policy - 2. However, for Policy - 3, LIC didn't provided the actuarial valuation report and hence, the company has considered actuarial valuation conducted by an Independent Actuary as per AS-15.

Based on the actuarial valuation obtained in this respect, the following table sets out the status of the gratuity plan and the amounts recognised in the Company's financial statements as at the balance sheet date.

I. ASSUMPTIONS:	**As at March 31, 2026**	**As at March 31, 2025**
Expected Return on Plan Assets		
Discount Rate	7.25% p.a.	7.25% p.a.
Salary Escalation	7% p.a.	7% p.a.
Withdrawal rate	1% to 3% depending on age	1% to 3% depending on age
Mortality Rate	Indian Assured Lives Mortality (2012-14) Table	Indian Assured Lives Mortality (2012-14) Table

II. CHANGE IN THE PRESENT VALUE OF DEFINED BENEFIT OBLIGATION:	**As at March 31, 2026**	**As at March 31, 2025**
Status of plan	Funded	Funded
Present Value of Defined Benefit of Obligation as at the beginning of the year	5942.67	4526.87
Current Service Cost	1007.97	1926.53
Interest Cost	352.63	324.69
(Benefit paid)	-85.80	.00
Past Service Cost	-2900.34	.00
Actuarial (Gains)/Losses on Obligations - Due to Change in Demographic assumptions	.00	.00
Actuarial (Gains)/Losses on Obligations - Due to Change in Financial assumptions	-264.64	-835.41
Present value of Defined Benefit of Obligation as at the end of the year	**4052.49**	**5942.67**

III. CHANGE IN THE FAIR VALUE OF PLANNED ASSET	**As at March 31, 2026**	**As at March 31, 2025**
Fair value of plan assets at the beginning of the year (Not Recognized in previous financial year)	6539	6100
Expected return on plan assets	447	507
Actuarial gain/(loss)	576	-68
Contributions by the employer	1394	
Benefits Paid	-86	
Fair value of plan assets at the end of the year	**8870**	**6539**

IV. RECONCILAITION OF DEFINED BENEFIT OLIGATION AND FAIR VALUE OF PLANNED ASSET	**As at March 31, 2026**	**As at March 31, 2025**
Defined Benefit obligation at the end of the year	4052	5943
Fair value of plan assets at the end of the year	8870	6539
Net liability/(asset) as at end of the year	-4818	-597

V. EXPENSES RECOGNIZED IN THE INCOME STATEMENT:	As at March 31, 2026	As at March 31, 2025
Current service cost	1008	1927
Interest cost	353	325
Actuarial (Gains)/Losses on Obligations - Due to Change in Demographic assumptions		
Actuarial (Gains)/Losses on Obligations - Due to Change in Financial assumptions	-265	-835
Actuarial (gains)/losses	-2900	
Experience adjustments on Plan asset	-576	68
Expected return on plan assets	-447	-507
Expense recognized in Statement of Profit & Loss	**-2827**	**977**

VI.CATEGORY OF ASSETS AT THE END OF THE YEAR	As at March 31, 2026	As at March 31, 2025
Insurer Managed Funds (100%) (Funds managed by LIC as per IRDA guidelines, category-wise composition of the plan assets is not available)	8870	6539
Expense recognized in Statement of Profit & Loss	**8870**	**6539**

VII. ACTUAL RETURN ON PLAN ASSET	As at March 31, 2026	As at March 31, 2025
Actual return on planned asset	447	507

VIII. RECONCILAITION OF DEFINED BENEFIT OLIGATION AND FAIR VALUE OF	As at March 31, 2026	As at March 31, 2025
Defined Benefit obligation at the end of the year	4052	5943
Fair value of plan assets at the end of the year	8870	6539

IX. EXPERIENCE ADJUSTMENTS	As at March 31, 2026	As at March 31, 2025
Status of plan	Funded	
On Plan Liability (Gains)/Losses		
Actuarial (Gains)/Losses on Obligations - Due to Change in Financial assumptions	-265	-835
On Plan Asset (Gains)/Losses	-576	68

X. The estimates of rate of salary increase considered in the actuarial valuation takes into account inflation, seniority, promotion and all other relevant factors including supply and demand in the employment market. During the year company have revise/rectify basic salary structure as per the law, and as per revise structure liability calculation also revised and as per the calculation there is excess provision of gratuity which was credited to the profit and loss accounts.

XI. The company operates an Funded gratuity plan wherein employees are entitled to the benefit as per scheme of the company for each completed year of service. The same is payable on retirement or termination whichever is earlier. The benefit vests only after five years of continuous service.

32.08 **Taxation:**

Company has followed accounting standard AS 22 for determination of tax expense in the accounts. Tax provision for current tax is made for income tax, based on the tax liability computed, after considering tax allowances and exemptions. For defer tax the relevant information is stated at note no. 5 to balance sheet.

32.09 **Related Party Disclosures (AS-18):**

Disclosers required by accounting standard 18 regarding related party transactions are as under.

Name of related parties and description of relationship.

Description of Relationship	**Name of the related party**
Key Managerial Personal	Pranav Rohitbhai Thaker
	Vimalkumar Natverlal Patel
	Narendra Singh Tanwar
	Purvesh Harshadbhai Mali
	Jayesh S Patel
	Parimal Arvindbhai Desai
	Girish Surajmal Pokharna
Wholly Owned Susidiary	Maitreya Lifescience Private Limited
Susidiary	Maitreya Hospital Private Limited
Associate concern of Company	OHM MRI Private Limited
	Tulip Agility Private Limited
Associate concern of key managerial person	Maitreya Heart and Vascular Care Private Limited
	Torin Pharmaceuticles Private Limited
Raltives/Related party of Key Managerial Presonal	Puspdant Parantapbhai Pandit
	Jyotikaben Parantapbhai Pandit
	Darshana Pranav Thaker
	Binti Singh
	Yamini Vimalkumar Patel
	Shiv Consulatancy Prop Yamini Vimalkumar Patel
	Dr. Vibha Singh Tanwar
	Big Xreay Dignostic Pvt Limited

Details of transaction with related party

Name of the party	Nature of relation	Nature of transaction	For the period ended 31.03.2026	For the period ended 31.03.2025
Pranav Rohitbhai Thaker		Loan received	.00	.00
	Whole Time Director	Loan repaid	.00	1146.60
		Sale of Pharmacy	3.16	.38
		Travelling Expenses	71.02	169.27
		Professional Fees paid	4937.36	4104.46
Vimalkumar Natverlal Patel	Whole Time Director	Loan received	.00	.00
		Loan repaid	.00	1033.00
		Sale of Pharmacy	.00	5.22
		Marketing Expenses	.00	.00
		Travelling Expenses	498.34	206.01
		Professional Fees paid	1281.27	212.01
		Amount receivable for Sale of Pharmacy	.00	.00
Narendra Singh Tanwar	Managing Director-CFO	Loan received	.00	.00
		Loan repaid	.00	3720.00
		Sale of Pharmacy	3.47	.00
		Professional Fees paid	12979.80	12784.29
Purvesh Harshadbhai Mali	Director	Professional Fees paid	600.00	1098.06
Jayesh S Patel	Director	Professional Fees paid	5.69	7.88
Parimal Arvindbhai Desai	Director	Professional Fees paid	24.73	646.55
Girish Surajmal Pokharna	Director	Professional Fees paid	2057.09	2492.48
Maitreya Lifescience Private Limited	Wholly Owned Susidiary	Amount of loan given	400.00	.00
		Amount received agaisnt loan given	5300.00	
		Professional Fees Received	.00	6270.93
Maitreya Hospital Private Limited	Subsidiary	Loan given	5000.00	.00

		Investment in Equity shares Capital During the year	.00	75000.00
		Loan received	30970.80	
		Amount received agaisnt loan given	11029.20	2620.80
Tulip Agility Private Limited	Associate concern of key managerial person	Laboratory Charges	37.98	34.56
		Deposit Given	.00	.00
		Loan given	7500.00	1500.00
		Investment in Capital Account	.00	.00
		Sale of Pharmacy	.00	436.54
		Professional Fees received	.00	1858.37
		Machinery Rent	.00	.00
Puspdant Parantapbhai Pandit	Raltives of Key Managerial Presonal	Hospital Equipments	200.00	
Darshana Pranav Thaker	Raltives of Key Managerial Presonal	Professional Fees paid	1800.00	1755.00
Yamini Vimalkumar Patel	Raltives of Key Managerial Presonal	Professional Fees paid	1800.00	1755.00
Shiv Consulatancy Prop Yamini Vimalkumar Patel	Related party of Key Managerial Presonal	Laboratory Charges	301.10	276.30
Dr. Vibha Singh Tanwar	Raltives of Key Managerial Presonal	Professional Fees paid	4800.00	4500.00
		Pharmacy Sales	33.57	400.57
		Amount receivable for Sale of Pharmacy	174.12	155.16
Big Xreay Dignostic Pvt Limited	Related party of Key Managerial Presonal	Professional Fees paid	1449.72	.00
Pranav Rohitbhai Thaker	Whole Time Director	Closing Balance of Loan		
		Amount receivable for Sale of Pharmacy	17.13	.00
Vimalkumar Natverlal Patel	Whole Time Director	Closing Balance of Loan		
Narendra Singh Tanwar	Managing Director-CFO	Closing Balance of Loan		
		Amount receivable for Sale of Pharmacy	46.62	.00
Maitreya Lifescience Private Limited	Wholly Owned Susidiary	Investment in Equity shares at the year end	100.00	100.00
Maitreya Hospital Private Limited	Subsidiary	Investment in Equity shares at the year end	75100.00	75100.00
		Closing Balance of Loan Receivable	.00	6029.20
		Closing Balance of Loan Payable	30970.80	.00
Maitreya Hospital Private Limited	Subsidiary	Investment in Share Application for Equity shares pending for allotment by Company at the year end		100
Tulip Agility Private Limited	Subsidiary	Closing Balance of Loan	29774.10	22274.10
OHM MRI Pvt Limited	**Associate concern of Company**	Investment in Equity shares at the year end	10.00	10.00

32.10

SEGMENT REPORTING:

32.11 In view of the Accounting Standard 17 “Segment Reporting” issued by the Institute of Chartered Accountants of India the disclosures in respect of segment information for the year ended 31st March 2026 is not applicable to the Company as the Company does not deal in varied products / services and hence not exposed to different risks and returns. Further the Company operates in only one geographical area and does not having any branches or any other outlets and hence not exposed to different risks and returns of geographical segmentation.

32.12 As certified by the management, no transactions has been entered in to by the Company during the F. Y. 2025-26 with any stuck off companies u/s. 248 of the Companies Act, 2013 or u/s. 560 of the Companies Act, 1956.

32.13 All the charges which are subject to register with the Ministry of Corporate Affairs has been duly registered. Bank Guarantee for MAYOJANA of Rs. 2963.97 (Thousands), Bank Guarantee for ESIC of Rs. 644.41 (Thousands) against fixed deposit for which charge to be created on Vehcile/ Fixed Deposits for which loan guarantee taken with ROC Ahmedabad with thirty days of sanctioned, is inadvetently missed and not registered with ROC,Ahemedabad. The charges which are needs to be satisfied has also been duly filed with MCA wherever applicable.

32.14 During the period under consideration , the Company has required to comply with the provisions of section 135 (Corporate Social Responsibility) of the Companies Act, 2013 and Company has applied the required amount of CSR limits as prescribed u/s. 135(1) of the Companies Act, 2013.

32.15 The Company has not sanctioned working capital limit in excess of Rs. 5 Crore by Bank/ Financial Institution on the basis of security of current assets and therefore no disclosure is applicable.

32.16 The Company has complied with clause (87) of section 2 of the Act read with the Companies (Restriction on number of Layers) Rules, 2017.

32.17 The Company has made Loan and advances in the nature of loans to promoters, directors, KMPs and the related parties in the during the year to the tune of Rs. 34274 , which is reported under related party transaction as per AS 18.

32.18 The Company does not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property.

32.19 The Group is not declared a wilfull defaulter by any Bank or Financial institution or any other lender.

32.2 During the year no Scheme of Arrangement has been formulated by the Group/pending with competent authority.

32.21 No funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities (“Intermediaries”) with the understanding, whether recorded in writing or otherwise, that the Intermediary shall lend or invest in party identified by or on behalf of the Company (Ultimate Beneficiaries). The Company has not received any fund from any party(s) (Funding Party) with the understanding that the Company shall whether, directly or indirectly lend or invest in other persons or entities identified by or on behalf of the Company (“Ultimate Beneficiaries”) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

32.22 The Company has not surrendered or disclosed any transactions, previously unrecorded as income in the books of account, in the tax assessments under the Income Tax Act, 1961 as income during the year.

32.23 The Company has not traded or invested in Crypto Currency or Virtual Currency during the financial year.

32.24 In the opinion of the Board of Directors of the Company, the Current Assets, Loans and Advances are approximately of the value stated, if realized in the ordinary course of business, except for which provision has been made in the accounts. The Company has requested account confirmation from Debotrs and Creditors as at the end of the year but till date there is no such confirmation have been received from the Debtors and Creditors, therefore what ever balance outstanding is subject to confirmation as well as reconciliation.

In the opinion of The Board of Directors, there were no contingent liabilities on the date of Balance Sheet, except as mentioned in below table regarding legal consumenr court cases against the Company.

A. Civil Proceedings againts Maitreya Medicare Limited

Parties to the Proceedings Suit etc. Name	**Forum**	**Details of the relief / prayers / claims along with details of any orders / decrees / directi / ons passed in the matter, (including any interim relief granted and / or applied for)**	**Amount involved**	**Current Status of the Matter**
United India Insurance Co. Ltd. - Surat Branch Mahager – Surat Paramount Health Services and Insurance Tpa Pvt. Ltd.- Surat Maitreya Hospital – Surat	Consumer		388617/-	Active
The New India Insurance Co. Ltd. - Surat Health India Insurance TPA Services Pvt. Ltd – Surat Aadhya Hospital – Surat Maitreya Multi Superspeciality Hospital & Research Centre – Surat	Consumer		361727/-	Active
The New India Insurance Co. Ltd. - Surat				

Branch Mahager – Surat Ericson Insurance TPA Pvt Ltd Maitreya Hospital – Surat	Consumer		186514/-	Active
SBI General Insurance Co Ltd – Surat Branch Manager – Surat Paramount Health Services and Insurance Tpa Pvt. Ltd.- Surat Maitreya Hospital – Surat	Consumer		291799/-	Active
The New India Insurance Co. Ltd. - Surat Heritage Health Tpa Private Limited – Surat Maitreya Multi Superspeciality Hospital & Research Centre – Surat	Consumer		61087/-	Active
The New India Insurance Co. Ltd. - Surat Divisional Manaer – Surat Health India Insurance TPA Services Pvt. Ltd Maitreya Hospital – Surat	Consumer		327694/-	Active
The New India Insurance Co. Ltd. - Surat Branch Mahager Heritage Health Tpa Private Limited – Surat Maitreya Hospital	Consumer		448116/-	Active
The Oriental Insurance co ltd – Surat Sr. Divisional Manager Vipul Medcorp Insurance TPA Pvt Ltd Maitreya Hospital	Consumer		245091/-	Active
Star Health and allied insurance company limited – Surat Maitreya Hospital – Surat	Consumer		200487/-	Active
Maitreya Multi Superspeciality Hospital & Research Centre – Surat Dr. Pranav Thaker – Surat Vimal Patel – Surat Dr. Narendra Singh Tanwar – Surat Dr. Suchay Parikh – Surat Dr. Ronak Nagoria – Surat	Consumer		470437/-	Active

32.25 The provision for depreciation and for all the known liabilities are adequate and not in excess of the amount reasonably necessary. However there is pending court litigation against the Company in the Consumer Court as per as per above table, all these case filed by patients against various insurance companies in which company is co-accuse. As per previous experiences Company Management are opinion that there will not be any liability on the Company and therefore no provisions for the same has been made in the books of accounts during the year.

32.26 All the balances of parties' accounts are subject to confirmation.

As Per Our Report of Even Dated Annexed
Saherwala & Co.
FRN 108969W

For MAITREYA MEDICARE LIIYA MEDICARE LIMITED

(ESMAYEEL O. SAHERWALA)
Chartered Accountant
M. NO. 122386
29th May 2026, Surat.
UDIN :

VIMAL PATEL
DIN- 08458999
Wholetime Director

NARENDRA TANWAR
DIN - 0008459007
MD AND CFO